CA2513117C - Gene expression markers for breast cancer prognosis - Google Patents
Gene expression markers for breast cancer prognosis Download PDFInfo
- Publication number
- CA2513117C CA2513117C CA2513117A CA2513117A CA2513117C CA 2513117 C CA2513117 C CA 2513117C CA 2513117 A CA2513117 A CA 2513117A CA 2513117 A CA2513117 A CA 2513117A CA 2513117 C CA2513117 C CA 2513117C
- Authority
- CA
- Canada
- Prior art keywords
- dna
- artificial sequence
- breast cancer
- probe
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 154
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 91
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 90
- 238000004393 prognosis Methods 0.000 title abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 155
- 206010028980 Neoplasm Diseases 0.000 claims description 77
- -1 FBX05 Proteins 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 75
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 claims description 53
- 101150052409 GRB7 gene Proteins 0.000 claims description 53
- 108700031843 GRB7 Adaptor Proteins 0.000 claims description 51
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 claims description 51
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 claims description 51
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 50
- 230000004083 survival effect Effects 0.000 claims description 47
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 claims description 40
- 102100026534 Procathepsin L Human genes 0.000 claims description 40
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims description 36
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 claims description 36
- 101000593405 Homo sapiens Myb-related protein B Proteins 0.000 claims description 34
- 102100034670 Myb-related protein B Human genes 0.000 claims description 34
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 claims description 28
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 claims description 28
- 102100032311 Aurora kinase A Human genes 0.000 claims description 27
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 claims description 27
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 claims description 25
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 claims description 25
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 claims description 25
- 101150093699 Scube2 gene Proteins 0.000 claims description 24
- 102100028932 Signal peptide, CUB and EGF-like domain-containing protein 2 Human genes 0.000 claims description 24
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 claims description 24
- 101001008919 Homo sapiens Kallikrein-10 Proteins 0.000 claims description 23
- 102100027613 Kallikrein-10 Human genes 0.000 claims description 23
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 23
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 23
- 230000007774 longterm Effects 0.000 claims description 23
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 23
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 22
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 22
- 102100033589 DNA topoisomerase 2-beta Human genes 0.000 claims description 21
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 21
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims description 21
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims description 21
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 claims description 20
- 101001071694 Homo sapiens Glutathione S-transferase Mu 1 Proteins 0.000 claims description 20
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims description 19
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 claims description 19
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims description 19
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 claims description 19
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 claims description 19
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 18
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 18
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 claims description 18
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 claims description 18
- 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 claims description 16
- 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 claims description 16
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 15
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 15
- 101000782132 Homo sapiens Zinc finger protein 217 Proteins 0.000 claims description 15
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 15
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 15
- 102100036595 Zinc finger protein 217 Human genes 0.000 claims description 15
- 238000003757 reverse transcription PCR Methods 0.000 claims description 14
- 101150029707 ERBB2 gene Proteins 0.000 claims description 13
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 claims description 11
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims description 11
- 101710156592 Putative TATA-binding protein pB263R Proteins 0.000 claims description 11
- 101710145783 TATA-box-binding protein Proteins 0.000 claims description 11
- 101150113535 chek1 gene Proteins 0.000 claims description 11
- 102100037904 CD9 antigen Human genes 0.000 claims description 10
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims description 10
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 10
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims description 10
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 10
- 208000030776 invasive breast carcinoma Diseases 0.000 claims description 10
- 102100028588 Protein ZNRD2 Human genes 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims description 8
- 102000008817 Trefoil Factor-1 Human genes 0.000 claims description 8
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 claims description 7
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 claims description 7
- 102100040296 TATA-box-binding protein Human genes 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100021572 Bcl-2-binding component 3, isoforms 1/2 Human genes 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 470
- 239000013615 primer Substances 0.000 description 243
- 239000000523 sample Substances 0.000 description 157
- 108091093088 Amplicon Proteins 0.000 description 117
- 230000002441 reversible effect Effects 0.000 description 113
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 69
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 50
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 45
- 108060006580 PRAME Proteins 0.000 description 38
- 102000036673 PRAME Human genes 0.000 description 38
- 201000011510 cancer Diseases 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 32
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 28
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 27
- 102100025136 Macrosialin Human genes 0.000 description 27
- 238000003752 polymerase chain reaction Methods 0.000 description 27
- 102000015694 estrogen receptors Human genes 0.000 description 25
- 108010038795 estrogen receptors Proteins 0.000 description 25
- 102100025403 Epoxide hydrolase 1 Human genes 0.000 description 24
- 101001077852 Homo sapiens Epoxide hydrolase 1 Proteins 0.000 description 24
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 21
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 21
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 20
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 101150006084 CHKB gene Proteins 0.000 description 17
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 17
- 101000742054 Homo sapiens Protein phosphatase 1D Proteins 0.000 description 17
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 17
- 102100038675 Protein phosphatase 1D Human genes 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 16
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 16
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 15
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 15
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 14
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 14
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 14
- 102100029283 Hepatocyte nuclear factor 3-alpha Human genes 0.000 description 13
- 101001062353 Homo sapiens Hepatocyte nuclear factor 3-alpha Proteins 0.000 description 13
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 description 13
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 13
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 13
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 108010058546 Cyclin D1 Proteins 0.000 description 12
- 102100033720 DNA replication licensing factor MCM6 Human genes 0.000 description 12
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 12
- 101001018484 Homo sapiens DNA replication licensing factor MCM6 Proteins 0.000 description 12
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 description 12
- 108010005173 SERPIN-B5 Proteins 0.000 description 12
- 102100030333 Serpin B5 Human genes 0.000 description 12
- 102100028847 Stromelysin-3 Human genes 0.000 description 12
- 238000010195 expression analysis Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102100038778 Amphiregulin Human genes 0.000 description 11
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 description 11
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 description 11
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 description 11
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 description 11
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 description 11
- 101000904787 Homo sapiens Serine/threonine-protein kinase ATR Proteins 0.000 description 11
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 description 11
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 11
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 102100031173 CCN family member 4 Human genes 0.000 description 10
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 10
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 10
- 102100039606 DNA replication licensing factor MCM3 Human genes 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 description 10
- 101000963174 Homo sapiens DNA replication licensing factor MCM3 Proteins 0.000 description 10
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 10
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 10
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 9
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 9
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 9
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 102000009310 vitamin D receptors Human genes 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 8
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 8
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 8
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 8
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 description 8
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 8
- 101000730643 Homo sapiens Zinc finger protein PLAGL1 Proteins 0.000 description 8
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 8
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 8
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 8
- 102100022224 Y-box-binding protein 1 Human genes 0.000 description 8
- 102100032570 Zinc finger protein PLAGL1 Human genes 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 102100026540 Cathepsin L2 Human genes 0.000 description 7
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 description 7
- 101000983577 Homo sapiens Cathepsin L2 Proteins 0.000 description 7
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 description 7
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 7
- 101001027925 Homo sapiens Metastasis-associated protein MTA1 Proteins 0.000 description 7
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 7
- 102100037517 Metastasis-associated protein MTA1 Human genes 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 101000829367 Homo sapiens Src substrate cortactin Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100023719 Src substrate cortactin Human genes 0.000 description 6
- 101000693967 Trachemys scripta 67 kDa serum albumin Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000005773 cancer-related death Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002987 primer (paints) Substances 0.000 description 6
- 238000003196 serial analysis of gene expression Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 5
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 description 5
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 5
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 5
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 239000011325 microbead Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000016362 Catenins Human genes 0.000 description 4
- 108010067316 Catenins Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 description 4
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 description 4
- 102000001195 RAD51 Human genes 0.000 description 4
- 108010068097 Rad51 Recombinase Proteins 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000009274 differential gene expression Effects 0.000 description 4
- 238000011223 gene expression profiling Methods 0.000 description 4
- 238000010841 mRNA extraction Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 3
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 3
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 101150109894 TGFA gene Proteins 0.000 description 3
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 3
- 108700012411 TNFSF10 Proteins 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 2
- 102000052589 Anaphase-Promoting Complex-Cyclosome Apc4 Subunit Human genes 0.000 description 2
- 101710091620 Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100494566 Escherichia coli cap2 gene Proteins 0.000 description 2
- 102000005233 Eukaryotic Initiation Factor-4E Human genes 0.000 description 2
- 108060002636 Eukaryotic Initiation Factor-4E Proteins 0.000 description 2
- 101150087882 GUS1 gene Proteins 0.000 description 2
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 2
- 101000869747 Homo sapiens Mitochondrial carrier protein SCaMC-3L Proteins 0.000 description 2
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 2
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101100112111 Caenorhabditis elegans cand-1 gene Proteins 0.000 description 1
- 101100404153 Caenorhabditis elegans nasp-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101000764817 Chromohalobacter salexigens (strain ATCC BAA-138 / DSM 3043 / CIP 106854 / NCIMB 13768 / 1H11) Oxygen-dependent choline dehydrogenase 1 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101000933461 Escherichia coli (strain K12) Beta-glucuronidase Proteins 0.000 description 1
- 102000004130 Fusion Regulatory Protein-1 Human genes 0.000 description 1
- 108010057784 Fusion Regulatory Protein-1 Proteins 0.000 description 1
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101100137537 Mus musculus Prap1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150072055 PAL1 gene Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100026651 Pro-adrenomedullin Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 101100209986 Rattus norvegicus Slc18a1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 101150110946 gatC gene Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
Description
Gene Expression Markers for Breast Cancer Prognosis Background of the Invention Field of the Invention The present invention provides genes and gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
Description of the Related Art Oncologists have a number of treatment options available to them, including different combinations of chemotherapeutic drugs that are characterized as "standard of care," and a number of drugs that do not carry a label claim for particular cancer, but for which there is evidence of efficacy in that cancer. Best likelihood of good treatment outcome requires that patients be assigned to optimal available cancer treatment, and that this assignment be made as quickly as possible following diagnosis.
Currently, diagnostic tests used in clinical practice are single analyte, and therefore do not capture the potential value of knowing relationships between dozens of different markers.
Moreover, diagnostic tests are frequently not quantitative, relying on inununohistochemistry.
This method often yields different results in different laboratories, in part because the reagents are not standardized, and in part because the interpretations are subjective and cannot be easily quantified. RNA-based tests have not often been used because of the problem of RNA
degradation over time and the fact that it is difficult to obtain fresh tissue samples from patients for analysis. Fixed paraffin-embedded tissue is more readily available and methods have been established to detect RNA in fixed tissue. However, these methods typically do not allow for the study of large numbers of genes (DNA or RNA) from small amounts of material.
Thus, traditionally fixed tissue has been rarely used other than for immunohistochemistry detection of proteins.
Recently, several groups have published studies concerning the classification of various cancer types by microarray gene expression analysis (see, e.g. Golub et al., Science 286:531-537 (1999); Bhattacharjae et al., Proc. Natl. Acad. Sci. USA 98:13790-13795 (2001);
Chen-Hsiang et al., Bioinformatics 17 (Suppl. 1):S316-S322 (2001); Ramaswamy et al., Proc.
NatL Acad. Sci. USA 98:15149-15154 (2001)). Certain classifications of human breast cancers based on gene expression patterns have also been reported (Martin et al., Cancer Res.
60:2232-2238 (2000); West et al., Proc. Natl. Acad. Sci. USA 98:11462-11467 (2001); Sorlie et al., Proc. Natl. Acad. Sci. USA 98:10869-10874 (2001); Yan et aL, Cancer Res. 61:8375-8380 (2001)). However, these studies mostly focus on improving and refining the already established classification of various types of cancer, including breast cancer, and generally do not provide new insights into the relationships of the differentially expressed genes, and do not link the findings to treatment strategies in order to improve the clinical outcome of cancer therapy.
Although modem molecular biology and biochemistry have revealed hundreds of genes whose activities influence the behavior of tumor cells, state of their differentiation, and their sensitivity or resistance to certain therapeutic drugs, with a few exceptions, the status of these genes has not been exploited for the purpose of routinely making clinical decisions about drug treatments. One notable exception is the use of estrogen receptor (ER) protein expression in breast carcinomas to select patients to treatment with ante-estrogen drugs, such as tamoxifen. Another exceptional example is the use of ErbB2 (Her2) protein expression in breast carcinomas to select patients with the Her2 antagonist drug Herceptin (Genentech, Inc., South San Francisco, CA).
Despite recent advances, the challenge of cancer treatment remains to target specific treatment regimens to pathogenically distinct tumor types, and ultimately personalize tumor treatment in order to maximize outcome. Hence, a need exists for tests that simultaneously provide predictive information about patient responses to the variety of treatment options.
This is particularly true for breast cancer, the biology of which is poorly understood. It is clear that the classification of breast cancer into a few subgroups, such as ErbB2+ subgroup, and subgroups characterized by low to absent gene expression of the estrogen receptor (ER) and a few additional transcriptional factors (Perou et al., Nature 406:747-752 (2000)) does not reflect the cellular and molecular heterogeneity of breast cancer, and does not allow the design of treatment strategies maximizing patient response.
Summary of the Invention The present invention provides a set of genes, the expression of which has prognostic value, specifically with respect to disease-free survival.
Description of the Related Art Oncologists have a number of treatment options available to them, including different combinations of chemotherapeutic drugs that are characterized as "standard of care," and a number of drugs that do not carry a label claim for particular cancer, but for which there is evidence of efficacy in that cancer. Best likelihood of good treatment outcome requires that patients be assigned to optimal available cancer treatment, and that this assignment be made as quickly as possible following diagnosis.
Currently, diagnostic tests used in clinical practice are single analyte, and therefore do not capture the potential value of knowing relationships between dozens of different markers.
Moreover, diagnostic tests are frequently not quantitative, relying on inununohistochemistry.
This method often yields different results in different laboratories, in part because the reagents are not standardized, and in part because the interpretations are subjective and cannot be easily quantified. RNA-based tests have not often been used because of the problem of RNA
degradation over time and the fact that it is difficult to obtain fresh tissue samples from patients for analysis. Fixed paraffin-embedded tissue is more readily available and methods have been established to detect RNA in fixed tissue. However, these methods typically do not allow for the study of large numbers of genes (DNA or RNA) from small amounts of material.
Thus, traditionally fixed tissue has been rarely used other than for immunohistochemistry detection of proteins.
Recently, several groups have published studies concerning the classification of various cancer types by microarray gene expression analysis (see, e.g. Golub et al., Science 286:531-537 (1999); Bhattacharjae et al., Proc. Natl. Acad. Sci. USA 98:13790-13795 (2001);
Chen-Hsiang et al., Bioinformatics 17 (Suppl. 1):S316-S322 (2001); Ramaswamy et al., Proc.
NatL Acad. Sci. USA 98:15149-15154 (2001)). Certain classifications of human breast cancers based on gene expression patterns have also been reported (Martin et al., Cancer Res.
60:2232-2238 (2000); West et al., Proc. Natl. Acad. Sci. USA 98:11462-11467 (2001); Sorlie et al., Proc. Natl. Acad. Sci. USA 98:10869-10874 (2001); Yan et aL, Cancer Res. 61:8375-8380 (2001)). However, these studies mostly focus on improving and refining the already established classification of various types of cancer, including breast cancer, and generally do not provide new insights into the relationships of the differentially expressed genes, and do not link the findings to treatment strategies in order to improve the clinical outcome of cancer therapy.
Although modem molecular biology and biochemistry have revealed hundreds of genes whose activities influence the behavior of tumor cells, state of their differentiation, and their sensitivity or resistance to certain therapeutic drugs, with a few exceptions, the status of these genes has not been exploited for the purpose of routinely making clinical decisions about drug treatments. One notable exception is the use of estrogen receptor (ER) protein expression in breast carcinomas to select patients to treatment with ante-estrogen drugs, such as tamoxifen. Another exceptional example is the use of ErbB2 (Her2) protein expression in breast carcinomas to select patients with the Her2 antagonist drug Herceptin (Genentech, Inc., South San Francisco, CA).
Despite recent advances, the challenge of cancer treatment remains to target specific treatment regimens to pathogenically distinct tumor types, and ultimately personalize tumor treatment in order to maximize outcome. Hence, a need exists for tests that simultaneously provide predictive information about patient responses to the variety of treatment options.
This is particularly true for breast cancer, the biology of which is poorly understood. It is clear that the classification of breast cancer into a few subgroups, such as ErbB2+ subgroup, and subgroups characterized by low to absent gene expression of the estrogen receptor (ER) and a few additional transcriptional factors (Perou et al., Nature 406:747-752 (2000)) does not reflect the cellular and molecular heterogeneity of breast cancer, and does not allow the design of treatment strategies maximizing patient response.
Summary of the Invention The present invention provides a set of genes, the expression of which has prognostic value, specifically with respect to disease-free survival.
2 Various embodiments of this invention provide a method of predicting the likelihood of long-term survival of a breast cancer patient without recurrence of breast cancer, comprising:
determining a level of an RNA transcript of MYBL2 or its expression product, in a breast cancer tumor sample from said patient; normalizing said level of the RNA transcript of MYBL2 or its expression product, to obtain a normalized expression level of MYBL2; wherein increased normalized expression level of MYBL2 indicates a decreased likelihood of long-term survival without breast cancer recurrence. The method may further comprise determining a normalized expression level of an RNA transcript of at least one further gene or its expression product. Such a further gene may be: GRB7, CTSL, Chkl, AIB1, CCNB I , MCM2, EBX05, Her2, STK15, SURV, EGFR, HIFI a, or TS; wherein increased normalized expression level of the at least one further gene indicates a decreased likelihood of long-term survival without breast cancer recurrence. The method may further comprise determining a normalized expression level of an RNA transcript of at least one further gene or its expression product. Such a further gene may be:
TP53BP2, PR, Bc12, EstR1, IGFBP2, BAG1, CEGP1, KLK10, p-Catenin, y-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGE1, or KRT19; wherein increased normalized expression level of the at least one further gene indicates an increased likelihood of long-term survival without breast cancer recurrence.
Various embodiments of this invention provide a method of preparing a personalized genomics profile for a patient, comprising the steps of: (a) subjecting RNA
extracted from breast tissue from the patient to gene expression analysis; (b) determining a level of an RNA transcript of MYBL2 or its expression product, wherein the level of the RNA transcript of MYBL2 or its expression product is normalized against at least one control gene to obtain normalized data, and optionally is compared to expression levels found in a breast cancer reference tissue set; and (c) creating a report summarizing the normalized data obtained by said gene expression analysis.
The present invention accommodates the use of archived paraffin-embedded biopsy material for assay of all markers in the set, and therefore is compatible with the most widely 2a
determining a level of an RNA transcript of MYBL2 or its expression product, in a breast cancer tumor sample from said patient; normalizing said level of the RNA transcript of MYBL2 or its expression product, to obtain a normalized expression level of MYBL2; wherein increased normalized expression level of MYBL2 indicates a decreased likelihood of long-term survival without breast cancer recurrence. The method may further comprise determining a normalized expression level of an RNA transcript of at least one further gene or its expression product. Such a further gene may be: GRB7, CTSL, Chkl, AIB1, CCNB I , MCM2, EBX05, Her2, STK15, SURV, EGFR, HIFI a, or TS; wherein increased normalized expression level of the at least one further gene indicates a decreased likelihood of long-term survival without breast cancer recurrence. The method may further comprise determining a normalized expression level of an RNA transcript of at least one further gene or its expression product. Such a further gene may be:
TP53BP2, PR, Bc12, EstR1, IGFBP2, BAG1, CEGP1, KLK10, p-Catenin, y-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGE1, or KRT19; wherein increased normalized expression level of the at least one further gene indicates an increased likelihood of long-term survival without breast cancer recurrence.
Various embodiments of this invention provide a method of preparing a personalized genomics profile for a patient, comprising the steps of: (a) subjecting RNA
extracted from breast tissue from the patient to gene expression analysis; (b) determining a level of an RNA transcript of MYBL2 or its expression product, wherein the level of the RNA transcript of MYBL2 or its expression product is normalized against at least one control gene to obtain normalized data, and optionally is compared to expression levels found in a breast cancer reference tissue set; and (c) creating a report summarizing the normalized data obtained by said gene expression analysis.
The present invention accommodates the use of archived paraffin-embedded biopsy material for assay of all markers in the set, and therefore is compatible with the most widely 2a
3 available type of biopsy material. It is also compatible with several different methods of tumor tissue harvest, for example, via core biopsy or fine needle aspiration.
Further, for each member of the gene set, the invention specifies oligonucleotide sequences that can be used in the test.
In one aspect, the invention concerns a method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, comprising determining the expression level of one or more prognostic RNA transcripts or their expression products in a breast cancer tissue sample obtained from the patient, normalized against the expression level of all RNA transcripts or their products in the breast cancer tissue sample, or of a reference set of RNA transcripts or their expression products, wherein the prognostic RNA transcript is the transcript of one or more genes selected from the group consisting of: TP53BP2, GRB7, PR, CD68, Bc12, KRT14, IRS1, CTSL, EstR1, Chkl, IGFBP2, BAG1, CEGP1, STK15, GSTM1, FHIT, RIZ1, AlB 1 , SLTRV, BBC3, IGF1R, p27, GATA3, ZNF217, EGFR, CD9, MYBL2, HIF1a, pS2, ErbB3, TOP2B, MDM2, RAD51C, KRT19, TS, Her2, KLK10, 13-Catenin, y-Catenin, MCM2, PI3KC2A, IGF1, TBP, CCNB1, FBX05, and DR5, wherein expression of one or more of GRB7, CD68, CTSL, Chkl, Al}3 1 , CCNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, MYBL2, HIF1a, and TS indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the expression of one or more of TP53BP2, PR, Bc12, KRT14, EstR1, IGFBP2, BAG1, CEGP1, KLK10, 13-Catenin, y-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGF1, and KRT19 indicates an increased likelihood of long-term survival without breast cancer recurrence.
In a particular embodiment, the expression levels of at least two, or at least 5, or at least 10, or at least 15 of the prognostic RNA transcripts or their expression products are determined. In another embodiment, the method comprises the determination of the expression levels of all prognostic RNA transcripts or their expression products.
In another particular embodiment, the breast cancer is invasive breast carcinoma.
In a further embodiment, RNA is isolated from a fixed, wax-embedded breast cancer tissue specimen of the patient. Isolation may be performed by any technique known in the art, for example from core biopsy tissue or fine needle aspirate cells.
In another aspect, the invention concerns an array comprising polynucleotides hybridizing to two or more of the following genes: a-Catenin, AlB1, AKT1, AKT2, 13-actin, BAG1, BBC3, Bc12, CCNB1, CCND1, CD68, CD9, CDH1, CEGP1, Chkl, CIAP1, cMet.2, Contig 27882, CTSL, DR5, EGFR, ElF4E, EPHX1, ErbB3, EstR1, FBX05, FHIT1 FRP1, GAPDH, GATA3, G-Catenin, GRB7, GRO1, GSTM1, GUS, HER2, HIF1A, HNF3A, IGF1R, IGFBP2, KLK10, KRT14, KRT17, KRT18, KRT19, KRT5, Maspin, MCM2, MCM3, MDM2, MMP9, MTA1, MYBL2, P14ARF, p27, P53, PI3KC2A, PR, PRAME, pS2, RAD51C,.3RB1, RIZ1, STK15, STMY3, SURV, TGFA, TOP2B, TP53BP2, TRAIL, TS, upa, VDR, VEGF, and ZNF217.
In particular embodiments, the array comprises polynucleotides hybridizing to at least 3, or at least 5, or at least 10, or at least 15, or at least 20, or all of the genes listed above.
In another specific embodiment, the array comprises polynucleotides hybridizing to the following genes: TP53BP2, GRB7, PR, CD68, Bc12, KRT14, IRS1, CTSL, EstR1, Chkl, IGFBP2, BAG1, CEGP1, STK15, GSTM1, FHIT, RIZ1, AlB1, SURV, BBC3, IGF1R, p27, GATA3, ZNF217, EGFR, CD9, MYBL2, HIF1a, pS2, RIZ1, ErbB3, TOP2B, MDM2, RAD51C, KRT19, TS, Her2, KLK10, 13-Catenin, y-Catenin, MCM2, PI3KC2A, IGF1, TBP, CCNB1, FBX05 and DR5.
The polynucleotides can be cDNAs, or oligonucleotides, and the solid surface on which they are displayed may, for example, be glass.
In another aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, comprising the steps of:
(1) determining the expression levels of the RNA transcripts or the expression products of genes or a gene set selected from the group consisting of (a) TP53BP2, Bc12, BAD, EPHX1, PDGFR13, DIABLO, XIAP, YB1, CA9, and KRT8;
(b) GRB7, CD68, TOP2A, Bc12, DIABLO, CD3, ID1, PPM1D, MCM6, and WISP1;
(c) PR, TP53BP2, PRAME, DIABLO, CTSL, IGFBP2, TIMP1, CA9, MMP9, and COX2;
(d) CD68, GRB7, TOP2A, Bc12, DIABLO, CD3, PPM1D, MCM6, and WISP1;
(e) Bc12, TP53BP2, BAD, EPHX1, PDGFR13, DIABLO, XIAP, YB1, CA9, and KRT8;
(f) KRT14, KRT5, PRA_ME, TP5311P2, GUS1, A1B1, MCM3, CCNE1, MCM6, and 11:301;
Further, for each member of the gene set, the invention specifies oligonucleotide sequences that can be used in the test.
In one aspect, the invention concerns a method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, comprising determining the expression level of one or more prognostic RNA transcripts or their expression products in a breast cancer tissue sample obtained from the patient, normalized against the expression level of all RNA transcripts or their products in the breast cancer tissue sample, or of a reference set of RNA transcripts or their expression products, wherein the prognostic RNA transcript is the transcript of one or more genes selected from the group consisting of: TP53BP2, GRB7, PR, CD68, Bc12, KRT14, IRS1, CTSL, EstR1, Chkl, IGFBP2, BAG1, CEGP1, STK15, GSTM1, FHIT, RIZ1, AlB 1 , SLTRV, BBC3, IGF1R, p27, GATA3, ZNF217, EGFR, CD9, MYBL2, HIF1a, pS2, ErbB3, TOP2B, MDM2, RAD51C, KRT19, TS, Her2, KLK10, 13-Catenin, y-Catenin, MCM2, PI3KC2A, IGF1, TBP, CCNB1, FBX05, and DR5, wherein expression of one or more of GRB7, CD68, CTSL, Chkl, Al}3 1 , CCNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, MYBL2, HIF1a, and TS indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the expression of one or more of TP53BP2, PR, Bc12, KRT14, EstR1, IGFBP2, BAG1, CEGP1, KLK10, 13-Catenin, y-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGF1, and KRT19 indicates an increased likelihood of long-term survival without breast cancer recurrence.
In a particular embodiment, the expression levels of at least two, or at least 5, or at least 10, or at least 15 of the prognostic RNA transcripts or their expression products are determined. In another embodiment, the method comprises the determination of the expression levels of all prognostic RNA transcripts or their expression products.
In another particular embodiment, the breast cancer is invasive breast carcinoma.
In a further embodiment, RNA is isolated from a fixed, wax-embedded breast cancer tissue specimen of the patient. Isolation may be performed by any technique known in the art, for example from core biopsy tissue or fine needle aspirate cells.
In another aspect, the invention concerns an array comprising polynucleotides hybridizing to two or more of the following genes: a-Catenin, AlB1, AKT1, AKT2, 13-actin, BAG1, BBC3, Bc12, CCNB1, CCND1, CD68, CD9, CDH1, CEGP1, Chkl, CIAP1, cMet.2, Contig 27882, CTSL, DR5, EGFR, ElF4E, EPHX1, ErbB3, EstR1, FBX05, FHIT1 FRP1, GAPDH, GATA3, G-Catenin, GRB7, GRO1, GSTM1, GUS, HER2, HIF1A, HNF3A, IGF1R, IGFBP2, KLK10, KRT14, KRT17, KRT18, KRT19, KRT5, Maspin, MCM2, MCM3, MDM2, MMP9, MTA1, MYBL2, P14ARF, p27, P53, PI3KC2A, PR, PRAME, pS2, RAD51C,.3RB1, RIZ1, STK15, STMY3, SURV, TGFA, TOP2B, TP53BP2, TRAIL, TS, upa, VDR, VEGF, and ZNF217.
In particular embodiments, the array comprises polynucleotides hybridizing to at least 3, or at least 5, or at least 10, or at least 15, or at least 20, or all of the genes listed above.
In another specific embodiment, the array comprises polynucleotides hybridizing to the following genes: TP53BP2, GRB7, PR, CD68, Bc12, KRT14, IRS1, CTSL, EstR1, Chkl, IGFBP2, BAG1, CEGP1, STK15, GSTM1, FHIT, RIZ1, AlB1, SURV, BBC3, IGF1R, p27, GATA3, ZNF217, EGFR, CD9, MYBL2, HIF1a, pS2, RIZ1, ErbB3, TOP2B, MDM2, RAD51C, KRT19, TS, Her2, KLK10, 13-Catenin, y-Catenin, MCM2, PI3KC2A, IGF1, TBP, CCNB1, FBX05 and DR5.
The polynucleotides can be cDNAs, or oligonucleotides, and the solid surface on which they are displayed may, for example, be glass.
In another aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, comprising the steps of:
(1) determining the expression levels of the RNA transcripts or the expression products of genes or a gene set selected from the group consisting of (a) TP53BP2, Bc12, BAD, EPHX1, PDGFR13, DIABLO, XIAP, YB1, CA9, and KRT8;
(b) GRB7, CD68, TOP2A, Bc12, DIABLO, CD3, ID1, PPM1D, MCM6, and WISP1;
(c) PR, TP53BP2, PRAME, DIABLO, CTSL, IGFBP2, TIMP1, CA9, MMP9, and COX2;
(d) CD68, GRB7, TOP2A, Bc12, DIABLO, CD3, PPM1D, MCM6, and WISP1;
(e) Bc12, TP53BP2, BAD, EPHX1, PDGFR13, DIABLO, XIAP, YB1, CA9, and KRT8;
(f) KRT14, KRT5, PRA_ME, TP5311P2, GUS1, A1B1, MCM3, CCNE1, MCM6, and 11:301;
4 (g) PRAME, TP53BP2, EstR1, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB;
(h) CTSL2, GRB7, TOP2A, CCNB1, Bc12, DIABLO, PRAME, EMS1, CA9, and EpCAM;
(i) EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB;
(k) Chkl, PRAME, TP53BP2, GRB7, CA9, CTSL, CCNB1, TOP2A, tumor size, and IGFBP2;
(1) IGFBP2, GRB7, PRAME, DIABLO, CTSL, 13-Catenin, PPM1D, Chkl, WISP1, and LOT1;
(m) HER2, TP53BP2, Bc12, DIABLO, TIMP1, EPHX1, TOP2A, TRAIL, CA9, and AREG;
(n) BAG1, TP53BP2, PRAME, 1L6, CCNB1, PAI1, AREG, tumor size, CA9, and Ki67;
(o) CEGP1, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, and AKT2, and FGF18;
(p) STK15, TP53BP2, PRAME, IL6, CCNE1, AKT2, DIABLO, cMet, CCNE2, and COX2;
(q) KLK10, EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, and BBC3;
(r) A161, TP53BP2, Bc12, DIABLO, TIMP1, CD3, p53, CA9, GRB7, and EPHX1 (s) BBC3, GRB7, CD68, PRAME, TOP2A, CCNB1, EPHX1, CTSL
GSTM1, and APC;
(0 CD9, GRB7, CD68, TOP2A, Bc12, CCNB1, CD3, DIABLO, 1D1, and PPM1D;
(w) EGFR, KRT14, GRB7, TOP2A, CCNB1, CTSL, Bc12, TP, KLK10, and CA9;
(x) HIF1a, PR, DIABLO, PRAME, Chkl, AKT2, GRB7, CCNE1, TOP2A, and CCNB1;
(y) MDM2, TP53BP2, DIABLO, Bc12, A161, TIMP1, CD3, p53, CA9, and HER2;
(z) MYBL2, TP53BP2, PRAME, I1L6, Bc12, DIABLO, CCNE1, EPHX1, TIMP1, and CA9;
(aa) p27, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, AKT2, and ID1;
(ab) RAD51, GRB7, CD68, TOP2A, CIAP2, CCNB1, BAG1, IL6, FGFR1, and TP53BP2;
(ac) SLTRV, GRB7, TOP2A, PRAME, CTSL, GSTM1, CCNB1, VDR, CA9; and CCNE2;
(ad) TOP2B, TP53BP2, DIABLO, Bc12, TIMP1, AIB1, CA9, p53, KRT8, and BAD;
(h) CTSL2, GRB7, TOP2A, CCNB1, Bc12, DIABLO, PRAME, EMS1, CA9, and EpCAM;
(i) EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB;
(k) Chkl, PRAME, TP53BP2, GRB7, CA9, CTSL, CCNB1, TOP2A, tumor size, and IGFBP2;
(1) IGFBP2, GRB7, PRAME, DIABLO, CTSL, 13-Catenin, PPM1D, Chkl, WISP1, and LOT1;
(m) HER2, TP53BP2, Bc12, DIABLO, TIMP1, EPHX1, TOP2A, TRAIL, CA9, and AREG;
(n) BAG1, TP53BP2, PRAME, 1L6, CCNB1, PAI1, AREG, tumor size, CA9, and Ki67;
(o) CEGP1, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, and AKT2, and FGF18;
(p) STK15, TP53BP2, PRAME, IL6, CCNE1, AKT2, DIABLO, cMet, CCNE2, and COX2;
(q) KLK10, EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, and BBC3;
(r) A161, TP53BP2, Bc12, DIABLO, TIMP1, CD3, p53, CA9, GRB7, and EPHX1 (s) BBC3, GRB7, CD68, PRAME, TOP2A, CCNB1, EPHX1, CTSL
GSTM1, and APC;
(0 CD9, GRB7, CD68, TOP2A, Bc12, CCNB1, CD3, DIABLO, 1D1, and PPM1D;
(w) EGFR, KRT14, GRB7, TOP2A, CCNB1, CTSL, Bc12, TP, KLK10, and CA9;
(x) HIF1a, PR, DIABLO, PRAME, Chkl, AKT2, GRB7, CCNE1, TOP2A, and CCNB1;
(y) MDM2, TP53BP2, DIABLO, Bc12, A161, TIMP1, CD3, p53, CA9, and HER2;
(z) MYBL2, TP53BP2, PRAME, I1L6, Bc12, DIABLO, CCNE1, EPHX1, TIMP1, and CA9;
(aa) p27, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, AKT2, and ID1;
(ab) RAD51, GRB7, CD68, TOP2A, CIAP2, CCNB1, BAG1, IL6, FGFR1, and TP53BP2;
(ac) SLTRV, GRB7, TOP2A, PRAME, CTSL, GSTM1, CCNB1, VDR, CA9; and CCNE2;
(ad) TOP2B, TP53BP2, DIABLO, Bc12, TIMP1, AIB1, CA9, p53, KRT8, and BAD;
5 (ae) ZNF217, GRB7, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, APC4, and f3-Catenin, in a breast cancer tissue sample obtained from the patient, normalized against the expression levels of all RNA transcripts or their expression products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;
(2) subjecting the data obtained in step (1) to statistical analysis; and (3) determining whether the likelihood of said long-term survival has increased or decreased.
In a further aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, comprising the steps of:
(1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of CD68;
CTSL; FBX05;
SURV; CCNB1; MCM2; Chkl; MYBL2; H1F1A; cMET; EGFR; TS; STK15, IGFR1; BC12;
HNF3A; TP53BP2; GATA3 ; BB C3 ; RAD51C ; BAG1 ; IGFBP2; PR; CD9; RBI; EPHX1;
CEGP1; TRAIL; DR5; p27; p53; MTA; RIZ1; ErbB3; TOP2B; EIF4E, wherein expression of the following genes in ER-positive cancer is indicative of a reduced likelihood of survival without cancer recurrence following surgery: CD68; CTSL; FBX05; SURV; CCNB1;
MCM2; Chkl; MYBL2; H1F1A; cMET; EGFR; TS; STK15, and wherein expression of the following genes is indicative of a better prognosis for survival without cancer recurrence following surgery: IGFR1; BC12; HNF3A; TP53BP2; GATA3; BBC3; RAD51C; BAG1;
IGFBP2; PR; CD9; RB1; EPHX1; CEGP1; TRAIL; DR5; p27; p53; MTA; RIZ1; ErbB3;
TOP2B; ElF4E.
(2) subjecting the data obtained in step (1) to statistical analysis; and (3) determining whether the likelihood of said long-term survival has increased or decreased.
In yet another aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-negative invasive breast cancer, without the recurrence of breast cancer, comprising determining the expression levels of the RNA transcripts or the expression products of genes of the gene set CCND1; UPA;
HNF3A; CDH1; Her2 ; GRB7; AKT1 ; STMY3 ; a-Catenin; VDR; GR01; KT14 ; KLK10;
Maspin, TGFa, and FRP1, wherein expression of the following genes is indicative of a
(2) subjecting the data obtained in step (1) to statistical analysis; and (3) determining whether the likelihood of said long-term survival has increased or decreased.
In a further aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, comprising the steps of:
(1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of CD68;
CTSL; FBX05;
SURV; CCNB1; MCM2; Chkl; MYBL2; H1F1A; cMET; EGFR; TS; STK15, IGFR1; BC12;
HNF3A; TP53BP2; GATA3 ; BB C3 ; RAD51C ; BAG1 ; IGFBP2; PR; CD9; RBI; EPHX1;
CEGP1; TRAIL; DR5; p27; p53; MTA; RIZ1; ErbB3; TOP2B; EIF4E, wherein expression of the following genes in ER-positive cancer is indicative of a reduced likelihood of survival without cancer recurrence following surgery: CD68; CTSL; FBX05; SURV; CCNB1;
MCM2; Chkl; MYBL2; H1F1A; cMET; EGFR; TS; STK15, and wherein expression of the following genes is indicative of a better prognosis for survival without cancer recurrence following surgery: IGFR1; BC12; HNF3A; TP53BP2; GATA3; BBC3; RAD51C; BAG1;
IGFBP2; PR; CD9; RB1; EPHX1; CEGP1; TRAIL; DR5; p27; p53; MTA; RIZ1; ErbB3;
TOP2B; ElF4E.
(2) subjecting the data obtained in step (1) to statistical analysis; and (3) determining whether the likelihood of said long-term survival has increased or decreased.
In yet another aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-negative invasive breast cancer, without the recurrence of breast cancer, comprising determining the expression levels of the RNA transcripts or the expression products of genes of the gene set CCND1; UPA;
HNF3A; CDH1; Her2 ; GRB7; AKT1 ; STMY3 ; a-Catenin; VDR; GR01; KT14 ; KLK10;
Maspin, TGFa, and FRP1, wherein expression of the following genes is indicative of a
6 reduced likelihood of survival without cancer recurrence: CCND1; UPA; HNF3A;
CDH1;
Her2; GRB7; AKT1; STMY3; a-Catenin; VDR; GRO1, and wherein expression of the following genes is indicative of a better prognosis for survival without cancer recurrence:
KT14; KLK10; Maspin, TGFa, and FRP1.
In a different aspect, the invention concerns a method of preparing a personalized genomics profile for a patient, comprising the steps of:
(a) subjecting RNA extracted from a breast tissue obtained from the patient to gene expression analysis;
(b) determining the expression level of one or more genes selected from the breast cancer gene set listed in any one of Tables 1-5, wherein the expression level is normalized against a control gene or genes and optionally is compared to the amount found in a breast cancer reference tissue set; and (c) creating a report summarizing the data obtained by the gene expression analysis.
The report may, for example, include prediction of the likelihood of long term survival of the patient and/or recommendation for a treatment modality of said patient.
In a further aspect, the invention concerns a method for amplification of a gene listed in Tables 5A and B by polymerase chain reaction (PCR), comprising performing said PCR by using an amplicon listed in Tables 5A and B and a primer-probe set listed in Tables 6A-F.
In a still further aspect, the invention concerns a PCR amplicon listed in Tables 5A and B.
In yet another aspect, the invention concerns a PCR primer-probe set listed in Tables 6A-F.
The invention further concerns a prognostic method comprising:
(a) subjecting a sample comprising breast cancer cells obtained from a patient to quantitative analysis of the expression level of the RNA transcript of at least one gene selected from the group consisting of GRB7, CD68, CTSL, Chkl, A1B1, CCNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, MYBL2, HIFI a, and TS, or their product, and (b) identifying the patient as likely to have a decreased likelihood of long-term survival without breast cancer recurrence if the normalized expression levels of the gene or genes, or their products, are elevated above a defined expression threshold.
In a different aspect, the invention concerns a prognostic method comprising:
CDH1;
Her2; GRB7; AKT1; STMY3; a-Catenin; VDR; GRO1, and wherein expression of the following genes is indicative of a better prognosis for survival without cancer recurrence:
KT14; KLK10; Maspin, TGFa, and FRP1.
In a different aspect, the invention concerns a method of preparing a personalized genomics profile for a patient, comprising the steps of:
(a) subjecting RNA extracted from a breast tissue obtained from the patient to gene expression analysis;
(b) determining the expression level of one or more genes selected from the breast cancer gene set listed in any one of Tables 1-5, wherein the expression level is normalized against a control gene or genes and optionally is compared to the amount found in a breast cancer reference tissue set; and (c) creating a report summarizing the data obtained by the gene expression analysis.
The report may, for example, include prediction of the likelihood of long term survival of the patient and/or recommendation for a treatment modality of said patient.
In a further aspect, the invention concerns a method for amplification of a gene listed in Tables 5A and B by polymerase chain reaction (PCR), comprising performing said PCR by using an amplicon listed in Tables 5A and B and a primer-probe set listed in Tables 6A-F.
In a still further aspect, the invention concerns a PCR amplicon listed in Tables 5A and B.
In yet another aspect, the invention concerns a PCR primer-probe set listed in Tables 6A-F.
The invention further concerns a prognostic method comprising:
(a) subjecting a sample comprising breast cancer cells obtained from a patient to quantitative analysis of the expression level of the RNA transcript of at least one gene selected from the group consisting of GRB7, CD68, CTSL, Chkl, A1B1, CCNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, MYBL2, HIFI a, and TS, or their product, and (b) identifying the patient as likely to have a decreased likelihood of long-term survival without breast cancer recurrence if the normalized expression levels of the gene or genes, or their products, are elevated above a defined expression threshold.
In a different aspect, the invention concerns a prognostic method comprising:
7 (a) subjecting a sample comprising breast cancer cells obtained from a patient to quantitative analysis of the expression level of the RNA transcript of at least one gene selected from the group consisting of TP53BP2, PR, Bc12, KRT14, EstR1, IGFBP2, BAG1, CEGP1, KLK10, f3-Catenin, 7-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGF1, and KRT19, and (b) identifying the patient as likely to have an increased likelihood of long-term survival without breast cancer recurrence if the normalized expression levels of the gene or genes, or their products, are elevated above a defined expression threshold.
The invention further concerns a kit comprising one or more of (1) extraction buffer/reagents and protocol; (2) reverse transcription buffer/reagents and protocol; and (3) qPCR buffer/reagents and protocol suitable for performing any of the foregoing methods.
The invention further concerns a kit comprising one or more of (1) extraction buffer/reagents and protocol; (2) reverse transcription buffer/reagents and protocol; and (3) qPCR buffer/reagents and protocol suitable for performing any of the foregoing methods.
8 Description of the Tables Table 1 is a list of genes, expression of which correlate with breast cancer survival.
Results from a retrospective clinical trial. Binary statistical analysis.
Table 2 is a list of genes, expression of which correlates with breast cancer survival in estrogen receptor (ER) positive patients. Results from a retrospective clinical trial. Binary statistical analysis.
Table 3 is a list of genes, expression of which correlates with breast cancer survival in estrogen receptor (ER) negative patients. Results from a retrospective clinical trial. Binary statistical analysis.
Table 4 is a list of genes, expression of which correlates with breast cancer survival.
Results from a retrospective clinical trial. Cox proportional hazards statistical analysis.
Tables 5A and B show a list of genes, expression of which correlate with breast cancer survival. Results from a retrospective clinical trial. The table includes accession numbers for the genes, and amplicon sequences used for PCR amplification.
Tables 6A-6F The table includes sequences for the forward and reverse primers (designated by "f' and "r", respectively) and probes (designated by "p") used for PCR
amplification of the amplicons listed in Tables 5A-B.
Detailed Description of the Preferred Embodiment A. Definitions Unless defined otherwise, technical and scientific terms used herein have the smile meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J.
Wiley & Sons (New York, NY 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, NY 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.
One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention.
Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defmed below.
Results from a retrospective clinical trial. Binary statistical analysis.
Table 2 is a list of genes, expression of which correlates with breast cancer survival in estrogen receptor (ER) positive patients. Results from a retrospective clinical trial. Binary statistical analysis.
Table 3 is a list of genes, expression of which correlates with breast cancer survival in estrogen receptor (ER) negative patients. Results from a retrospective clinical trial. Binary statistical analysis.
Table 4 is a list of genes, expression of which correlates with breast cancer survival.
Results from a retrospective clinical trial. Cox proportional hazards statistical analysis.
Tables 5A and B show a list of genes, expression of which correlate with breast cancer survival. Results from a retrospective clinical trial. The table includes accession numbers for the genes, and amplicon sequences used for PCR amplification.
Tables 6A-6F The table includes sequences for the forward and reverse primers (designated by "f' and "r", respectively) and probes (designated by "p") used for PCR
amplification of the amplicons listed in Tables 5A-B.
Detailed Description of the Preferred Embodiment A. Definitions Unless defined otherwise, technical and scientific terms used herein have the smile meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J.
Wiley & Sons (New York, NY 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, NY 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.
One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention.
Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defmed below.
9 The term "microarray" refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.
The term "polynucleotide," when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single-and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide"
specifically includes cDNAs. The term includes DNAs (including cDNAs) and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA
characteristic of viruses and cells, including simple and complex cells.
The term "oligonucleotide" refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available.
However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.
The terms "differentially expressed gene," "differential gene expression" and their synonyms, which are used interchangeably, refer to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as breast cancer, relative to its expression in a normal or control subject. The terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease.
It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA
levels, surface expression, secretion or other partitioning of a polypeptide, for example.
Differential gene expression may include a comparison of expression between two or more genes or their gene products, or a comparison of the ratios of the expression between two or more genes or their gene products, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease.
Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages. For the purpose of this invention, "differential gene expression" is considered to be present when there is at least an about two-fold, preferably at least about four-fold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.
The phrase "gene amplification" refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as "amplicon." Usually, the amount of the messenger RNA (mRNA) produced, i.e., the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.
The term "diagnosis" is used herein to refer to the identification of a molecular or pathological state, disease or condition, such as the identification of a molecular subtype of head and neck cancer, colon cancer, or other type of cancer.
The term "prognosis" is used herein to refer to the prediction of the likelihood of cancer-attributable death or progression, including recurrence, metastatic spread, and drug resistance, of a neoplastic disease, such as breast cancer.
The term "prediction" is used herein to refer to the likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs, and also the extent of those responses, or that a patient will survive, following surgical removal or the primary tumor and/or chemotherapy for a certain period of time without cancer recurrence.
The predictive methods of the present invention can be used clinically to make treatment decisions by choosing the most appropriate treatment modalities for any particular patient.
The predictive methods of the present invention are valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such as surgical intervention, chemotherapy with a given drug or drug combination, and/or radiation therapy, or whether long-term survival of the patient, following sugery and/or termination of chemotherapy or other treatment modalities is likely.
The term "long-term" survival is used herein to refer to survival for at least 3 years, more preferably for at least 8 years, most preferably for at least 10 years following surgery or other treatment.
The term "tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
The "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so.
For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
"Stringent conditions" or "high stringency conditions", as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50 C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Fico11/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaC1, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA
(50 tig/m1), 0.1% SDS, and 10% dextran sulfate at 42 C, with washes at 42 C in 0.2 x SSC
(sodium chloride/sodium citrate) and 50% formamide at 55 C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 C.
"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37 C in a solution comprising:
20%
formamide, 5 x SSC (150 mM NaC1, 15 mI\4 trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 C.
The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
In the context of the present invention, reference to "at least one," "at least two," "at least five," etc. of the genes listed in any particular gene set means any one or any and all combinations of the genes listed.
The terms "expression threshold," and "defined expression threshold" are used interchangeably and refer to the level of a gene or gene product in question above which the gene or gene product serves as a predictive marker for patient survival without cancer recurrence. The threshold is defined experimentally from clinical studies such as those described in the Example below. The expression threshold can be selected either for maximum sensitivity, or for maximum selectivity, or for minimum error. The determination of the expression threshold for any situation is well within the knowledge of those skilled in the art.
B. Detailed Description The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning:
A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis"
(M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology"
(Academic Press, Inc.); "Handbook of Experimental Immunology", 4th edition (D.M. Weir &
C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Cabs, eds., 1987); "Current Protocols in Molecular Biology"
(F.M. Ausubel et al., eds., 1987); and "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994).
1. Gene Expression Profiling In general, methods of gene expression profiling can be divided into two large groups:
methods based on hybridization analysis of polynucleotides, and methods based on sequencing of polynucleotides. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker & Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNAse protection assays (Hod, Biotechniques 13:852-854 (1992)); and reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)).
Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.
Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPS S).
2. Reverse Transcriptase PCR (RT-PCR) Of the techniques listed above, the most sensitive and most flexible quantitative method is RT-PCR, which can be used to compare mRNA levels in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure.
The first step is the isolation of mRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors, including breast, lung, colon, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.
General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest.
56:A67 (1987), and De Andres et al., BioTechniques 18:42044 (1995). In particular, RNA
isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPureTM Complete DNA and RNA
Purification Kit (EPICENTRE , Madison, WI), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA
prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.
As RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.
Although the PCR step can use a variety of thermostable DNA-dependent DNA
polymerases, it typically employs the Taq DNA polymerase, which has a 5' -3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. Thus, TaqMan PCR typically utilizes the 5'-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used.
Two oligonucleotide primers are used to generate an amplicon typical of a PCR
reaction. A
third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
TaqMan RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700TM Sequence Detection SystemTm (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700TM Sequence Detection SystemTM.
The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler.
During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.
5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle.
As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (CO.
To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and 3-actin.
A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held et al., Genome Research 6:986-994 (1996).
The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles {for example: T.E.
Godfrey et al,. J. Molec. Diagnostics 2: 84-91 [2000]; K. Specht et al., Am.
J. Pathol. 158:
419-29 [2001]}. Briefly, a representative process starts with cutting about 10 [tm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR.
According to one aspect of the present invention, PCR primers and probes are designed based upon intron sequences present in the gene to be amplified. In this embodiment, the first step in the primer/probe design is the delineation of intron sequences within the genes. This can be done by publicly available software, such as the DNA BLAT
software developed by Kent, W.J., Genome Res. 12(4):656-64 (2002), or by the BLAST
software including its variations. Subsequent steps follow well established methods of PCR
primer and probe design.
In order to avoid non-specific signals, it is important to mask repetitive sequences within the introns when designing the primers and probes. This can be easily accomplished by using the Repeat Masker program available on-line through the Baylor College of Medicine, which screens DNA sequences against a library of repetitive elements and returns a query sequence in which the repetitive elements are masked. The masked intron sequences can then be used to design primer and probe sequences using any commercially or otherwise publicly available primer/probe design packages, such as Primer Express (Applied Biosystems); MGB assay-by¨design (Applied Biosystems); Primer3 (Steve Rozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general users and for biologist programmers.
In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, pp 365-386) The most important factors considered in PCR primer design include primer length, melting temperature (Tm), and G/C content, specificity, complementary primer sequences, and 3'-end sequence. In general, optimal PCR primers are generally 17-30 bases in length, and contain about 20-80%, such as, for example, about 50-60% G+C bases. Tm's between 50 and 80 C, e.g. about 50 to 70 C are typically preferred.
For further guidelines for PCR primer and probe design see, e.g. Dieffenbach, C.W. et al., "General Concepts for PCR Primer Design" in: PCR Primer, A Laboratoly Manual, Cold Spring Harbor Laboratory Press, New York, 1995, pp. 133-155; Innis and Gelfand, "Optimization of PCRs" in: PCR Protocols, A Guide to Methods and Applications, CRC
Press, London, 1994, pp. 5-11; and Plasterer, T.N. Primerselect; Primer and probe design.
Methods MoL Biol. 70:520-527 (1997).
3. MicToan-ays Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of breast cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology.
In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.
In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA
clones are applied to a substrate in a dense array. Preferably at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions.
Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA
probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera.
Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA
abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)).
Micro array analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's micro array technology.
The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.
4. Serial Analysis of Gene Expression (SAGE) Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g.
Velculescu et aL, Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).
5. MassARRAY Technology The MassARRAY (Sequenom, San Diego, California) technology is an automated, high-throughput method of gene expression analysis using mass spectrometry (MS) for detection. According to this method, following the isolation of RNA, reverse transcription and PCR amplification, the cDNAs are subjected to primer extension. The cDNA-derived primer extension products are purified, and dipensed on a chip array that is pre-loaded with the components needed for MALTI-TOF MS sample preparation. The various cDNAs present in the reaction are quantitated by analyzing the peak areas in the mass spectrum obtained.
6. Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS) This method, described by Brenner et al., Nature Biotechnology 18:630-634 (2000), is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 [tm diameter microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template-containing microbeads in a flow cell at a high density (typically greater than 3 x 106 microbeads/cm2). The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately provide, in a single operation, hundreds of thousands of gene signature sequences from a yeast cDNA library.
7. Immunohistochemistry Immunohistochemistry methods are also suitable for detecting the expression levels of the prognostic markers of the present invention. Thus, antibodies or antisera, preferably polyclonal antisera, and most preferably monoclonal antibodies specific for each marker are used to detect expression. The antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase.
Alternatively, unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody. Immunohistochemistry protocols and kits are well known in the art and are commercially available.
8. Proteomics The term "proteome" is defined as the totality of the proteins present in a sample (e.g.
tissue, organism, or cell culture) at a certain point of time. Proteomics includes, among other things, study of the global changes of protein expression in a sample (also referred to as "expression proteomics"). Proteomics typically includes the following steps:
(1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual proteins recovered from the gel, e.g. my mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods, to detect the products of the prognostic markers of the present invention.
9. General Description of the mRNA Isolation, Purification and Amplification The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles {for example: T.E.
Godfrey et al. J. Molec. Diagnostics 2: 84-91 [2000]; K. specht et al., Am. J.
Pathol. 158:
419-29 [2001]}. Briefly, a representative process starts with cutting about 10 pm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumor sample examined.
The term "polynucleotide," when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single-and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide"
specifically includes cDNAs. The term includes DNAs (including cDNAs) and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA
characteristic of viruses and cells, including simple and complex cells.
The term "oligonucleotide" refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available.
However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.
The terms "differentially expressed gene," "differential gene expression" and their synonyms, which are used interchangeably, refer to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as breast cancer, relative to its expression in a normal or control subject. The terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease.
It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA
levels, surface expression, secretion or other partitioning of a polypeptide, for example.
Differential gene expression may include a comparison of expression between two or more genes or their gene products, or a comparison of the ratios of the expression between two or more genes or their gene products, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease.
Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages. For the purpose of this invention, "differential gene expression" is considered to be present when there is at least an about two-fold, preferably at least about four-fold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.
The phrase "gene amplification" refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as "amplicon." Usually, the amount of the messenger RNA (mRNA) produced, i.e., the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.
The term "diagnosis" is used herein to refer to the identification of a molecular or pathological state, disease or condition, such as the identification of a molecular subtype of head and neck cancer, colon cancer, or other type of cancer.
The term "prognosis" is used herein to refer to the prediction of the likelihood of cancer-attributable death or progression, including recurrence, metastatic spread, and drug resistance, of a neoplastic disease, such as breast cancer.
The term "prediction" is used herein to refer to the likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs, and also the extent of those responses, or that a patient will survive, following surgical removal or the primary tumor and/or chemotherapy for a certain period of time without cancer recurrence.
The predictive methods of the present invention can be used clinically to make treatment decisions by choosing the most appropriate treatment modalities for any particular patient.
The predictive methods of the present invention are valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such as surgical intervention, chemotherapy with a given drug or drug combination, and/or radiation therapy, or whether long-term survival of the patient, following sugery and/or termination of chemotherapy or other treatment modalities is likely.
The term "long-term" survival is used herein to refer to survival for at least 3 years, more preferably for at least 8 years, most preferably for at least 10 years following surgery or other treatment.
The term "tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
The "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so.
For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
"Stringent conditions" or "high stringency conditions", as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50 C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Fico11/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaC1, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA
(50 tig/m1), 0.1% SDS, and 10% dextran sulfate at 42 C, with washes at 42 C in 0.2 x SSC
(sodium chloride/sodium citrate) and 50% formamide at 55 C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 C.
"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37 C in a solution comprising:
20%
formamide, 5 x SSC (150 mM NaC1, 15 mI\4 trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50 C.
The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
In the context of the present invention, reference to "at least one," "at least two," "at least five," etc. of the genes listed in any particular gene set means any one or any and all combinations of the genes listed.
The terms "expression threshold," and "defined expression threshold" are used interchangeably and refer to the level of a gene or gene product in question above which the gene or gene product serves as a predictive marker for patient survival without cancer recurrence. The threshold is defined experimentally from clinical studies such as those described in the Example below. The expression threshold can be selected either for maximum sensitivity, or for maximum selectivity, or for minimum error. The determination of the expression threshold for any situation is well within the knowledge of those skilled in the art.
B. Detailed Description The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning:
A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis"
(M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology"
(Academic Press, Inc.); "Handbook of Experimental Immunology", 4th edition (D.M. Weir &
C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Cabs, eds., 1987); "Current Protocols in Molecular Biology"
(F.M. Ausubel et al., eds., 1987); and "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994).
1. Gene Expression Profiling In general, methods of gene expression profiling can be divided into two large groups:
methods based on hybridization analysis of polynucleotides, and methods based on sequencing of polynucleotides. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker & Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNAse protection assays (Hod, Biotechniques 13:852-854 (1992)); and reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)).
Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.
Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPS S).
2. Reverse Transcriptase PCR (RT-PCR) Of the techniques listed above, the most sensitive and most flexible quantitative method is RT-PCR, which can be used to compare mRNA levels in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure.
The first step is the isolation of mRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors, including breast, lung, colon, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.
General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest.
56:A67 (1987), and De Andres et al., BioTechniques 18:42044 (1995). In particular, RNA
isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPureTM Complete DNA and RNA
Purification Kit (EPICENTRE , Madison, WI), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA
prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.
As RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.
Although the PCR step can use a variety of thermostable DNA-dependent DNA
polymerases, it typically employs the Taq DNA polymerase, which has a 5' -3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. Thus, TaqMan PCR typically utilizes the 5'-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used.
Two oligonucleotide primers are used to generate an amplicon typical of a PCR
reaction. A
third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
TaqMan RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700TM Sequence Detection SystemTm (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700TM Sequence Detection SystemTM.
The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler.
During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.
5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle.
As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (CO.
To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and 3-actin.
A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held et al., Genome Research 6:986-994 (1996).
The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles {for example: T.E.
Godfrey et al,. J. Molec. Diagnostics 2: 84-91 [2000]; K. Specht et al., Am.
J. Pathol. 158:
419-29 [2001]}. Briefly, a representative process starts with cutting about 10 [tm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR.
According to one aspect of the present invention, PCR primers and probes are designed based upon intron sequences present in the gene to be amplified. In this embodiment, the first step in the primer/probe design is the delineation of intron sequences within the genes. This can be done by publicly available software, such as the DNA BLAT
software developed by Kent, W.J., Genome Res. 12(4):656-64 (2002), or by the BLAST
software including its variations. Subsequent steps follow well established methods of PCR
primer and probe design.
In order to avoid non-specific signals, it is important to mask repetitive sequences within the introns when designing the primers and probes. This can be easily accomplished by using the Repeat Masker program available on-line through the Baylor College of Medicine, which screens DNA sequences against a library of repetitive elements and returns a query sequence in which the repetitive elements are masked. The masked intron sequences can then be used to design primer and probe sequences using any commercially or otherwise publicly available primer/probe design packages, such as Primer Express (Applied Biosystems); MGB assay-by¨design (Applied Biosystems); Primer3 (Steve Rozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general users and for biologist programmers.
In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, pp 365-386) The most important factors considered in PCR primer design include primer length, melting temperature (Tm), and G/C content, specificity, complementary primer sequences, and 3'-end sequence. In general, optimal PCR primers are generally 17-30 bases in length, and contain about 20-80%, such as, for example, about 50-60% G+C bases. Tm's between 50 and 80 C, e.g. about 50 to 70 C are typically preferred.
For further guidelines for PCR primer and probe design see, e.g. Dieffenbach, C.W. et al., "General Concepts for PCR Primer Design" in: PCR Primer, A Laboratoly Manual, Cold Spring Harbor Laboratory Press, New York, 1995, pp. 133-155; Innis and Gelfand, "Optimization of PCRs" in: PCR Protocols, A Guide to Methods and Applications, CRC
Press, London, 1994, pp. 5-11; and Plasterer, T.N. Primerselect; Primer and probe design.
Methods MoL Biol. 70:520-527 (1997).
3. MicToan-ays Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of breast cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology.
In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.
In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA
clones are applied to a substrate in a dense array. Preferably at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions.
Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA
probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera.
Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA
abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)).
Micro array analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's micro array technology.
The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.
4. Serial Analysis of Gene Expression (SAGE) Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g.
Velculescu et aL, Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).
5. MassARRAY Technology The MassARRAY (Sequenom, San Diego, California) technology is an automated, high-throughput method of gene expression analysis using mass spectrometry (MS) for detection. According to this method, following the isolation of RNA, reverse transcription and PCR amplification, the cDNAs are subjected to primer extension. The cDNA-derived primer extension products are purified, and dipensed on a chip array that is pre-loaded with the components needed for MALTI-TOF MS sample preparation. The various cDNAs present in the reaction are quantitated by analyzing the peak areas in the mass spectrum obtained.
6. Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS) This method, described by Brenner et al., Nature Biotechnology 18:630-634 (2000), is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 [tm diameter microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template-containing microbeads in a flow cell at a high density (typically greater than 3 x 106 microbeads/cm2). The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately provide, in a single operation, hundreds of thousands of gene signature sequences from a yeast cDNA library.
7. Immunohistochemistry Immunohistochemistry methods are also suitable for detecting the expression levels of the prognostic markers of the present invention. Thus, antibodies or antisera, preferably polyclonal antisera, and most preferably monoclonal antibodies specific for each marker are used to detect expression. The antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase.
Alternatively, unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody. Immunohistochemistry protocols and kits are well known in the art and are commercially available.
8. Proteomics The term "proteome" is defined as the totality of the proteins present in a sample (e.g.
tissue, organism, or cell culture) at a certain point of time. Proteomics includes, among other things, study of the global changes of protein expression in a sample (also referred to as "expression proteomics"). Proteomics typically includes the following steps:
(1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual proteins recovered from the gel, e.g. my mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods, to detect the products of the prognostic markers of the present invention.
9. General Description of the mRNA Isolation, Purification and Amplification The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles {for example: T.E.
Godfrey et al. J. Molec. Diagnostics 2: 84-91 [2000]; K. specht et al., Am. J.
Pathol. 158:
419-29 [2001]}. Briefly, a representative process starts with cutting about 10 pm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumor sample examined.
10. Breast Cancer Gene Set, Assayed Gene Subsequences, and Clinical Application of Gene Expression Data An important aspect of the present invention is to use the measured expression of certain genes by breast cancer tissue to provide prognostic information. For this purpose it is necessary to correct for (normalize away) both differences in the amount of RNA assayed and variability in the quality of the RNA used. Therefore, the assay typically measures and incorporates the expression of certain normalizing genes, including well known housekeeping genes, such as GAPDH and Cypl. Alternatively, normalization can be based on the mean or median signal (Ct) of all of the assayed genes or a large subset thereof (global normalization approach). On a gene-by-gene basis, measured normalized amount of a patient tumor mRNA
is compared to the amount found in a breast cancer tissue reference set. The number (N) of breast cancer tissues in this reference set should be sufficiently high to ensure that different reference sets (as a whole) behave essentially the same way. If this condition is met, the identity of the individual breast cancer tissues present in a particular set will have no significant impact on the relative amounts of the genes assayed. Usually, the breast cancer tissue reference set consists of at least about 30, preferably at least about 40 different FPE
breast cancer tissue specimens. Unless noted otherwise, normalized expression levels for each mRNA/tested tumor/patient will be expressed as a percentage of the expression level measured in the reference set. More specifically, the reference set of a sufficiently high number (e.g. 40) of tumors yields a distribution of normalized levels of each mRNA species.
The level measured in a particular tumor sample to be analyzed falls at some percentile within this range, which can be determined by methods well known in the art. Below, unless noted otherwise, reference to expression levels of a gene assume normalized expression relative to the reference set although this is not always explicitly stated.
Further details of the invention will be described in the following non-limiting Example Example A Phase 11 Study of Gene Expression in 79 Malignant Breast Tumors A gene expression study was designed and conducted with the primary goal to molecularly characterize gene expression in paraffin-embedded, fixed tissue samples of invasive breast ductal carcinoma, and to explore the correlation between such molecular profiles and disease-free survival.
Study design Molecular assays were performed on paraffin-embedded, formalin-fixed primary breast tumor tissues obtained from 79 individual patients diagnosed with invasive breast cancer. All patients in the study had 10 or more positive nodes. Mean age was 57 years, and mean clinical tumor size was 4.4 cm. Patients were included in the study only if histopathologic assessment, performed as described in the Materials and Methods section, indicated adequate amounts of tumor tissue and homogeneous pathology.
Materials and Methods Each representative tumor block was characterized by standard histopathology for diagnosis, semi-quantitative assessment of amount of tumor, and tumor grade. A
total of 6 sections (10 microns in thickness each) were prepared and placed in two Costar Brand Microcentrifuge Tubes (Polypropylene, 1.7 mL tubes, clear; 3 sections in each tube). If the tumor constituted less than 30% of the total specimen area, the sample may have been crudely dissected by the pathologist, using gross microdissection, putting the tumor tissue directly into the Costar tube.
If more than one tumor block was obtained as part of the surgical procedure, the block most representative of the pathology was used for analysis.
Gene Expression Analysis mRNA was extracted and purified from fixed, paraffm-embedded tissue samples, and prepared for gene expression analysis as described in section 9 above.
Molecular assays of quantitative gene expression were performed by RT-PCR, using the ABI PRISM 79001m Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA). ABI PRISM 7900TM consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 384-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 384 wells, and detected at the CCD.
The system includes software for running the instrument and for analyzing the data.
Analysis and Results Tumor tissue was analyzed for 185 cancer-related genes and 7 reference genes.
The threshold cycle (CT) values for each patient were normalized based on the median of the 7 reference genes for that particular patient. Clinical outcome data were available for all patients from a review of registry data and selected patient charts.
Outcomes were classified as:
0 died due to breast cancer or to unknown cause or alive with breast cancer recurrence;
1 alive without breast cancer recurrence or died due to a cause other than breast cancer Analysis was performed by:
1. Analysis of the relationship between normalized gene expression and the binary outcomes of 0 or 1.
2. Analysis of the relationship between normalized gene expression and the time to outcome (0 or 1 as defined above) where patients who were alive without breast cancer recurrence or who died due to a cause other than breast cancer were censored.
This approach was used to evaluate the prognostic impact of individual genes and also sets of multiple genes.
Analysis of patients with invasive breast carcinoma by binary approach In the first (binary) approach, analysis was performed on all 79 patients with invasive breast carcinoma. A t test was performed on the groups of patients classified as either no recurrence and no breast cancer related death at three years, versus recurrence, or breast cancer-related death at three years, and the p-values for the differences between the groups for each gene were calculated.
Table 1 lists the 47 genes for which the p-value for the differences between the groups was <0.10. The first column of mean expression values pertains to patients who neither had a metastatic recurrence of nor died from breast cancer. The second column of mean expression values pertains to patients who either had a metastatic recurrence of or died from breast cancer.
Table 1 Mean Mean t-value df p Valid N
Valid N
Bc12 -0.15748 -1.22816 4.00034 75 0.000147 PR -2.67225 -5.49747 3.61540 75 0.000541 IGF1R -0.59390 -1.71506 3.49158 75 0.000808 BAG1 0.18844 -0.68509 3.42973 75 0.000985 35 CD68 -0.52275 0.10983 -3.41186 75 0.001043 EstR1 -0.35581 -3.00699 3.32190 75 0.001384 CTSL -0.64894 -0.09204 -3.26781 75 0.001637 IGFBP2 -0.81181 -1.78398 3.24158 75 0.001774 35 42 GATA3 1.80525 0.57428 3.15608 75 0.002303 35 TP53BP2 -4.71118 -6.09289 3.02888 75 0.003365 35 42 EstR1 3.67801 1.64693 3.01073 75 0.003550 35 CEGP1 -2.02566 -4.25537 2.85620 75 0.005544 SURV -3.67493 -2.96982 -2.70544 75 0.008439 p27 0.80789 0.28807 2.55401 75 0.012678 35 Chk1 -3.37981 -2.80389 -2.46979 75 0.015793 BBC3 -4.71789 -5.62957 2.46019 75 0.016189 ZNF217 1.10038 0.62730 2.42282 75 0.017814 35 EGFR -2.88172 -2.20556 -2.34774 75 0.021527 CD9 1.29955 0.91025 2.31439 75 0.023386 35 MYBL2 -3.77489 -3.02193 -2.29042 75 0.024809 HIF1A -0.44248 0.03740 -2.25950 75 0.026757 GRB7 -1.96063 -1.05007 -2.25801 75 0.026854 pS2 -1.00691 -3.13749 2.24070 75 0.028006 RIZ1 -7.62149 -8.38750 2.20226 75 0.030720 ErbB3 -6.89508 -7.44326 2.16127 75 0.033866 TOP2B 0.45122 0.12665 2.14616 75 0.035095 35 MDM2 1.09049 0.69001 2.10967 75 0.038223 35 PRAM E -6.40074 -7.70424 2.08126 75 0.040823 GUS -1.51683 -1.89280 2.05200 75 0.043661 RAD51C -5.85618 -6.71334 2.04575 75 0.044288 35 42 AIB1 -3.08217 -2.28784 -2.00600 75 0.048462 STK15 -3.11307 -2.59454 -2.00321 75 0.048768 GAPDH -0.35829 -0.02292 -1.94326 75 0.055737 35 42 FHIT -3.00431 -3.67175 1.86927 75 0.065489 KRT19 2.52397 2.01694 1.85741 75 0.067179 35 TS -2.83607 -2.29048 -1.83712 75 0.070153 GSTM1 -3.69140 -4.38623 1.83397 75 0.070625 G- 0.31875 -0.15524 1.80823 75 0.074580 35 Catenin AKT2 0.78858 0.46703 1.79276 75 0.077043 35 CCNB1 -4.26197 -3.51628 -1.78803 75 0.077810 PI3KC2A -2.27401 -2.70265 1.76748 75 0.081215 35 42 FBX05 -4.72107 -4.24411 -1.75935 75 0.082596 DR5 -5.80850 -6.55501 1.74345 75 0.085353 CIAP1 -2.81825 -3.09921 1.72480 75 0.088683 MCM2 -2.87541 -2.50683 -1.72061 75 0.089445 CCND1 1.30995 0.80905 1.68794 75 0.095578 35 El F4E -5.37657 -6.47156 1.68169 75 0.096788 In the foregoing Table 1, negative t-values indicate higher expression, associated with worse outcomes, and, inversely, higher (positive) t-values indicate higher expression associated with better outcomes. Thus, for example, elevated expression of the CD68 gene (t-value = -3.41, CT mean alive< CT mean deceased) indicates a reduced likelihood of disease free survival. Similarly, elevated expression of the BC12 gene (t-value =
4.00; CT mean alive> CT mean deceased) indicates an increased likelihood of disease free survival.
Based on the data set forth in Table 1, the expression of any of the following genes in breast cancer above a defined expression threshold indicates a reduced likelihood of survival without cancer recurrence following surgery: Grb7, CD68, CTSL, Chkl, Her2, STK15, AIB1, SURV, EGFR, MYBL2, HIFla.
Based on the data set forth in Table 1, the expression of any of the following genes in breast cancer above a defined expression threshold indicates a better prognosis for survival without cancer recurrence following surgery: TP53BP2, PR, Bc12, KRT14, EstR1, IGFBP2, BAG1, CEGP1, KLK10, 13 Catenin, GSTM1, FHIT, Rizl, IGF1, BBC3, IGFR1, TBP, p27, IRS1, IGF1R, GATA3, CEGP1, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, RAD51, and KRT19.
Analysis of ER positivepatients bybinaiy approach 57 patients with normalized CT for estrogen receptor (ER) >0 (i.e., ER
positive patients) were subjected to separate analysis. A t test was performed on the two groups of patients classified as either no recurrence and no breast cancer related death at three years, or recurrence or breast cancer-related death at three years, and the p-values for the differences between the groups for each gene were calculated. Table 2, below, lists the genes where the p-value for the differences between the groups was <0.105. The first column of mean expression values pertains to patients who neither had a metastatic recurrence nor died from breast cancer. The second column of mean expression values pertains to patients who either had a metastatic recurrence of or died from breast cancer.
Table 2 Mean Mean t-value df p Valid N Valid N
IGF1R -0.13975 -1.00435 3.65063 55 0.000584 BcI2 0.15345 -0.70480 3.55488 55 0.000786 CD68 -0.54779 0.19427 -3.41818 55 0.001193 HN F3A 0.39617 -0.63802 3.20750 55 0.002233 CTSL -0.66726 0.00354 -3.20692 55 0.002237 TP53BP2 -4.81858 -6.44425 3.13698 55 0.002741 30 27 GATA3 2.33386 1.40803 3.02958 55 0.003727 30 BBC3 -4.54979 -5.72333 2.91943 55 0.005074 RAD51C -5.63363 -6.94841 2.85475 55 0.006063 30 27 BAG1 0.31087 -0.50669 2.61524 55 0.011485 IGFBP2 -0.49300 -1.30983 2.59121 55 0.012222 30 27 FBX05 -4.86333 -4.05564 -2.56325 55 0.013135 EstR1 0.68368 -0.66555 2.56090 55 0.013214 PR -1.89094 -3.86602 2.52803 55 0.014372 SU RV -3.87857 -3.10970 -2.49622 55 0.015579 CD9 1.41691 0.91725 2.43043 55 0.018370 30 RBI -2.51662 -2.97419 2.41221 55 0.019219 EPHX1 -3.91703 -5.85097 2.29491 55 0.025578 CEGP1 -1.18600 -2.95139 2.26608 55 0.027403 CCN B1 -4.44522 -3.35763 -2.25148 55 0.028370 TRAIL 0.34893 -0.56574 2.20372 55 0.031749 EstR1 4.60346 3.60340 2.20223 55 0.031860 30 D R5 -5.71827 -6.79088 2.14548 55 0.036345 MCM2 -2.96800 -2.48458 -2.10518 55 0.039857 Chk1 -3.46968 -2.85708 -2.08597 55 0.041633 p27 0.94714 0.49656 2.04313 55 0.045843 30 MYBL2 -3.97810 -3.14837 -2.02921 55 0.047288 GUS -1.42486 -1.82900 1.99758 55 0.050718 P53 -1.08810 -1.47193 1.92087 55 0.059938 HIF1A -0.40925 0.11688 -1.91278 55 0.060989 cMet -6.36835 -5.58479 -1.88318 55 0.064969 EGFR -2.95785 -2.28105 -1.86840 55 0.067036 MTA1 -7.55365 -8.13656 1.81479 55 0.075011 RIZ1 -7.52785 -8.25903 1.79518 55 0.078119 ErbB3 -6.62488 -7.10826 1.79255 55 0.078545 TOP2B 0.54974 0.27531 1.74888 55 0.085891 30 ElF4E -5.06603 -6.31426 1.68030 55 0.098571 TS -2.95042 -2.36167 -1.67324 55 0.099959 STK15 -3.25010 -2.72118 -1.64822 55 0.105010 For each gene, a classification algorithm was utilized to identify the best threshold value (CT) for using each gene alone in predicting clinical outcome.
Based on the data set forth in Table 2, expression of the following genes in ER-positive cancer above a defined expression level is indicative of a reduced likelihood of survival without cancer recurrence following surgery: CD68; CTSL; FBX05;
SLTRV;
CCNB1; MCM2; Chkl; MYBL2; HIF1A; cMET; EGFR; TS; STK15. Many of these genes (CD68, CTSL, SLTRV, CCNB1, MCM2, Chkl, MYBL2, EGFR, and STK15) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-positive breast cancer. Based on the data set forth in Table 2, expression of the following genes in ER-positive cancer above a defined expression level is indicative of a better prognosis for survival without cancer recurrence following surgery: IGFR1; BC12; HNF3A;
TP53BP2;
GATA3; BBC3; RAD51C; BAG1; IGFBP2; PR; CD9; RB1; EPHX1; CEGP1; TRAIL; DR5;
p27; p53; MTA; RIZ1; ErbB3; TOP2B; ElF4E. Of the latter genes, IGFR1; BC12;
TP53BP2;
GATA3; BBC3; RAD51C; BAG1; IGFBP2; PR; CD9; CEGP1; DR5; p27; RIZ1; ErbB3;
TOP2B; EIF4E have also been identified as indicators of good prognosis in the previous analysis, not limited to ER-positive breast cancer.
Analysis of ER negative patients by binary approach Twenty patients with normalized CT for estrogen receptor (ER) <1.6 (i.e., ER
negative patients) were subjected to separate analysis. A t test was performed on the two groups of patients classified as either no recurrence and no breast cancer related death at three years, or recurrence or breast cancer-related death at three years, and the p-values for the differences between the groups for each gene were calculated. Table 3 lists the genes where the p-value for the differences between the groups was <0.118. The first column of mean expression values pertains to patients who neither had a metastatic recurrence nor died from breast cancer. The second column of mean expression values pertains to patients who either had a metastatic recurrence of or died from breast cancer.
Table 3 Mean Mean t-value df 13 Valid N
Valid N
KRT14 -1.95323 -6.69231 4.03303 18 0.000780 KLK10 -2.68043 -7.11288 3.10321 18 0.006136 CCND1 -1.02285 0.03732 -2.77992 18 0.012357 Upa -0.91272 -0.04773 -2.49460 18 0.022560 HNF3A -6.04780 -2.36469 -2.43148 18 0.025707 Maspin -3.56145 -6.18678 2.40169 18 0.027332 CDH1 -3.54450 -2.34984 -2.38755 18 0.028136 HER2 -1.48973 1.53108 -2.35826 18 0.029873 5 15 =
GRB7 -2.55289 0.00036 -2.32890 18 0.031714 AKT1 -0.36849 0.46222 -2.29737 18 0.033807 TGFA -4.03137 -5.67225 2.28546 18 0.034632 FRP1 1.45776 -1.39459 2.27884 18 0.035097 STMY3 -1.59610 -0.26305 -2.23191 18 0.038570 Contig 2 _4.27585 -7.34338 2.18700 18 0.042187 A-Catenin -1.19790 -0.39085 -2.15624 18 0.044840 5 15 VDR -4.37823 -2.37167 -2.15620 18 0.044844 GRO1 -3.65034 -5.97002 2.12286 18 0.047893 MCM3 -3.86041 -5.55078 2.10030 18 0.050061 B-actin 4.69672 5.19190 -2.04951 18 0.055273 HIFI A -0.64183 -0.10566 -2.02301 18 0.058183 MMP9 -8.90613 -7.35163 -1.88747 18 0.075329 VEGF 0.37904 1.10778 -1.87451 18 0.077183 PRAM E -4.95855 -7.41973 1.86668 18 0.078322 AlB1 -3.12245 -1.92934 -1.86324 18 0.078829 KRT5 -1.32418 -3.62027 1.85919 18 0.079428 KRT18 1.08383 2.25369 -1.83831 18 0.082577 KRT17 -0.69073 -3.56536 1.78449 18 0.091209 P14ARF -1.87104 -3.36534 1.63923 18 0.118525 5 15 =
Based on the data set forth in Table 3, expression of the following genes in ER-negative cancer above a defined expression level is indicative of a reduced likelihood of survival without cancer recurrence (p<0.05): CCND1; UPA; NF3A; CDH1; Her2;
GRB7;
AKT1; STMY3; a-Catenin; VDR; GROl. Only 2 of these genes (Her2 and Grb7) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-negative breast cancer. Based on the data set forth in Table 3, expression of the following genes in ER-negative cancer above a defined expression level is indicative of a better prognosis for survival without cancer recurrence (KT14; KLK10; Maspin, TGFa, and FRP1. Of the latter genes, only KLK10 has been identified as an indicator of good prognosis in the previous analysis, not limited to ER-negative breast cancer.
Analysis of multiple genes and indicators of outcome Two approaches were taken in order to determine whether using multiple genes would provide better discrimination between outcomes.
First, a discrimination analysis was performed using a forward stepwise approach.
Models were generated that classified outcome with greater discrimination than was obtained with any single gene alone.
According to a second approach (time-to-event approach), for each gene a Cox Proportional Hazards model (see, e.g. Cox, D. R., and Oakes, D. (1984), Analysis of Survival Data, Chapman and Hall, London, New York) was defined with time to recurrence or death as the dependent variable, and the expression level of the gene as the independent variable.
The genes that have a p-value < 0.10 in the Cox model were identified. For each gene, the Cox model provides the relative risk (RR) of recurrence or death for a unit change in the expression of the gene. One can choose to partition the patients into subgroups at any threshold value of the measured expression (on the CT scale), where all patients with expression values above the threshold have higher risk, and all patients with expression values below the threshold have lower risk, or vice versa, depending on whether the gene is an indicator of bad (RR>1.01) or good (RR<1.01) prognosis. Thus, any threshold value will define subgroups of patients with respectively increased or decreased risk.
The results are summarized in Table 4. The third column, with the heading: exp(coef), shows RR
values.
Table 4 Gene coef exp(coef) se(coef) TP53BP2 -0.21892 0.803386 0.068279 -3.20625 0.00134 GRB7 0.235697 1.265791 0.073541 3.204992 0.00135 PR -0.10258 0.90251 0.035864 -2.86018 0.00423 CD68 0.465623 1.593006 0.167785 2.775115 0.00552 Bc12 -0.26769 0.765146 0.100785 -2.65603 0.00791 KRT14 -0.11892 0.887877 0.046938 -2.53359 0.0113 PRAME -0.13707 0.871912 0.054904 -2.49649 0.0125 CTSL 0.431499 1.539564 0.185237 2.329444 0.0198 EstR1 -0.07686 0.926018 0.034848 -2.20561 0.0274 Chk1 0.284466 1.329053 0.130823 2.174441 0.0297 IGFBP2 -0.2152 0.806376 0.099324 -2.16669 0.0303 HER2 0.155303 1.168011 0.072633 2.13818 0.0325 BAG1 -0.22695 0.796959 0.106377 -2.13346 0.0329 CEGP1 -0.07879 0.924236 0.036959 -2.13177 0.033 STK15 0.27947 1.322428 0.132762 2.105039 0.0353 KLK10 -0.11028 0.895588 0.05245 -2.10248 0.0355 B.Catenin -0.16536 0.847586 0.084796 -1.95013 0.0512 EstR1 -0.0803 0.922842 0.042212 -1.90226 0.0571 GSTM1 -0.13209 0.876266 0.072211 -1.82915 0.0674 TOP2A -0.11148 0.894512 0.061855 -1.80222 0.0715 AlB1 0.152968 1.165288 0.086332 1.771861 0.0764 FHIT -0.15572 0.855802 0.088205 -1.7654 0.0775 RIZ1 -0.17467 0.839736 0.099464 -1.75609 0.0791 SURV 0.185784 1.204162 0.106625 1.742399 0.0814 IGF1 -0.10499 0.900338 0.060482 -1.73581 0.0826 BBC3 -0.1344 0.874243 0.077613 -1.73163 0.0833 IGF1R -0.13484 0.873858 0.077889 -1.73115 0.0834 DIABLO 0.284336 1.32888 0.166556 1.707148 0.0878 TBP -0.34404 0.7089 0.20564 -1.67303 0.0943 p27 -0.26002 0.771033 0.1564 -1.66256 0.0964 IRS1 -0.07585 0.926957 0.046096 -1.64542 0.0999 The binary and time-to-event analyses, with few exceptions, identified the same genes as prognostic markers. For example, comparison of Tables 1 and 4 shows that 10 genes were represented in the top 15 genes in both lists. Furthermore, when both analyses identified the same gene at [p<0.10], which happened for 21 genes, they were always concordant with respect to the direction (positive or negative sign) of the correlation with survival/recurrence.
Overall, these results strengthen the conclusion that the identified markers have significant prognostic value.
For Cox models comprising more than two genes (multivariate models), stepwise entry of each individual gene into the model is performed, where the first gene entered is pre-selected from among those genes having significant univariate p-values, and the gene selected for entry into the model at each subsequent step is the gene that best improves the fit of the model to the data. This analysis can be performed with any total number of genes. In the analysis the results of which are shown below, stepwise entry was performed for up to 10 genes.
Multivariate analysis is performed using the following equation:
RR----exp[coef(geneA) x Ct(geneA) + coef(geneB) x Ct(geneB) + coef(geneC) x Ct(geneC) + ......... ].
In this equation, coefficients for genes that are predictors of beneficial outcome are positive numbers and coefficients for genes that are predictors of unfavorable outcome are negative numbers. The "Ct" values in the equation are ACts, i.e. reflect the difference between the average normalized Ct value for a population and the normalized Ct measured for the patient in question. The convention used in the present analysis has been that ACts below and above the population average have positive signs and negative signs, respectively (reflecting greater or lesser mRNA abundance). The relative risk (RR) calculated by solving this equation will indicate if the patient has an enhanced or reduced chance of long-term survival without cancer recurrence.
Multivariate gene analysis of 79 patients with invasive breast carcinoma A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 79 patients with invasive breast carcinoma. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival:
(a) TP53BP2, Bc12, BAD, EPHX1, PDGFRJ3, DIABLO, XIAP, YB1, CA9, and KRT8.
(b) GRB7, CD68, TOP2A, Bc12, DIABLO, CD3, EDI, PPM1D, MCM6, and WISP1.
(c) PR, TP53BP2, PRAME, DIABLO, CTSL, IGFBP2, TIMP1, CA9, MMP9, and COX2.
(d) CD68, GRB7, TOP2A, Bc12, DIABLO, CD3, Dl, PPM1D, MCM6, and WISP1.
(e) Bc12, TP53BP2, BAD, EPHX1, PDGFRO, DIABLO, XIAP, YB1, CA9, and KRT8.
(f) KRT14, KRT5, PRAME, TP53BP2, GUS1, ADM, MCM3, CCNE1, MCM6, and ID1.
(g) PRAME, TP53BP2, EstR1, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB.
(h) CTSL2, GRB7, TOP2A, CCNB1, Bc12, DIABLO, PRAME, EMS1, CA9, and EpCAM.
(i) EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB.
(k) Chkl, PRAME, p53BP2, GRB7, CA9, CTSL, CCNB1, TOP2A, tumor size, and IGFBP2.
(1) IGFBP2, GRB7, PRAME, DIABLO, CTSL, 0-Catenin, PPM1D, Chkl, WISP1, and LOT1 .
(in) HER2, TP53BP2, Bc12, DIABLO, TIMP1, EPHX1, TOP2A, TRAIL, CA9, and AREG.
(n) BAG1, TP53BP2, PRAME, IL6, CCNB1, PAIL AREG, tumor size, CA9, and Ki67.
(o) CEGP1, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, and AKT2, and FGF18.
(p) STK15, TP53BP2, PRAME, IL6, CCNE1, AKT2, DIABLO, cMet, CCNE2, and COX2.
(q) KLK10, EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, and BBC3.
(r) AD31, TP53BP2, Bc12, DIABLO, TIMP1, CD3, p53, CA9, GRB7, and EPHX1 (s) BBC3, GRB7, CD68, PRAME, TOP2A, CCNB1, EPHX1, CTSL
GSTM1, and APC.
(t) CD9, GRB7, CD68, TOP2A, Bc12, CCNB1, CD3, DIABLO, ID1, and PPM1D.
(w) EGFR, KRT14, GRB7, TOP2A, CCNB1, CTSL, Bc12, TP, KLK10, and CA9.
(x) HIF1a, PR, DIABLO, PRAME, Chkl, AKT2, GRB7, CCNE1, TOP2A, and CCNB1.
(y) MDM2, TP53BP2, DIABLO, Bc12, AJB1, TIMP1, CD3, p53, CA9, and HER2.
(z) MYBL2, TP53BP2, PRAME, IL6, Bc12, DIABLO, CCNE1, EPHX1, TIMP1, and CA9.
(aa) p27, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, AKT2, and D31.
(ab) RAD51, GRB7, CD68, TOP2A, CIAP2, CCNB1, BAG1, IL6, FGFR1, and TP53BP2.
(ac) SURV, GRB7, TOP2A, PRAME, CTSL, GSTM1, CCNB1, VDR, CA9, and CCNE2.
(ad) TOP2B, TP53BP2, DIABLO, Bc12, TEMPI., AD31, CA9, p53, KRT8, and BAD.
(ae) ZNF217, GRB7, p53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, APC4, and 0-Catenin.
. .
While the present invention has been described with reference to what are considered to be the specific embodiments, it is to be understood that the invention is not limited to such embodiments. To the contrary, the invention is intended to cover various modifications and equivalents included within the scope of the appended claims. For example, while the disclosure focuses on the identification of various breast cancer associated genes and gene sets, and on the personali7ed prognosis of breast cancer, similar genes, gene sets and methods concerning other types of cancer are specifically within the scope herein.
=
Table 5A
Gene ¨Accession Seq AlB1 NM_006534GCGGCGAGTTTCCGATTTAAAGCTGAGCTGCGAGGAAAATGGCGGCGGGAGGATCAAAATACTTGCTGGA
TGGTGGACTCA
A =
AKT2 NM_001626TCCTGCCACCCTTCAAACCTCAGGTCACGTCCGAGGTCGACACAAGGTACTTCGATGATGAA1-TTACCGCC =
= APC
NM_000038GGACAGCAGGAATGTGTTTCTCCATACAGGTCACGGGGAGCCAATGGTTCAGAAACAAATCGAGTGGGT
AREG
NM_001657TGTGAGTGAAATGCC1ICTAGTAGTGAACCGTCCTCGGGAGCCGACTATGACTACTCAGAAGAGTATGAT
AACGAACCACAA
6-actin NM_001101 CAGCAGATGTGGATCAGCAAGCAGGAGTATGACGAGTCCGGCCCCTCCATCGTCCACCGCAAATGC' B.Catenin NAL001904 GGCTCTTGTGCGTACTGTCCITCGGGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCITCGICATCTG
A
BAD
CAG =
CGTTGTCAGCACTTGGAATACAAGATGGTTGCCGGGTCATGTTAATTGGGAAAAAGAACAGTCCACAGGAAGAGGTTGA
AC
NM_014417CCTGGAGGGTCCTGTACAATCTCATCATGGGACTCCTGCCCITACCCAGGGGCCACAGAGCCCCCGAGAT
GGAGCCCAATTAG
Bc12 NM_000633CAGATGGACCTAGTACCCACTGAGATITCCACGCCGAAGGACAGCGATGGGAAAAATGCCCTIAAATCAT
AGG
'0A9 AG
NM_03196ETTCAGGTTGTTGCAGGAGACCATGTACATGACTGTCTCCATTATTGATCGGTTCATGCAGAATAAITGTG
TGCCCAAGAAGATG
CCND1 NM_001758 GCATGTICGTGGCCTCTAAGATGAAGGAGACCATCCCCCTGACGGCCGAGAAGCTGTGCATCTACACCG .
NM_001238AAAGAAGATGATGACCGGGITTACCCAAACTCAACGTGCAAGCCTCGGATTATTGCACCATCCAGAGGCT
C.
CCNE2 NM_057749ATGCTGIGGCTCCTTCCTAACTGGGGCTITC1-CD3z NM_000734AGATGAAGTGGAAGGCGCTTTTCACCGCGGCCATCCTGCAGGCACAGTTGCCGATTACAGAGGCA
COBB NM_001251 TGGTTCCCAGCCCTGTGTCCACCTCCAAGCCCAGATTCAGATTCGAGTCATGTACACAACCCAGGGTGGAGGAG.
COB
NM_001769GGGCGTGGAACAGITTATCTCAGACATCTGCCCCAAGAAGGACGTACTCGAAACCTTCACCGM
CORI
NM_004360TGAGTGTCCCCCGGTATCTTCCCCG000TGCCAATCCCGATGAAATTGGAAATTTTATTGATGAAAATCT
GAAAGCGGCTG
NM_020974TGACAATCAGCACACCTGCATTCACCGCTCGGAAGAGGGCCTGAGCTGCATGAATAAGGATCACGGCTGT
AGTCACA
Chk1 NM_001274GATAAATTGGTACAAGGGATCAGCT1n-CCCAGCCCACATGTOCTGATCATATGCTTTTGAATAGTCAGTTACTTGGCACCC
NM_001166TGCCTGTGGTGGGAAGCTCAGTAACTGGGAACCAAAGGATGATGCTATGTCAGAACACCGGAGGCATTTT
CC
clAP2 NM_001165GGATATTTCCGTGGCTCT1-A1-cMet NM 000245 GACATTTCCAGTCCTGCAGTCAATGCCTCTCTGCCCCACCCTTTGITCAGIGTGGCTGGTGCCACGACAAATGTGTGCG
ATCGGAG
Contig278AKE00618."GGCATCCIGGCCCAAAGTTTCCCAAATCCAGGCGGCTAGAGGCCCACTGCTTCCCAACTA
CCAGCTGAGGGGGIC
COX2 NM_000963TCTGCAGAGTTGGAAGCACTCTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCC1-TCTGGTAGAAAAGCCTCGGC ' CTSL
NM..001912GGGAGGCTTATCTCACTGAGTGAGCAGAATCTGGTAGACTGCTCTGGGCCTCAAGGCAATGAAGGCTGC
AATGG
,NM_001333'TGTCTCACTGAGCGAGCAGAATCTGGTGGACTGTTCGCGTCCTCAAGGCAATCAGGGCTGCAATGGT
NM_004938CGCTGACATCATGAATGTTCCTCGACCGGCTGGAGGCGAGTITGGATATGACAAAGACACATCGTTGCTG
AAAGAGA
DIABLO NM_019887 CACAATGGCGGCTCTGAAGAGTTGGCTGTCGCGCAGCGTAACTTCATTCTTCAGGTACAGACAGTGITTGTGT
DRS
NM_003842CTCTGAGACAGTGCTTCGATGACTTTGCAGACTTGGTGCCCTTTGACTCCTGGGAGCCGCTCATGAGGAA
EGFR NN1_005228TGTCGATGGACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAAT
ElF4E
NM_001968GATCTAAGATGGCGACTGTCGAACCGGAAACCACCCCTACTCCTAATCCCCCGACTACAGAAGAGGAGAA
AACGGAATCTAA
GGCAGTGTCACTGAGTCCITGAAATCCTCCCCTGCCCCGCGGGTCTCTGGATTGGGACGCACAGTGCA
EpCAM
NM_002354.GGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGCGGGCTCTTT4AGGCCAAGC
AGTGCA
EPHX1 NM_000120 'EthB3 NM_001982CGG1TATGTCATGCCAGATACACACCTCAAAGGTACTCCCTCCTCCCGGGAAGGCACCOTTIC1TCAGTG
GGTCTCAGTTC =
EsiR1 NM_000125CGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCC
=
NM_012177GGCTATTCCTCATTTICTCTACAAAGIGGCCTCAGTGAACATGAAGAAGGTAGCCTCCIGGAGGAGAATT
TCGGTGACAGTCTACAATCC
CACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTGCCTGTGAAGTGGATGGCACCC
Fl-HT NM:002012 CCAGTGGAGCGCTTCCATGACCIGCGTCCTGATGAAGTGGCCGATTTGTTTCAGACGACCCAGAGAG
=FRP1 NM_003012TTGGTACCTGTGGGTTAGCATCAAG1TCTCCCCAGGGTAGAAT1-G-Catenin NM_002230 TCAGCAGCAAGGGCATCATGGAGGAGGATGAGGCCTGCGGGCGCCAGTACACGCTCAAGAAAACCACC =
. GAPDH
NM_002046ATTCCACCCATGGCAAATTCCATGGCACCGTCAAGGCTGAGAACGGGAAGCTTGTCATCAATGGAAATCC
CATC
GATA3 NM_002051 CAAAGGAGCTCACTGTGGTGTCTGTGTTCCAACCACTGAATCTGGACCCCATCTGTGAATAAGCCATTCTGACTC
NM_005310CCATCTGCATCCATCTTGTTTGGGCTCCCCACCC1TGAGAAGTGCCTCAGATAATACCCTGGTGGCC
GR01 NM_001511 CGAAAAGATGCTGAACAGTGACAAATCCAACTGACCAGAAGGGAGGAGGAAGCTCACTGGTGGCTGITCCTGA
NM_000561AAGCTATGAGGAAAAGAAGTACACGATGGGGGACGCTCCTGATTATGACAGAAGCCAGTGGCTGAATGA4 AAATTCAAGCTGGGCC
GUS NM_000181 CCCACTCAGTAGCCAAGTCACAATGTTTGGAAAACAGCCCGTTTACTTGAGCAAGACTGATACCACCTGCGTG
NN1_001530TGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGGCCACATTCACGTATATGATACCAACA
GTAACCAACCTCA
NM_004496TCCAGGATGTTAGGAACTGTGAAGATGGAAGGGCATGAAACCAGCGACTGGAACAGCTACTACGCAGACA
CGC
NM_002165AGAACCGCAAGGTGAGCAAGGTGGAGATTCTCCAGCACGTCATCGACTACATCAGGGACCTTCAGTTGGA
NM_000618TCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCTGCCAAGTCAGCTCGCTC
TGTCCG
11M_000875GCATGGTAGCCGAAGATTTCACAGTCAA4ATCGGAGAT1ITGGTATGACGCGAGATATCTATGAGACAG
ACTATTACCGGAAA
NM_000597GTGGACAGCACCATGAACATGTTIGGGCGGGGGAGGCAGTGCTGGCCGGAAGCCCCTCAAGTCGGGTATG
AAGG
ILB
NM_000600CCTGAACCTTCCAAAGATGGCTGAAAAAGATGGATGCTTCCAATCTGGATTCAATGAGGAGACTTGCCTG
GT "
NM_005544CCACAGCTCACCTTCTGTCAGGTGTCCATCCCAGCTCCAGCCAGCTCCCAGAGAGGAAGAGACTGGCACT
GAGG =
1<1-67 NM_002417CGGACITTGGGTGCGACTTGACGAGCGGTGGTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGGA
AGAGTTGTA.A.-NM_002776GCCCAGAGGCTCCATCGTCCATCCTC1TCCTCCCCAGTCGGCTGAACTCTCCCCTIGTCTGCACTG1-TCAAACCTCTG
AGCCACAGTGGAC
NM_000422CGAGGATTGGTTCTTCAGCA5GACAGAGGAACTGAACCGCGAGGTGGCCACCAACAGTGAGCTGGTGCAG
AGT =
NM_000224AGAGATCGAGGCTCTCAAGGAGGAGCTGCTCTTCATGAAGAAGAACCACGAAGAGGAAGTAAAAGGCC
=
KRTis NM_002276TGAGCGGCAGAATCAGGAGTACCAGCGGCTCATGGACATCAAGTCGCGGCTGGAGCAGGAGATTGCCACC
TACCGCA
KRT5 A1_000424 TCAGTGGAGAAGGAGTTGGACCAGTCAACATCTCTGTTGICACAAGCAGTGITTCCTCTGGATATGGCA
KRT8 NM_002.273 GGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAGATCAACTTCGTCAGGCAG
CTATATG
LOT1earisNM_002656GGAAAGACCACCTGAAAAACCACCTCCAGACCCACGACCCCAACAAAATGGCCTTTGGGTG
TGAGGAGTGIGGGAAGAAGTAC .
Maspin TOCTGCC
NM_004526GAC1TTTGCCCGCTACCITTCATTCCGGCGTGACAACAATGAGCTGTTGCTCTICATACTGAAGCAGTTA
GTGGC
NM_002386GGAGAACAATCCCCTTGAGACAQAATATGGCCITTCTGTCTACAAGGATCACCAGACCATCACCATCCAG
GAGAT
TGATGGICCTATGIGTCACATICATCACAGGTTTCATACCAACACAGGCTICAGCACTTCCTITGGTGTGITTCCTGTC
CCA
MDM2 NM_002392CTACAGGGACGCCATCGAATCCGGATC1-TGATGCTGGIGTAAGTGAACA1-TCAGGTGATTGGTTGGAT
NM_004994GAGAACCAATCTCACCGACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTG
NM_004689CCGCCCTCACCTGAAGAGAAACGCGCTCCTTGGCGGACACTGGGGGAGGAGAGGAAGAAGCGCGGCTAAC
MYBL2 NM_002466 GCCGAGATCGCCAAGATGTTGCCAGGGAGGACAGACAATGCTGTGAAGAATCACTGGAACTCTACCATCAAAAG
CCCTCGTGCTGATGCTACTGAGGAGCCAGCGTCTAGGGCAGGAGCCGCTTCCTAGAAGACCAGGICATGATG
p27 NM_004064 P53 NM_000546 CITTGAACCCTTGCTTGCAAJAGGTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGG
PAH NM_000602 CCGCAACGTGGlITTCTCACCCTATGGGGTGGCCTCGGIGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAG
CA
PDGFRb NM_002609CCAGCTCTCC1TCCAGCTACAGATCAATGTCCCTGTCCGAGTGCTGGAGCTAAGTGAGAGCCACCC
NM_002645ATACCAATCACCGCACAAACCCAGGCTATTTGITAAGTCCAGTCACAGCGCAAAGAAACATATGCGGAGA
AAATGCTAGTGTG
PPM113 NM_003620 GCCATCCGCAAAGGCTTTCTCGCTTGTCACCTTGCCATGTGGAAGAAACTGGCGGAATGGCC
PR
NM_000926GCATCAGGCTGICATTATGGTGTCCTTACCTGTGGGAGCTGTAAGGICTICTTTAAGAGGGCAATGGAAG
GGCAGCACAACTACT
PRAMS
pS2 NM 003225 GCCCTCCCAGTGTGCAAATAAGGGCTGCTGTITCGACGACACCGTTCGTGGGGTCCCCTGGTGCTTCTATCCTAATACC
ATCGACG
RAD51C NM_ 055218 GAACTTCTTGAGCAGGAGCATACCCAGGGCTTCATAATCACCTTCTGTTCAGCACTAGATGATATTCTTGGGGGTGGA
=
RB1 NM_000321 CGAAGCCCTTACAAGITTCCTAGTTCACCCTTACGGATTCCTGGAGGGAACATCTATATTTCACCCCTGAAGAGTCC
STK15 NM_003600 CATCTICCAGGAGGACCACTCTCTGTGGCACCCTGGACTACCTGCCCCCTGAAATGATTGAAGGTCGGA
STMY3 NM_005940 CCTGGAGGCTGCAACATACCTCAATCCTGIOCCAGGCCGGATCCTCCTGAAGCCCITTTCGCAGCACTGCTATCCTCCA
AAGCCATTGTA
=
Table 5B
=
. .
SURV =
NM_0011611TGTTITGATTCCCGGGCTTACCAGGTGAGAAGTGAGGGAGGAAGAAGGCAGTGTCC0TTITGCTAGAGC
TGACAGCTTTG
The NM_003194GCCCGAAACGCCGAATATAATCCCAAGCGG1TTGCTGCGGTAATCATGAGGA1AAGAGAGCCACG
TGFA NM_003236 GGTGTGCCACAGACCTTCCTACTTGGGCTGTAATCACOTGTGOAGCCT-Timpi Nm_003254 TCCOTGCGGTOCCAGATAGCCTGAATOCTGCCCGGAGTGGAACTGAAGCCTGCAGAGTGTGOACCCTGTTOCCAC
TOP2A NM_001087 AATCGAAGGGGGAGAGTGATGACTTCCATATGGACTTTGACTCAGOTGTGGCTOCTOGGGCAAAATOTGTAC
NN1_0010S5TGTGGACATOTTOCCCTCAGACTT000TACTGAGGCAOCTTCTOTGCCACGAA0CGGTCGGGCTAG
TP NM_001B53 CTATATGCAGCCAGAGATGTGACAGCOACCGTGGACAGCCTGCCACTCATCACAGCGTOCATTOTCAGTAAGAAACTCG
TGG
NM_005426GGGCCAAATATTCAGAAGCTTTTATATCAGAGGACCACCATAGGGGOCATGGAGACCATCTCTGTCC0AT
CATACCCATCO
TRAIL NM_003810 CTTCACAGTGOTCCTGCAGTCTCTOTOTGTGGCTGTAACTTACGTGTACTTTACCAAGGAGCTGAAGCAGATG
TS NM_001071 GCCTCGGTGTGOOTTTCAACATCGCCAGOTAGGCCCIGCTCACGTACATGATTGCGCACATCACG
upa W/1_002658 VOR NM_000376 GCGCTGGATTTCAGAAAGAGCCAAGTCTGGATCTGGGACCCITTOCTTCUTTOCCTGGCTTGTAACT =
GTGOTGICTIGGGTGCATTOGAGCCTTGCCTTGCTGCTOTACCTCCACGATGCCAAGTGGTOCCAGGCTGC
VEGFB NM_003377 TGACGATGGCCIGGAGTGTGTGCCCACTGGGCAGCACCAAGTCOGGATGCAGATCOTCATGATCCGGTACC
NASP1 NM_003882 AGAGGCATCCATGAACTTCACACTTGCGGGCTGCATGAGCACACGCTCGTATCAACCCAAGTAGTGTGGAGTTTG .
=
NM_001107GCAGTTGGAAGACACAGGAAAGTATC000AAAITGCAGATTTATCAACGGC1TTTATCTTGAAAATAGTG
CCACGCA
NM_004559AGACTGIGGAGITTGATG7TGTTGAAGGAGAAAAGGGTGCGGAGGCAGCA.AATGTTACA3GICCTGGTG
GIGTTCC
NN1_005526ACCCAGTAGCAAGGAGAAGCCCACTCACTGCTCCGAGTGCGGGAAAGCTTTCAGAACCTACCACCAGCT
G
=
'=
=
=
=
=
=
=
=
, .
Table 6A
. -.
.
Gene Accession = Probe Name S eq Len , .
AIB1 . NM .
_006534 S1994/A1B1f3 GCGGCGAGTTTCCGATTTA 19 ' Al B1 *NM 006534 S1995/AIB1r3 .TGAGTCCACCATCCAGCAAGT
_ . 21 ' A1B1 NM_006534 S5055/AIB1 .p3 AKT1 NM _005163 S0010/AKT1.13 AKT1 NM_005163 S0012/AKT1.r3 TCCCGGTACACCACGTTCTT 20 AKT1 NM 005163 S4776/AKT1.p3 _001626 S0828/AKT2.f3 TCCTGCCACCCTTCAAACC 19 AKT2 NM 001626 S0829/AKT2.r3 GGCGGTAAATTCATCATCGAA '.
_ 21 , AKT2 NM_001626 S4727/AKT2.p3 CAGGTCAC GTC C GA
GGTCGACACA = 24 APC NM_000038 S0022/APC.f4 GGACAGCAGGAATGTGTTTC
APC NM_000038 S0024/APC.r4 ACCCACTCGATTTGTTTCTG 20 APC NM_000038 S4888/APC.p4 CATTGGCTCCCCGTGACCTGTA 22 ' AREG NM_001657 S0025/AREG.f2 TGTGAGTGAAATGCCTTCTAGTAGTGA . 27 .
AREG NM_001657 S0027/AREG.r2 TTGTGGTTCGTTATCATACTCTTCTGA 27 AREG NM_001657 S4889/AREG.p2 CCGTCCTCGGGAGCCGACTATGA 23 B-actin NM_001101 S0034/B-acti.f2_ B-actin . NM_001101 S0036/B-acti.r2 B-actin NM_001101 S4730/B-acti.p2 B-Catenin NM_001904 S2150/B-Cate.f3 GGCTCTTGTGCGTACTGTCCTT 22 B-Catenin NM_001904 S2151/B-Cate.r3 TCAGATGACGAAGAGCACAGATG 23 B-Catenin NM 001904 . ' S5046/B-Cate.p3 AGGCTCAGTGATGTCTTCCCTGTCACCAG 29 BAD NM:032989 S2011/BAD.f1 GGGTCAGGTGCCTCGAGAT 19 BAD NM_032989 S2012/BAD.r1 CTGCTCACTCGGCTCAAACTC . 21 BAD .NM_032989 S5058/BAD.p1 . TGGGCCCAGAGCATGTTCCAGATC . . 24 BAG1 ', NM_004323 .S1386/BAG1.f2 = CGTTGTCAGCACTTGGAATACAA ' . 23 ' BAG1 NM_004323 S1387/BAG1.r2 GTTCAACCTCTTCCTGTGGACTGT 24 BAG1 . NM 004323 34731/BAG1 .p2 = CCCAATTAACATGACCCGGCAACCAT
26 =
BBC3 NM:014417 S1584/BBC3.f2 CCTGGAGGGTCCTGTACAAT = 20 ..
BBC3 NM_014417 = S1585/BBC3.r2 ,.= CTAATTGGGCTCCATCTCG 19 = BBC3 NM_014417 S4890/BBC3.p2 CATCATGGG,ACTCCTGCCCTTACC = - 24 Bc12 NM 000633 S0043/Bc12.f2 _ CAGATGGACCTAGTACCCACTGAGA ' 25 Bc12 NM 000633 S0045/Bc12.r2 CCTATGATTTAAGGGCA II ii I CC = . 24 BcI2 NM 000633 S4732/8c12.p2 CA9 NM:001216 S1398/CA9.f3 ATCCTAGCCCTGG I 1 1 1 1GG .20 CA9 NM 001216 .S1399/CA9.r3 CTGCCTTCTCATCTGCACAA
_ 20 CA9 NM 001216 S4938/CA9.p3 CCNB1 NM:031966 S1720/CCNB1.f2 TTCAGGTTGTTGCAGGAGAC . 20 CCNB1 NM_031966 S1721/CCNB1.r2 . CATCTTCTTGGGCACACAAT 20 CCNB1 NM 031966 S4733/CCNB1.p2 TGTCTCCATTATTGATCGGTTCATGCA 27 CCND1 NM 001758 S0053/CCND1.f3 GCATGTTCGTGGCCTCTAAGA 21 . CCND1 NM_001758 S0060/CCND1.r3 CGGTGTAGATGCACAGCTTCTC 22 CCND1 NM 001758 64986/CaND1.p3 AAGGAGACCATCCCCCTGACGGC 23. .
.
CCNE1 NM_001238 S1446/CCNE1.f1 WGAAGATGATGACCGGGTTTAC. 24 =
CCNE1 NM_001238 = 51447/CCNE1.r1 CCNE1 NM_001238 S4944/CCNE1.p1 CAAACTCAACGTGCAAGCCTCGGA 24 CCNE2 NM057749 .S1458/CCNE2.f2 . ATGCTGTGGCTCCTTCCTAACT 22 CCNE2 NM 057749 S1459/CCNE2.r2 ACCCAAATTGTGATATACAAAAAGGTT 27 CCNE2 NM_057749 S4945/CCNE2.p2 TACCAAGCAACCTACATGTCAAGAAAGCCC 30 CD3z NM 000734 S0064/CD3z.f1 AGATGAAGTGGAAGGCGCTT . 20 .
CD3z NM-000734 S0066/CD3z.r1 TGCCTCTGTAATCGGCAACTG 21 .
' CD3z NM 000734 S4988/CD3z.p1 CD68 NM_001251 S0067/CD68.f2 C D68 NM 001251 S0069/CD68.r2 C D68 NM:001251 S4734/CD68.p2 CD9 NM 001769 .S0686/C09,f1 .
=
CD9 NM 001769 S0687/CD9.r1 CACGGTGAAGGTTTCGAGT 19 .
CD9 NM_001769 34792/CD9.p1 AGACATCTGa cC CAAGAAG GAC GT 24 CDH1 NM_004360 S0073/CDH1.f3 TGAGTGTCCCCCGGTATCTTC 21 . .
=
' CDH1 NM_004360 S0075/CDH 1 .r3 ________ CAGCCGCTTTCAGA I I I I CAT
CDH1 NM_004360 S4990/CDH1.p3 TGCCAATCCCGATGAAATTGGAAATTT 27 CEGP1 NM_020974 S1494/CEGP1.f2 TGACAATCAGCACACCTGCAT 21 ..
_.. .
Table 6B
, .
. , CEGP1 NM_020974 S1495/CEGP1.r2 .TGTGACTACAGCCGTGATCCTTA 23 =
CEGP1 = NM_020974 S4735/CEGP1.p2 CAGGCCCTCTTCCGAGCGGT 20 Chk1 NM 001274 S1422/Chk1.f2 _ GATAAA1TGGTACAAGGGATCAGCTT 26 Chk1 NM 001274 Si23/Chk1.r2 ' GGGTGCCAAGTAACTGACTATTCA
_ 24 =
Chk1 NM 001274 S4941/Chk1.p2 CCAGCCCACATGTCCTGATCATATGC . 26 =
CIAP1 NM 001166 S0764/CIAPl.f2 TGCCTGTGGTGGGAAGCT
_ 18 CIAP1 NM 001166 S0765/CIAP1.r2 GGAAAATGCCTCCGGTGTT
_ 19 =
CIAP1 NM_001166 S4802/CIAP1.p2 TGACATAGCATCATCCITTGGTTCCCAGTT 30 clAP2 NM 001165 S0076/cIAP2.f2 GGATATTTCCGTGGCTCTTATTCA
_ 24 clAP2 . NM_001165 S0078/cIAP2.r2 CTTCTCATCAAGG6AGAAAAATCTT . 25 . clAP2 NM_001165 S4991/cIAP2.p2= TCTCCATCAAATCCTGTAAACTCCAGAGCA 30 cMet NM_000245 S0082./cM et.f2 cMet NM_000245 S0084/cMet.r2 CTCCGATCGCACACATTTGT 20 cMet NM_000245 S4993/cMet.p2 TGCCTCTCTGCCCCAC6CTTTGT 23 Contig 27882 AK00618 S2633/Contig.f3 GGCATCCTGGCCCAAAdT 18 Contig 27882 AK000618 - S2634/Contig.r3 Contig 27882 AK000618 . S4977/Contig.p3 COX2 NM_000963 S0088/C0X2J1 TCTGCAGAGTTGGAAGCACTCTA =23 COX2 NM_000963 S0090/C0X2.r1 GCCGAGGCTTTTCTACCAGAA 21 COX2 NM_000963 S4995/C0X2.p1 = CAGGATACAGCTCCACAGCATCGATGTC . . 28 , CTSL NM_001912 S1303/CTSL.f2 GGGAGGCTTATCTCACTGAGTGA . . 23 CTSL NM_001912 81304/CTSL.r2 CCATTGCAGCCTTCATTGC 19 CTSL NM_001912 = S4899/CTSL.p2 CTSL2 NM 001333 . S4354/CTSL2.f1 CTSL2 NM 001333 S4355/CTSL2.r1 CTSL2 ' NM_001333 S4356/CTS1.2.p1 DAP K1 i NM_004938 S1768/DAPK1.f3 CGCTGACATCATGAATGTTCCT . 22 DAPK1 = NM_004938 S1769/DAPK1.r3 TCTCTTTCAGCAACGATGTGTCTT 24 .DAPK1 NM 004938 84927/DAPK1.p3 TCATATCCAAACTCGCCTCCAGCCG 25 .
' DIABLO . NM:019887 S0808/DIABLO.f1 CACAATGGCGGCTCTGAAG 19 =
DIABLO . NM_019887 S0809/DIABLO.r1 ACACAAACACTGTCTGTACCTGAAGA 26 DIABLO NM_019887 ' S4813/DIABLO.p1 AAGTTACGCTGCGCGACAGCCAA . 23 DR5 NM_003842 S2551/DR5.f2 CTCTGAGACAGTGCTTCGATGACT 24 DR5 NM_003842 S2552/DR5.r2 = CCATGAdGCCCAACTTCCT 19 DR5 NM_003842 S4979/DR5.p2 CAGACTTGGTGCCCTTTGACTCC , 23 EGFR NM_005228 S0103/EGFR.f2 . TGTCGATGGACTTCCAGAAC 20 EGFR NM_005228 S0105/EGFR.r2 ATTGGGACAGCTTGGATCA 19 EGFR NM_005228 S4999/EGFR.p2 ' CACCIGGGCAGCTGCCAA 18 El F4E NM 001968 S0106/E1F4E.f1 ElF4E NM:001968 . S0108/E1F4E.r1 - TTAGATTCCG I 1 i i ElF4E NM_001968 55000/E1F4E.p1 ACCACCCCTACTCCTAATCCCCCGACT 27 , EMS1 NM_005231 =S2663/EMS1.11 GGCAGTGTCACTGAGTCCTTGA 22 ' EMS1 NM_005231 S2664/EMS1.r1 TGCACTGTGCGTCCCAAT 18 .
EMS1 NM_005231 . .S4956/ES1.p1 EpCAM . NM_002354 S1807/EpCAM.f1 GGGCCCTCCAGAACAATGAT 20 EpCAM . NM_002354 S1808/EpCAM.r1 TGCACTGCTTGGCCTTAAAGA 21 EpCAM NM_002354 S4984/EpCAM.p1 CCGCTCTCATCGCAGTCAGGATCAT 25 EPHX1 NM_000120 S 1 865/EPHX1.f2 AC C GTAGGCTCTGCTCTGAA 20 EPHX1 NM_000120 S1866/EPHX1:r2 TGGTCCAGGTGGAAAACTTC 20 EPHX1 = NM_000120 S4754/EPHX1.p2 AGGCAGCCAGACCCACAGGA . 20 =
ErbB3 NM_001982 $0112/ErbB3J1 CGGTTATGTCATGCCAGATACAC 23 ErbB3 NM_001982 S0114/ErbB3.r1 GAACTGAGACCCACTGAAGAAAGG . 24 ErbB3 NM_001982 S5002/ErbB3.pi - CCTCAAAGGTACTCCCTCCTCCCGG 25 EstR1 NM_000125 80115/EstR1.11 EstR1 NM 000125 S0117/EstR1.r1 ' GGCTAGTGGGCGCATGTAG 19 EstR1 NM_000125 S4737/EstR1.p1 CTGGAGATGCTGGACGCCC 19 FBX05 NM 012177 S2017/FBX05.r1 GGATTGTAGACTGTCACCGAAATTC . 25 FBX05 NM 012177 S2018/FBX05.fl FBX05 NM:012177 S5061/FBX05.p1 CCTCCAG GAG GCTACCTTCTTCATGTTCAC .30 .
FGF18 . NM_003862 S1665/FGF18.f2 CGGTAGTCAAGTCCGGATCAA 21 .
FGF18 NM_003862 81666/FGF.18.r2 GCTTOCCTITGCGGTTCA. 18 FGF18 NM_003862 S4914/FGF18.p2 CAAGGAGACGGAATTCTACCTGTGC 25 =
. .
. .
Table 6C
. .
FGFR1 NM _023109 S0818/FGFR1.f3 CACGGGACATTCACCACATC 20 =
FGFR1 NM_023109 S0819/FGFR1.r3 GGGTGCCATCCACTTCACA 19 FGFR1 NM 023109 S4816/FGFR1.p3 ATAAAAAGACAACCAACGGCCGACTGC 27 FHIT NM _002012 S2443/FH1T.f1 CCAGTGGAGCGCTTCCAT = ' 18' FHIT NM_ 002012 S2444/FHIT.r1 CTCTCTGGGTCGTCTGAAACAA .
FHIT NM_002012 S2445/FHIT.p1 TCGGCCACTTCATCAGGACGCAG 23 . FHIT NM_002012 S4921/FHIT.p1 . FRP1 NM_ 003012 S1804/FRP1.f3 FRP1 NM _003012 S1805/FRP 1.r3 FRP1 NM_003012 S4983/FRP1.p3 TCCCCAGGGTAGAATTCAATCAGAGC 26 G-Catenin NM_002230 S2153/G-Cate.f1 TCAGCAGCAAGGGCATCAT . 19 G-Catenin NM_002230 S2154/G-Cate.r1 GGTGG I il G-Catenin NM_002230 S5044/G-Cate.p1 GAP DH NM_002046 S0374/GAPDH.f1 ATTCCACCCATGGCAAATTC 20 GAPDH NM 002046 S0375/GAPDH.r1 GATGGGATTTCCATTGATGACA 22 _ GAPDH NM_002046 S4738/GAPDH.p1 CCGTTCTCAGCCTTGACGGTGC 22 GATA3 NM 002051 S0127/GATA3.f3 CAAAGGAGCTCACTGTGGTGTCT 23 _ GATA3 . NM_002051 S0129/GATA3.r3 GAGTCAGAATGGCTTATTCACAGATG 26 GATA3 NM_002051 S5005/GATA3.p3 TGTTCCAACCACTGAATCTGGACC 24 GRB7 NM_ 005310 50130/GRB7.f2 CCATCTGCATCCATCTTGTT 20 GRB7 NM _00531'0 50132/GRB7.r2 GRB7 NM_005310 S4726/GRB7.p2 CTCCCCACCCTTGAGAAGTGCCT 23.
6R01 NM_001511 S0133/GR01.f2 CGAAAAGATGCTGAACAGTGACA 23 GRO1 NM_001511 S0135/GR01.12 TCAGGAACAGCCACCAGTGA 20 GRO1 NM_001511 =S5006/GR01.p2 CTTCCTCCTCCCTTCTGGTCAGTTGGAT 28 GSTM1 , - NM_000561 S2026/GSTM1.r1 GGCCCAGCTTGAA H H ICA
GSTM1 = NM_000561 S2027/GSTM1.fl AAGCTATGAGGAAAAGAAGTACACGAT 27 GSTM1 NM_000561 54739/GSTM1.p1 TCAGCCACTGGCTTCTGTCATAATCAGGAG 30 GUS NM _000181 ' S0139/GUS.f1 CCCACTCAGTAGCCAAGTCA 20 . .
GUS NM _000181 S0141/GUS.r1 GUS NM_000181 S4740/GUS.p1 _______________________ TCAAGTAAACGGGCTG
HER2 NM _004448 S0142/HER2.f3 HER2 NM_ 004448 S0144/HER2.r3 CCTCTCGCAAGTGCTCCAT 19 HER2 NM 004448 S4729/HER2.p3 CCAGACCATAGCACACTCGGGCAC . 24 .
HIF1A NM:001530 S1207/H1F1A.f3 TGAACATAAAGTCTGCAACATGGA 24 HIF1A NM 001530 S1208/HIF1A.r3 HIF1A NM:001530 S4753/HIF1A.p3 TTGCACTGCACAGGCCACATTCAC 24 HNF3A NM 004496 S0148/HNF3A.f1 TCCAGGATGTTAGGAACTGTGAAG 24 HNF3A NM_ 004496 S0150/HNF3A.r1 HNF3A NM_004496 S5008/HNF3A.p1 AGTCGCTGGTTTCATGCCCTTCCA 24 ID1 NM _002165 SO820/101.11 101 . NM_002165 S0821/1131 .r1 ID-1 NM 002165 S4832/ID1.pl IGF1 NM 000618 S0154/1G.F1.f2 ToCGGAGCTGTGATCTAAGGA 21 ..
IGF1 NM_000618 30156/1GF1 .r2 IGF1 NM_000618 S5010/1GF1.p2 TGTATTGCGCACCCCTCAAGCCTG 24 IGF1R NM_000875 Si 249/1GF1R.f3 IGF1R NM_000875 S1250/1GF1R.r3 TTTCCGGTAATAGTCTGTCTCATAGATATC 30 IGF1R NM 000875 34895/IGF1R.p3 CGCGTCATACCAAAATCTCCGATTTTGA 28 IGFBP2 NM = 000597 S1129/IGFBP2s1 CCTTCATACCCGACTTGAGG 20 _ I GFBP2 NM_000597 S4837/1GF6P2.p1 CTTCCGGCCAGCACTGCCTC 20 IL6 NM 000600 S0760/1L6.f3 IL6 NM 000600 S0761/1L6.r3 11_6 NM 000600 S4800/IL6.p3 _______________________ CCAGATTGGAAGCATCCATC I I I I ICA 27 .
IRS1 NM_ 005544 S1943/IRS1.f3 CCACAGCTCACCTTCTGTCA 20 ' 1RS1 NM 005544 31944/IRS1s3 CCTCAGTGCCAGTCTCTTCC = 20.
1RS1 NM 005544 S5050/IRS1.p 3 Ki-67 NM:002417 S0436/K1-67.f2 CGGACTTTGGGTGCGACTT 19 Ki-67 NM 002417 S0437/K1-67.r2 TTACAACTCTTCCACTGGGACGAT 24 .
KI-67 NM:002417 S4741/11-67.p2 KLK10 NM_002776 32624/KLK10.13 . .
' Table 6D
_ = =
KLK10 NM_002776 S2625/KLK10.r3 ' CAGAGGTTTGAACAGTGCAGACA 23 ' KLK10 NM_002776 S4978/KLK10.p3 = CCTCTTCCTCCCCAGTCGGCTGA 23 KRT14 NM 000526 81853/KRT14f1 GGCCTGCTGAGATCAAAGAC
_ . 20 KRT14 NM 000526 S1854/KRT14.r1 GTCCACTGTGGCTGTGAGAA
_ 20 =
KRT14 NM_000526 S5037/KRT14.p1 TGTTCCTCAGGTCCTCAATGGTCTTG 26 KRT17 NM 000422 S0172/KRT17.f2 CGAGGATTGGTTCTTCAGCAA
_ 21 KRT17 NM 000422 S0174/KRT17.r2 ACTCTGCACCAGCTCACTGTTG
_ 22 KRT17 NM_000422 S5013/KRT17.p2 CACCTCGCGGTTCAGTTCCTCTGT 24 -KRT18 NM 000224 S1710/KRT18.f2 AGAGATCGAGGCTCTCAAGG
_ 20 .
=
KRT18 NM_000224 S1711/KRT18.r2 __ GGCC 1 HI
.
KRT18 NM_000224 S4762/KRT18.p2 TGGTTCTTCTTCATGAAGAGCAGCTCC 27 KRT19 NM_002276 S1515/KRT19.f3 TGAGCGGCAGAATCAGGAGTA
. 21 KRT19 NM_002276 S1516/KRT19.r3 TGCGGTAGGTGGCAATCTC 19 =
KRT19 NM_002276 S4866/KRT19.p3 CTCATGGACATCAAGTCGCGGCTG 24 KRT5 NM 000424 S0175/KRT5.f3 TCAGTGGAGAAGGAGTTGGA
_ 20 KRT5 NM_000424 S0177/KRT5.r3 TGCCATATCCAGAGGAAACA20 =
KRT5 NM_000424 S5015/KRT5.p3 KRT8 . NM_002273 S2588/KRT8.f3 KRT8 .NM_002273 S2589/KRT8.r3 CATATAGCTGCCTGAGGAAGTTGAT 25 =
KRT8 NM_002273 S4952/KRT8.p3 CGTCGGTCAGCCCTTCCAGGC 21 LOT1 variant 1 NM_002656 , S0692/LOT1 v.f2 . GGAAAGACCACCTGAAAAACCA 22 LOT1 variant 1 NM_002656= S0693/LOT1 v.r2 LOT1 variant 1 NM_002656 = S4793/LOT1 v.p2 ACCCACGACCCCAACAAAATGGC 23 Maspin NM_002639 S0836/Maspin.f2 CAGATGGCCACTTTGAGAACATT 23 Maspin NM_002639 S0837/Maspin.r2 GGCAGCATTAACCACAAGGATT 22 Maspin . NM_002639 . S4835/Maspin.p2 . AGCTGACAACAGTGTGAACGACCAG.ACC 28 MCM2 NM_004526 S1602./MCM2.f2 GACTTTTGCCCGCTACCTITC '21 ' MCM2 NM,004526 , . S1603/MCM2.r2 MCM2 NM_004526 54900/MCM2.p2 ACAGCTCATTGTTGTCACGCCG GA =24 , =
. MCM3 NM_002388 S1524/MCM3.f3 = GGAGAACAATCCCCTTGAGA
MCM3 .NM_002388 S1525/MCM3.r3 ' ATCTCCTGGATGGTGATGGT 20 . MCM3 NM_002388 S4870/MCM3.p3 TGGCCTTTCTGTCTACAAGGATCACCA 27 MCM6 ' . NM_005915 S1704/MCM6.f3 TGATGGTCCTATGTGTCACATTCA 24 MCM6 NM 005915 S1705/MCM6.r3 TGGGACAGGAAACACACCAA
_ 20 .
MCM6 NM_005915 S4919/MCM6.p3 CAGGTTTCATACCAACACAGGCTTCAGCAC 30 MDM2 NM 002392 S0830/MDM2.fl MDM2 NM 002392 S0831/MDM2.r1 MDM2 NM_002392 S4834/MDM2.p1 CTTACACCAGCATCAAGATCCGG , ' 23 MMP9 NM004994 S0656/MMP9.fl GAGAACCAATCTCACCGACA 20 .
MMP9 NM_004994 S0657/MMP9.r1 CACCCGAGTGTAACCATAGC 20 MMP9 NM 004994 = S4760/MMP9.p1 ACAGGTATTCCTCTGCCAGCTGCC = = 24 MTA1 NM_ 004689 S2369/MTA1.f1 CCGCCCTCACCTGAAGAGA 19 MTA1 NM_004689 S2370/MTA1.r1 GGAATAAGTTAGCCGOGOTTOT 22 MTA1 NM 004689 54855/MTAl.p1 COCAGTGTCCGCCAAGGAGCG 21 '=
MYBL2 NM_002466 S3270/MYBL2.f1 GCCGAGATCGCCAAGATG 18 MYBL2 NM_002466 S3271/MYBL.2.r1 __ C i 1 i MYBL2 NM 002466 S4742/MYBL2.p1 CAGCATTGTCTGTCCTCCCTGGCA 24 P14ARF S76-535 S2842JP14ARF.f1 CCCTCGTGCTGATGCTACT . 19 ' P14ARF S78535 S2843/P14ARF.r1 CATCATGACCTGGTCTTCTAGG 22 P14ARF S78535 S4971/P14ARF.p1 CTGCCCTAGACGCTGGCTCCTC 22 p27 NM_004064 S0205/p27.f3 CGGTGGACCACGAAGAGTTAA 21 p27 NM_004064 S0207/p27.r3 GGCTCGCCTCTTCCATGTC 19 p27 NM_004064 S4750/p27.p3 CCGGGACTTGGAGAAGCACTGCA . 23 P53 NM 000546 S0208/P53.f2 CTTTGAACCCTTGCTTGCAA 20 P53 NM_ 000546 S0210/P53.r2 CCCGGGACAAAGCAAATG 18 P53 . NM_000546 S5065/P53.p2 AAGTCCTGGGTGCTTCTGACGCACA , 25 PAH NM_000602 S0211/PAl1 .f3 _______ CCGCAACGTGG I I I I
PAll NM_ 000602 S5066/PAI1.p3 CTCGGTGTTGGCCATGOTCCAG 22 =
PDGFRb NM...0,02609 S1346/PDGFRb.f3 CCAGCTCTCCTTCCAGCTAC 20 =
PDGF.Rb NM 002609 Si47/PDGFRb.r3 GOGTGGCTCTCACTTAGCTC
_ 20 PDGFRb NM_002609 S4931/P DGFR b. p3 ATCAATGTCCCTGTCCGAGTGCTG 24 , * CA 02513117 2013-09-26 . =
Table 6E
= =
PI3KC2A NM_002645 S2020/P13KC2.1-1 ___ CACACTAGCAI i 11CTCCGCATA 23 =
P I3KC2A NM_002645 82021/P13KC2.f1 ATACCAATCACCGCACAAACC - 21 =
PI3KC2A , NM_002645 55062/P13KC2.p1 TGCGCTGTGACTGGACTTAACAAATAGCCT 30 PP MID " NM_003620 S3159/PPM1D.fl GCCATCCGCAAAGGCTTT = 18 P PM1D NM_003620 S3160/PPM1D.r1 GGCCATTCCGCCAGTTTC 18 ' = P PM1D NM_003620 S4856/PPM1D.p1 TCGCTTGTCAbCT7GCCATGTGG 23 PR NM- 000926 S1336/PR.f6 = GCATCAGGCTGTCATTATGG 20 _ PR NM 000926 S1337/PR.r6 AGTAGTTGTGCTGCCCTTCC ' 20 PR NM:000926 S4743/PR.p6 TGTCCITACCTGTGGGAGCTGTAAGGTC 28 FRAME NM 006115 S1985/PRAME.f3 TCTCCATATCTGCCTTGCAGAGT 23 _ .
FRAME NM 006115 S1986/PRAME.r3 GCACGTGGGTCAGATTGCT . 19 _ .
FRAME NM 006115 S4756/PRAME.p3 TCCTGCAGCACCTCATCGGGCT = 22 pS2 - NM:003225 S0241/pS2.f2 GC
pS2 NM_003225 S0243/pS2.r2 CGTCGATGGTATTAGGATAGAAGCA 25 pS2 NM_003225 S5026/pS2.p2 TGCTGTTTCGACGACACCGTTCG 23 RAD51C NM_058216 = S2606/RAD51C.f3 GAACTTCTTGAGCAGGAGCATACC = 24 RAD51C NM_058216 S2607/RAD51C.r3 TCCACCCCCAAGAATATCATCTAGT 25 RAD51C . NM_058216 S4764/RAD51 C. p3 AGGGCTTCATAATCACCTTCTGTTC 25 RB1 .NM_000321 S2700/RB1.fl CGAAGCCCTTACAAGTTTCC 20 RBI NM .000321 S2701/RB1.r1 RBI NM 000321 34765/RB1.p1 R1Z1 NM:012231 S1320/RIZ1J2 RIZ1 NM_012231 S1321/RIZ1.r2 R IZ1 NM_012231 S4761/RIZ1.p2 STK15 NM_ 003600 S0794/STK15.f2 CATCTTCCAGGAGGACCACT 20 STK15 NM 003600 S0795/STK1.5.r2 STK15 - NM 003600 ' S4745/STK15.p2 CTCTGTGGCACCCTGGACTACCTG 24 STMY3 NM:005940 = S2067/STMY3.f3 CCTGGAGGCTGCAACATACC 20 STMY3 NM_005940 S2068/STMY3.r3 TACAATGGCTTTGGAGGATAGCA 23 .
STMY3 = NM_005940 S4746/STMY3.p3 ATCCTCCTGAAGCCCTMCGCAGC = 25 . .
SURV NM_ 001168 S0259/SURV.f2 = TGTTTTGATTCCCGGGCTTA 20 SU RV NM_001168 S0261/SURV.r2 = SURV NM 001168 S4747/S U kv. p 2 TBP NM_ 003194 S 0262/TB P.f1 TB P NM 003194 S0264/TBP.r1 CGTGGCTCTCTTATCCTCATGAT " . 23 .
TBP NM:003194 S4751fTBP.p1 TACCGCAGCAAACCGCTTGGG 21 TGFA NM_003236 = S0489/TGFA.f2 , GGTGTGCCACAGACCTTCCT 20 .
TGFA NM_003236 S0490/TGFA.r2 ACGGAGTTCTTGACAGAG 1 1 i 1 GA 24 TGFA NM_003236 = S4768/TGFA.p2 TIMP1 NM_003254 S1695/11MP i .f3 TCCCTGCGGTCCCAGATAG = 19 TIMP1 NM_003254 S1696/TIMP1.r3 GTGGGAACAGGGTGGACACT 20 TIMP1 NM_003254 S4918/TIMPl.p3 ATCCTGCCCGGAGTGGAACTGAAGC 25 =
TOP2A NM_001067 60271TTOP2A.f4 AATCCAAGGGGGAGAGTGAT 20 =
TOP2A = NM 001067 S0273/TOP2A.r4 GTACAGATTTTGCCCGAGGA 20 .
TOP2A .NM_001067 S4777/TOP2A.p4 CATATGGACTTTGACTCAGCTGTGGC 26 .
TOP2B NM_001068 S0274/TOP2B.f2 TGTGGACATCTTCCCCTCAGA 21 TOP2B = NM 001068 S0276/TOP2B.r2 CTAGCCCGACC GGTTC GT 18 TOP2B NM_001068, S4778/TOP 2B. p2 TTCCCTACTGAGCCACCTTCTCTG 24 TP NM 001953 S0277/TP.13 CTATATGCAGCCAGAGATGTGACA 24 TP NM_001953 S0279/TP.r3 CCACGAGTTraTTACTGAGAATGG ' 24 TP NM_001953 S4779/TP.p3 ACAGCCTGCCACTCATCACAGCC 23 TP538P2 NM_005426 S1931/TP53BP.f2 GGGCCAAATATTCAGAAGC 19 TP533P2 NM 005426 S1932/TP53BP.r2 GGATGGGTATGATGGGACAG 20 TP53BP2 NM:005426 S5049/TP533P.p2 CCACCATAGCGGCCATGGAG 20 TRAIL NM_003810 S2539/TRA1L.f1 CTTCACAGTGCTCCTGCAGTCT 22 TRAIL = NM_003810 S2540/TRAIL.r1 CATCTGCTTCAG CTCGTTG
GT = = . 21 TRAIL NM 003810 S4980/TRAIL.p1 AAGTACACGTAAGTTACAGCCACACA ' 26 TS NM 001071 S0280/TS.f1 GCCTCGGTGTGCCTTTCA 18 TS NM-001071 80282/TS.r1 CGTGATGTGCGCAATCATG 19 TS NM:001071 S4780/TS.pl CATCGCCAGCTACGCCCTGCTC 22 =
up a NM_002658 S0283/upa.f3 GTGGATGTGCCCTGAAGGA. 19 up a NM_002658 S0285/upa.r3 CTGCGGATCCAGGGTAAGAA ' 20 =
40 .
Table 6F
=
upa NM_002658 S4769/upa.p3 AAGCCAGGCGTCTACACGAGAGTCTCAC 28 VDR = NM 000376 S2745NDR.f2 GCCCTGGATTTCAGAAAGAG 20 VDR NM 000376 S2746NDR.r2 AGTTACAAGCCAGGGAAGGA 20 VD R NM_000376 S4962N0 R. p2 VEGF NM 003376 60286NEGF.f1 VEGF NM-003376 60288NEGF.r1 GCAGCCTGGGACCACTTG . 18 VEGF NM_003376 64782NEGF.p1 TTGCCTTGCTGCTCTACCTCCACCA 25 VEGFB NM 003377 S2724NEGFB.f1 VEGFB NM 003377 S2725NEGFB.r1 GGTACCGGATCATGAGGATCTG 22 VEGFB NM_003377 64960NEGFB.p1 CTGGGCAGCACCAAGTCCGGA 21 WISP1 NM 003882 61671NVISP1 .f1 WISP1 NM 003882 S1672/WISP1 .r1 WISP1 NM_003882 S4915/VVISP1.pl CGGGCTGCATCAGCACACGC 20 GCAGTTGGAAGACACAGGAAAGT . 23 XIAP NM 001167 S0291/XIAP.r1 XIAP NM_001167 S4752/XIAP.p1 TCCCCAAATTGCAGATTTATCAACGGC 27 YB-1 NM 004559 S1194/YB-1.f2 YB-1 NM_004559 S1195NB-1.r2 GGAACACCACCAGGACCTGTAA 22 YB-1 NM_004559 S4843NB-1.p2 ______________ TTGCTGCCTCCGCACCC IIIi CT
ZNF217 NM 006526 S2739/ZNF217.f3 ACCCAGTAGCAAGGAGAAGC 20 ZNF217 NM_006526 S2740/ZNF217.r3 CAGCTGGTGGTAGGTTCTGA 20 ZNF2l 7 NM 006526 S4961/ZN F217. p3 CACTCACTGCTCCGAGTGCGG 21 =
=
=
=
SEQUENCE LISTING
<110> GENOMIC HEALTH, INC.
RUSH UNIVERSITY MEDICAL CENTER
COBLEIGH, Melody SHAK, Steven BAKER, Joffre CRONIN, Maureen <120> GENE EXPRESSION MARKERS FOR BREAST
CANCER PROGNOSIS
<130> 39740-0008 PCT
<140> PCT/US2004/000985 <141> 2004-01-14 <150> US 60/440,861 <151> 2003-01-15 <160> 440 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 1 gcggcgagtt tccgatttaa agctgagctg cgaggaaaat ggcggcggga ggatcaaaat 60 acttgctgga tggtggactc a 81 <210> 2 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 2 cgcttctatg gcgctgagat tgtgtcagcc ctggactacc tgcactcgga gaagaacgtg 60 gtgtaccggg a 71 <210> 3 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 3 tcctgccacc cttcaaacct caggtcacgt ccgaggtcga cacaaggtac ttcgatgatg 60 aatttaccgc c 71 <210> 4 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 4 ggacagcagg aatgtgtttc tccatacagg tcacggggag ccaatggttc agaaacaaat 60 cgagtgggt 69 <210> 5 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 5 tgtgagtgaa atgccttcta gtagtgaacc gtcctcggga gccgactatg actactcaga 60 agagtatgat aacgaaccac aa 82 <210> 6 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> amplicon <400> 6 cagcagatgt ggatcagcaa gcaggagtat gacgagtccg gcccctccat cgtccaccgc 60 aaatgc 66 <210> 7 <211> 80 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 7 ggctcttgtg cgtactgtcc ttcgggctgg tgacagggaa gacatcactg agcctgccat 60 ctgtgctctt cgtcatctga 80 <210> 8 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 8 gggtcaggtg cctcgagatc gggcttgggc ccagagcatg ttccagatcc cagagtttga 60 gccgagtgag cag 73 =
<210> 9 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 9 cgttgtcagc acttggaata caagatggtt gccgggtcat gttaattggg aaaaagaaca 60 gtccacagga agaggttgaa c 81 <210> 10 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 10 cctggagggt cctgtacaat ctcatcatgg gactcctgcc cttacccagg ggccacagag 60 cccccgagat ggagcccaat tag 83 <210> 11 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 11 cagatggacc tagtacccac tgagatttcc acgccgaagg acagcgatgg gaaaaatgcc 60 cttaaatcat agg 73 <210> 12 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 12 atcctagccc tggtttttgg cctccttttt gctgtcacca gcgtcgcgtt ccttgtgcag 60 atgagaaggc ag 72 <210> 13 <211> 84 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 13 ttcaggttgt tgcaggagac catgtacatg actgtctcca ttattgatcg gttcatgcag 60 aataattgtg tgcccaagaa gatg 84 <210> 14 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 14 gcatgttcgt ggcctctaag atgaaggaga ccatccccct gacggccgag aagctgtgca 60 tctacaccg 69 <210> 15 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 15 aaagaagatg atgaccgggt ttacccaaac tcaacgtgca agcctcggat tattgcacca 60 tccagaggct c 71 <210> 16 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 16 atgctgtggc tccttcctaa ctggggcttt cttgacatgt aggttgcttg gtaataacct 60 ttttgtatat cacaatttgg qt 82 <210> 17 <211> 65 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 17 agatgaagtg gaaggcgctt ttcaccgcgg ccatcctgca ggcacagttg ccgattacag 60 aggca 65 <210> 18 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 18 tggttcccag ccctgtgtcc acctccaagc ccagattcag attcgagtca tgtacacaac 60 ccagggtgga ggag 74 <210> 19 <211> 64 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 19 gggcgtggaa cagtttatct cagacatctg ccccaagaag gacgtactcg aaaccttcac 60 cgtg 64 <210> 20 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 20 tgagtgtccc ccggtatctt ccccgccctg ccaatcccga tgaaattgga aattttattg 60 atgaaaatct gaaagcggct g 81 <210> 21 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 21 tgacaatcag cacacctgca ttcaccgctc ggaagagggc ctgagctgca tgaataagga 60 tcacggctgt agtcaca 77 <210> 22 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 22 gataaattgg tacaagggat cagcttttcc cagcccacat gtcctgatca tatgcttttg 60 aatagtcagt tacttggcac cc 82 <210> 23 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 23 tgcctgtggt gggaagctca gtaactggga accaaaggat gatgctatgt cagaacaccg 60 gaggcatttt cc 72 <210> 24 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 24 ggatatttcc gtggctctta ttcaaactct ccatcaaatc ctgtaaactc cagagcaaat 60 caagattttt ctgccttgat gagaag 86 <210> 25 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 25 gacatttcca gtcctgcagt caatgcctct ctgccccacc ctttgttcag tgtggctggt 60 gccacgacaa atgtgtgcga tcggag 86 <210> 26 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 26 ggcatcctgg cccaaagttt cccaaatcca ggcggctaga ggcccactgc ttcccaacta 60 ccagctgagg gggtc 75 <210> 27 <211> 79 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 27 tctgcagagt tggaagcact ctatggtgac atcgatgctg tggagctgta tcctgccctt 60 ctggtagaaa agcctcggc 79 <210> 28 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 28 gggaggctta tctcactgag tgagcagaat ctggtagact gctctgggcc tcaaggcaat 60 gaaggctgca atgg 74 <210> 29 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 29 tgtctcactg agcgagcaga atctggtgga ctgttcgcgt cctcaaggca atcagggctg 60 caatggt 67 <210> 30 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 30 cgctgacatc atgaatgttc ctcgaccggc tggaggcgag tttggatatg acaaagacac 60 atcgttgctg aaagaga 77 <210> 31 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 31 cacaatggcg gctctgaaga gttggctgtc gcgcagcgta acttcattct tcaggtacag 60 acagtgtttg tgt 73 <210> 32 <211> 84 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 32 ctctgagaca gtgcttcgat gactttgcag acttggtgcc ctttgactcc tgggagccgc 60 tcatgaggaa gttgggcctc atgg 84 <210> 33 <211> 62 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 33 tgtcgatgga cttccagaac cacctgggca gctgccaaaa gtgtgatcca agctgtccca 60 at 62 <210> 34 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 34 gatctaagat ggcgactgtc gaaccggaaa ccacccctac tcctaatccc ccgactacag 60 aagaggagaa aacggaatct aa 82 <210> 35 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 35 ggcagtgtca ctgagtcctt gaaatcctcc cctgccccgc gggtctctgg attgggacgc 60 acagtgca 68 <210> 36 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 36 gggccctcca gaacaatgat gggctttatg atcctgactg cgatgagagc gggctcttta 60 aggccaagca gtgca 75 <210> 37 <211> 76 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 37 accgtaggct ctgctctgaa tgactctcct gtgggtctgg ctgcctatat tctagagaag 60 ttttccacct ggacca 76 <210> 38 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 38 cggttatgtc atgccagata cacacctcaa aggtactccc tcctcccggg aaggcaccct 60 ttcttcagtg ggtctcagtt c 81 <210> 39 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 39 cgtggtgccc ctctatgacc tgctgctgga gatgctggac gcccaccgcc tacatgcgcc 60 cactagcc 68 <210> 40 <211> 90 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 40 ggctattcct cattttctct acaaagtggc ctcagtgaac atgaagaagg tagcctcctg 60 gaggagaatt tcggtgacag tctacaatcc 90 <210> 41 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 41 cggtagtcaa gtccggatca agggcaagga gacggaattc tacctgtgca tgaaccgcaa 60 aggcaagc 68 <210> 42 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 42 cacgggacat tcaccacatc gactactata aaaagacaac caacggccga ctgcctgtga 60 agtggatggc accc 74 <210> 43 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 43 ccagtggagc gcttccatga cctgcgtcct gatgaagtgg ccgatttgtt tcagacgacc 60 cagagag 67 <210> 44 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 44 ttggtacctg tgggttagca tcaagttctc cccagggtag aattcaatca gagctccagt 60 ttgcatttgg atgtg 75 <210> 45 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 45 tcagcagcaa gggcatcatg gaggaggatg aggcctgcgg gcgccagtac acgctcaaga 60 aaaccacc 68 <210> 46 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 46 attccaccca tggcaaattc catggcaccg tcaaggctga gaacgggaag cttgtcatca 60 atggaaatcc catc 74 <210> 47 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 47 caaaggagct cactgtggtg tctgtgttcc aaccactgaa tctggacccc atctgtgaat 60 aagccattct gactc 75 <210> 48 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 48 ccatctgcat ccatcttgtt tgggctcccc acccttgaga agtgcctcag ataataccct 60 ggtggcc 67 <210> 49 <211> 73 <212> DNA
<213> Aritificial sequence <220>
<223> Amplicon <400> 49 cgaaaagatg ctgaacagtg acaaatccaa ctgaccagaa gggaggagga agctcactgg 60 tggctgttcc tga 73 <210> 50 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 50 aagctatgag gaaaagaagt acacgatggg ggacgctcct gattatgaca gaagccagtg 60 gctgaatgaa aaattcaagc tgggcc 86 <210> 51 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 51 cccactcagt agccaagtca caatgtttgg aaaacagccc gtttacttga gcaagactga 60 taccacctgc gtg 73 <210> 52 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 52 cggtgtgaga agtgcagcaa gccctgtgcc cgagtgtgct atggtctggg catggagcac 60 ttgcgagagg 70 <210> 53 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 53 tgaacataaa gtctgcaaca tggaaggtat tgcactgcac aggccacatt cacgtatatg 60 ataccaacag taaccaacct ca 82 <210> 54 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 54 tccaggatgt taggaactgt gaagatggaa gggcatgaaa ccagcgactg gaacagctac 60 tacgcagaca cgc 73 <210> 55 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 55 agaaccgcaa ggtgagcaag gtggagattc tccagcacgt catcgactac atcagggacc 60 ttcagttgga 70 <210> 56 <211> 76 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 56 tccggagctg tgatctaagg aggctggaga tgtattgcgc acccctcaag cctgccaagt 60 cagctcgctc tgtccg 76 <210> 57 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 57 gcatggtagc cgaagatttc acagtcaaaa tcggagattt tggtatgacg cgagatatct 60 atgagacaga ctattaccgg aaa 83 <210> 58 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 58 gtggacagca ccatgaacat gttgggcggg ggaggcagtg ctggccggaa gcccctcaag 60 tcgggtatga agg 73 <210> 59 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 59 cctgaacctt ccaaagatgg ctgaaaaaga tggatgcttc caatctggat tcaatgagga 60 gacttgcctg gt 72 <210> 60 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 60 ccacagctca ccttctgtca ggtgtccatc ccagctccag ccagctccca gagaggaaga 60 gactggcact gagg 74 <210> 61 <211> 80 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 61 cggactttgg gtgcgacttg acgagcggtg gttcgacaag tggccttgcg ggccggatcg 60 tcccagtgga agagttgtaa 80 <210> 62 <211> 78 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 62 gcccagaggc tccatcgtcc atcctcttcc tccccagtcg gctgaactct ccccttgtct 60 gcactgttca aacctctg 78 <210> 63 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 63 ggcctgctga gatcaaagac tacagtccct acttcaagac cattgaggac ctgaggaaca 60 agattctcac agccacagtg gac 83 <210> 64 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 64 cgaggattgg ttcttcagca agacagagga actgaaccgc gaggtggcca ccaacagtga 60 gctggtgcag agt 73 <210> 65 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 65 agagatcgag gctctcaagg aggagctgct cttcatgaag aagaaccacg aagaggaagt 60 aaaaggcc 68 <210> 66 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 66 tgagcggcag aatcaggagt accagcggct catggacatc aagtcgcggc tggagcagga 60 gattgccacc taccgca 77 <210> 67 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 67 tcagtggaga aggagttgga ccagtcaaca tctctgttgt cacaagcagt gtttcctctg 60 gatatggca 69 <210> 68 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 68 ggatgaagct tacatgaaca aggtagagct ggagtctcgc ctggaagggc tgaccgacga 60 gatcaacttc ctcaggcagc tatatg 86 a <210> 69 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 69 ggaaagacca cctgaaaaac cacctccaga cccacgaccc caacaaaatg gcctttgggt 60 gtgaggagtg tgggaagaag tac 83 <210> 70 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 70 cagatggcca ctttgagaac attttagctg acaacagtgt gaacgaccag accaaaatcc 60 ttgtggttaa tgctgcc 77 <210> 71 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 71 gacttttgcc cgctaccttt cattccggcg tgacaacaat gagctgttgc tcttcatact 60 gaagcagtta gtggc 75 <210> 72 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 72 ggagaacaat ccccttgaga cagaatatgg cctttctgtc tacaaggatc accagaccat 60 caccatccag gagat 75 <210> 73 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 73 tgatggtcct atgtgtcaca ttcatcacag gtttcatacc aacacaggct tcagcacttc 60 ctttggtgtg tttcctgtcc ca 82 a <210> 74 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 74 ctacagggac gccatcgaat ccggatcttg atgctggtgt aagtgaacat tcaggtgatt 60 ggttggat 68 <210> 75 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 75 gagaaccaat ctcaccgaca ggcagctggc agaggaatac ctgtaccgct atggttacac 60 tcgggtg 67 <210> 76 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 76 ccgccctcac ctgaagagaa acgcgctcct tggcggacac tgggggagga gaggaagaag 60 cgcggctaac ttattcc 77 <210> 77 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 77 gccgagatcg ccaagatgtt gccagggagg acagacaatg ctgtgaagaa tcactggaac 60 tctaccatca aaag 74 <210> 78 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 78 ccctcgtgct gatgctactg aggagccagc gtctagggca gcagccgctt cctagaagac 60 caggtcatga tg 72 =
<210> 79 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 79 cggtggacca cgaagagtta acccgggact tggagaagca ctgcagagac atggaagagg 60 cgagcc 66 <210> 80 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 80 ctttgaaccc ttgcttgcaa taggtgtgcg tcagaagcac ccaggacttc catttgcttt 60 gtcccggg 68 <210> 81 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 81 ccgcaacgtg gttttctcac cctatggggt ggcctcggtg ttggccatgc tccagctgac 60 aacaggagga gaaacccagc a 81 <210> 82 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 82 ccagctctcc ttccagctac agatcaatgt ccctgtccga gtgctggagc taagtgagag 60 ccaccc 66 <210> 83 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 83 ataccaatca ccgcacaaac ccaggctatt tgttaagtcc agtcacagcg caaagaaaca 60 tatgcggaga aaatgctagt gtg 83 <210> 84 <211> 62 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 84 gccatccgca aaggctttct cgcttgtcac cttgccatgt ggaagaaact ggcggaatgg 60 cc 62 <210> 85 <211> 85 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 85 gcatcaggct gtcattatgg tgtccttacc tgtgggagct gtaaggtctt ctttaagagg 60 gcaatggaag ggcagcacaa ctact 85 <210> 86 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 86 tctccatatc tgccttgcag agtctcctgc agcacctcat cgggctgagc aatctgaccc 60 acgtgc 66 <210> 87 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 87 gccctcccag tgtgcaaata agggctgctg tttcgacgac accgttcgtg gggtcccctg 60 gtgcttctat cctaatacca tcgacg 86 <210> 88 <211> 78 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 88 gaacttcttg agcaggagca tacccagggc ttcataatca ccttctgttc agcactagat 60 gatattcttg ggggtgga 78 =
<210> 89 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 89 cgaagccctt acaagtttcc tagttcaccc ttacggattc ctggagggaa catctatatt 60 tcacccctga agagtcc 77 <210> 90 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 90 ccagacgagc gattagaagc ggcagcttgt gaggtgaatg atttggggga agaggaggag 60 gaggaagagg agga 74 <210> 91 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 91 catcttccag gaggaccact ctctgtggca ccctggacta cctgccccct gaaatgattg 60 aaggtcgga 69 <210> 92 <211> 90 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 92 cctggaggct gcaacatacc tcaatcctgt cccaggccgg atcctcctga agcccttttc 60 gcagcactgc tatcctccaa agccattgta 90 <210> 93 <211> 80 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 93 tgttttgatt cccgggctta ccaggtgaga agtgagggag gaagaaggca gtgtcccttt 60 tgctagagct gacagctttg 80 <210> 94 <211> 65 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 94 gcccgaaacg ccgaatataa tcccaagcgg tttgctgcgg taatcatgag gataagagag 60 ccacg 65 <210> 95 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 95 ggtgtgccac agaccttcct acttggcctg taatcacctg tgcagccttt tgtgggcctt 60 caaaactctg tcaagaactc cgt 83 <210> 96 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 96 tccctgcggt cccagatagc ctgaatcctg cccggagtgg aactgaagcc tgcacagtgt 60 ccaccctgtt cccac 75 <210> 97 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 97 aatccaaggg ggagagtgat gacttccata tggactttga ctcagctgtg gctcctcggg 60 caaaatctgt ac 72 <210> 98 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 98 tgtggacatc ttcccctcag acttccctac tgagccacct tctctgccac gaaccggtcg 60 ggctag 66 =
<210> 99 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 99 ctatatgcag ccagagatgt gacagccacc gtggacagcc tgccactcat cacagcctcc 60 attctcagta agaaactcgt gg 82 <210> 100 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 100 gggccaaata ttcagaagct tttatatcag aggaccacca tagcggccat ggagaccatc 60 tctgtcccat catacccatc c 81 <210> 101 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 101 cttcacagtg ctcctgcagt ctctctgtgt ggctgtaact tacgtgtact ttaccaacga 60 gctgaagcag atg 73 <210> 102 <211> 65 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 102 gcctcggtgt gcctttcaac atcgccagct acgccctgct cacgtacatg attgcgcaca 60 tcacg 65 <210> 103 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 103 gtggatgtgc cctgaaggac aagccaggcg tctacacgag agtctcacac ttcttaccct 60 ggatccgcag 70 <210> 104 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 104 gccctggatt tcagaaagag ccaagtctgg atctgggacc ctttccttcc ttccctggct 60 tgtaact 67 <210> 105 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 105 ctgctgtctt gggtgcattg gagccttgcc ttgctgctct acctccacca tgccaagtgg 60 tcccaggctg c 71 <210> 106 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 106 tgacgatggc ctggagtgtg tgcccactgg gcagcaccaa gtccggatgc agatcctcat 60 gatccggtac c 71 <210> 107 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 107 agaggcatcc atgaacttca cacttgcggg ctgcatcagc acacgctcct atcaacccaa 60 gtactgtgga gtttg 75 <210> 108 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 108 gcagttggaa gacacaggaa agtatcccca aattgcagat ttatcaacgg cttttatctt 60 gaaaatagtg ccacgca 77 =
<210> 109 <211> 76 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 109 agactgtgga gtttgatgtt gttgaaggag aaaagggtgc ggaggcagca aatgttacag 60 gtcctggtgg tgttcc 76 <210> 110 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 110 acccagtagc aaggagaagc ccactcactg ctccgagtgc ggcaaagctt tcagaaccta 60 ccaccagctg 70 <210> 111 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 111 gcggcgagtt tccgattta 19 <210> 112 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 112 tgagtccacc atccagcaag t 21 <210> 113 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 113 atggcggcgg gaggatcaaa a 21 <210> 114 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 114 cgcttctatg gcgctgagat 20 <210> 115 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 115 tcccggtaca ccacgttctt 20 <210> 116 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 116 cagccctgga ctacctgcac tcgg 24 <210> 117 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 117 tcctgccacc cttcaaacc 19 <210> 118 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 118 ggcggtaaat tcatcatcga a 21 <210> 119 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 119 caggtcacgt ccgaggtcga caca 24 <210> 120 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 120 ggacagcagg aatgtgtttc 20 <210> 121 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 121 acccactcga tttgtttctg 20 <210> 122 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 122 cattggctcc ccgtgacctg ta 22 <210> 123 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 123 tgtgagtgaa atgccttcta gtagtga 27 <210> 124 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 124 ccgtcctcgg gagccgacta tga 23 <210> 125 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 125 ttgtggttcg ttatcatact cttctga 27 <210> 126 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 126 cagcagatgt ggatcagcaa g 21 <210> 127 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 127 gcatttgcgg tggacgat 18 <210> 128 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 128 aggagtatga cgagtccggc ccc 23 <210> 129 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 129 ggctcttgtg cgtactgtcc tt 22 <210> 130 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer =
<400> 130 tcagatgacg aagagcacag atg 23 <210> 131 <211> 29 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 131 aggctcagtg atgtcttccc tgtcaccag 29 <210> 132 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 132 gggtcaggtg cctcgagat 19 <210> 133 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 133 ctgctcactc ggctcaaact c 21 <210> 134 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 134 tgggcccaga gcatgttcca gatc 24 <210> 135 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 135 cgttgtcagc acttggaata caa 23 <210> 136 =
<211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 136 gttcaacctc ttcctgtgga ctgt 24 <210> 137 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 137 cccaattaac atgacccggc aaccat 26 <210> 138 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 138 cctggagggt cctgtacaat 20 <210> 139 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 139 ctaattgggc tccatctcg 19 <210> 140 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 140 catcatggga ctcctgccct tacc 24 <210> 141 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 141 cagatggacc tagtacccac tgaga 25 <210> 142 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 142 ttccacgccg aaggacagcg at 22 <210> 143 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 143 cctatgattt aagggcattt ttcc 24 <210> 144 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 144 atcctagccc tggtttttgg 20 <210> 145 <211> 20 <212> DNA
<213> Artificial sequence <220>
<223> reverse primer <400> 145 ctgccttctc atctgcacaa 20 <210> 146 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 146 tttgctgtca ccagcgtcgc 20 <210> 147 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 147 ttcaggttgt tgcaggagac 20 <210> 148 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 148 catcttcttg ggcacacaat 20 <210> 149 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 149 tgtctccatt attgatcggt tcatgca 27 <210> 150 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 150 gcatgttcgt ggcctctaag a 21 <210> 151 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 151 cggtgtagat gcacagcttc tc 22 <210> 152 <211> 23 <212> DNA
<213> Artificial Sequence =
<220>
<223> probe <400> 152 aaggagacca tccccctgac ggc 23 <210> 153 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 153 aaagaagatg atgaccgggt ttac 24 <210> 154 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 154 gagcctctgg atggtgcaat 20 <210> 155 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 155 caaactcaac gtgcaagcct cgga 24 <210> 156 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 156 atgctgtggc tccttcctaa ct 22 <210> 157 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 157 acccaaattg tgatatacaa aaaggtt 27 <210> 158 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 158 taccaagcaa cctacatgtc aagaaagccc 30 <210> 159 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 159 agatgaagtg gaaggcgctt 20 <210> 160 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 160 caccgcggcc atcctgca 18 <210> 161 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 161 tgcctctgta atcggcaact g 21 <210> 162 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 162 tggttcccag ccctgtgt 18 <210> 163 <211> 28 <212> DNA
<213> Artificial Sequence =
<220>
<223> probe <400> 163 ctccaagccc agattcagat tcgagtca 28 <210> 164 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 164 ctcctccacc ctgggttgt 19 <210> 165 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 165 gggcgtggaa cagtttatct 20 <210> 166 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 166 cacggtgaag gtttcgagt 19 <210> 167 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 167 agacatctgc cccaagaagg acgt 24 <210> 168 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 168 =
tgagtgtccc ccggtatctt c 21 <210> 169 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 169 cagccgcttt cagattttca t 21 <210> 170 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 170 tgccaatccc gatgaaattg gaaattt 27 <210> 171 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 171 tgacaatcag cacacctgca t 21 <210> 172 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 172 tgtgactaca gccgtgatcc tta 23 <210> 173 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 173 caggccctct tccgagcggt 20 <210> 174 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 174 gataaattgg tacaagggat cagctt 26 <210> 175 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 175 gggtgccaag taactgacta ttca 24 <210> 176 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 176 ccagcccaca tgtcctgatc atatgc 26 <210> 177 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 177 tgcctgtggt gggaagct 18 <210> 178 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 178 ggaaaatgcc tccggtgtt 19 <210> 179 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 179 tgacatagca tcatcctttg gttcccagtt 30 <210> 180 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 180 ggatatttcc gtggctctta ttca 24 <210> 181 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 181 tctccatcaa atcctgtaaa ctccagagca 30 <210> 182 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 182 cttctcatca aggcagaaaa atctt 25 <210> 183 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 183 gacatttcca gtcctgcagt ca 22 <210> 184 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 184 tgcctctctg ccccaccctt tgt 23 <210> 185 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 185 ctccgatcgc acacatttgt 20 <210> 186 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 186 ggcatcctgg cccaaagt 18 <210> 187 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 187 gaccccctca gctggtagtt g 21 <210> 188 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 188 cccaaatcca ggcggctaga ggc 23 <210> 189 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 189 tctgcagagt tggaagcact cta 23 <210> 190 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 190 caggatacag ctccacagca tcgatgtc 28 <210> 191 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 191 gccgaggctt ttctaccaga a 21 <210> 192 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 192 gggaggctta tctcactgag tga 23 <210> 193 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 193 ccattgcagc cttcattgc 19 <210> 194 <211> 29 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 194 ttgaggccca gagcagtcta ccagattct 29 <210> 195 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 195 tgtctcactg agcgagcaga a 21 <210> 196 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 196 accattgcag ccctgattg 19 <210> 197 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 197 cttgaggacg cgaacagtcc acca 24 <210> 198 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 198 cgctgacatc atgaatgttc ct 22 <210> 199 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 199 tctctttcag caacgatgtg tctt 24 <210> 200 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 200 tcatatccaa actcgcctcc agccg 25 <210> 201 <211> 19 <212> DNA
<213> Artificial Sequence <220>
=
<223> forward primer <400> 201 cacaatggcg gctctgaag 19 <210> 202 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 202 acacaaacac tgtctgtacc tgaaga 26 <210> 203 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 203 aagttacgct gcgcgacagc caa 23 <210> 204 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 204 ctctgagaca gtgcttcgat gact 24 <210> 205 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 205 ccatgaggcc caacttcct 19 <210> 206 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 206 cagacttggt gccctttgac tcc 23 <210> 207 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 207 tgtcgatgga cttccagaac 20 <210> 208 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 208 cacctgggca gctgccaa 18 <210> 209 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 209 attgggacag cttggatca 19 <210> 210 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 210 gatctaagat ggcgactgtc gaa 23 <210> 211 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 211 ttagattccg ttttctcctc ttctg 25 <210> 212 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 212 accaccccta ctcctaatcc cccgact 27 <210> 213 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 213 ggcagtgtca ctgagtcctt ga 22 <210> 214 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 214 tgcactgtgc gtcccaat 18 <210> 215 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 215 atcctcccct gccccgcg 18 <210> 216 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 216 gggccctcca gaacaatgat 20 <210> 217 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 217 tgcactgctt ggccttaaag a 21 =
<210> 218 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 218 ccgctctcat cgcagtcagg atcat 25 <210> 219 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 219 accgtaggct ctgctctgaa 20 <210> 220 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 220 tggtccaggt ggaaaacttc 20 <210> 221 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 221 aggcagccag acccacagga 20 <210> 222 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 222 cggttatgtc atgccagata cac 23 <210> 223 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 223 cctcaaaggt actccctcct cccgg 25 <210> 224 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 224 gaactgagac ccactgaaga aagg 24 <210> 225 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 225 cgtggtgccc ctctatgac 19 <210> 226 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 226 ctggagatgc tggacgccc 19 <210> 227 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 227 ggctagtggg cgcatgtag 19 <210> 228 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 228 ggattgtaga ctgtcaccga aattc 25 <210> 229 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 229 ggctattcct cattttctct acaaagtg 28 <210> 230 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 230 cctccaggag gctaccttct tcatgttcac 30 <210> 231 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 231 cggtagtcaa gtccggatca a 21 <210> 232 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 232 gcttgccttt gcggttca 18 <210> 233 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 233 caaggagacg gaattctacc tgtgc 25 <210> 234 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 234 cacgggacat tcaccacatc 20 <210> 235 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 235 gggtgccatc cacttcaca 19 <210> 236 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 236 ataaaaagac aaccaacggc cgactgc 27 <210> 237 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 237 ccagtggagc gcttccat 18 <210> 238 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 238 ctctctgggt cgtctgaaac aa 22 <210> 239 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 239 tcggccactt catcaggacg cag 23 <210> 240 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 240 ttggtacctg tgggttagca 20 <210> 241 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 241 cacatccaaa tgcaaactgg 20 <210> 242 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 242 tccccagggt agaattcaat cagagc 26 <210> 243 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 243 tcagcagcaa gggcatcat 19 <210> 244 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 244 ggtggttttc ttgagcgtgt act 23 <210> 245 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 245 cgcccgcagg cctcatcct 19 <210> 246 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 246 attccaccca tggcaaattc 20 <210> 247 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 247 gatgggattt ccattgatga ca 22 <210> 248 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 248 ccgttctcag ccttgacggt gc 22 <210> 249 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 249 caaaggagct cactgtggtg tct 23 <210> 250 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe =
<400> 250 tgttccaacc actgaatctg gacc 24 <210> 251 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 251 gagtcagaat ggcttattca cagatg 26 <210> 252 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 252 ccatctgcat ccatcttgtt 20 <210> 253 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 253 ctccccaccc ttgagaagtg cct 23 <210> 254 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 254 ggccaccagg gtattatctg 20 <210> 255 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 255 cgaaaagatg ctgaacagtg aca 23 <210> 256 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 256 tcaggaacag ccaccagtga 20 <210> 257 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 257 cttcctcctc ccttctggtc agttggat 28 <210> 258 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 258 ggcccagctt gaatttttca 20 <210> 259 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 259 aagctatgag gaaaagaagt acacgat 27 <210> 260 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 260 tcagccactg gcttctgtca taatcaggag 30 <210> 261 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 261 cccactcagt agccaagtca 20 <210> 262 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 262 tcaagtaaac gggctgtttt ccaaaca 27 <210> 263 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 263 cacgcaggtg gtatcagtct 20 <210> 264 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 264 cggtgtgaga agtgcagcaa 20 <210> 265 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 265 ccagaccata gcacactcgg gcac 24, <210> 266 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 266 cctctcgcaa gtgctccat 19 <210> 267 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 267 tgaacataaa gtctgcaaca tgga 24 <210> 268 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 268 tgaggttggt tactgttggt atcatata 28 <210> 269 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 269 ttgcactgca caggccacat tcac 24 <210> 270 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 270 tccaggatgt taggaactgt gaag 24 <210> 271 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 271 gcgtgtctgc gtagtagctg tt 22 <210> 272 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 272 agtcgctggt ttcatgccct tcca 24 <210> 273 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 273 agaaccgcaa ggtgagcaa 19 <210> 274 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 274 tccaactgaa ggtccctgat g 21 <210> 275 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 275 tggagattct ccagcacgtc atcgac 26 <210> 276 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 276 tccggagctg tgatctaagg a 21 <210> 277 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 277 tgtattgcgc acccctcaag cctg 24 =
<210> 278 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 278 cggacagagc gagctgactt 20 <210> 279 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 279 gcatggtagc cgaagatttc a 21 <210> 280 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 280 tttccggtaa tagtctgtct catagatatc 30 <210> 281 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 281 cgcgtcatac caaaatctcc gattttga 28 <210> 282 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 282 gtggacagca ccatgaaca 19 <210> 283 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 283 ccttcatacc cgacttgagg 20 <210> 284 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 284 cttccggcca gcactgcctc 20 <210> 285 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 285 cctgaacctt ccaaagatgg 20 <210> 286 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 286 accaggcaag tctcctcatt 20 <210> 287 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 287 ccagattgga agcatccatc tttttca 27 <210> 288 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 288 ccacagctca ccttctgtca 20 <210> 289 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 289 cctcagtgcc agtctcttcc 20 <210> 290 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 290 tccatcccag ctccagccag 20 <210> 291 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 291 ccacttgtcg aaccaccgct cgt 23 <210> 292 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 292 cggactttgg gtgcgactt 19 <210> 293 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 293 ttacaactct tccactggga cgat 24 <210> 294 <211> 18 <212> DNA
=
<213> Artificial Sequence <220>
<223> forward primer <400> 294 gcccagaggc tccatcgt 18 <210> 295 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 295 cagaggtttg aacagtgcag aca 23 <210> 296 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 296 cctcttcctc cccagtcggc tga 23 <210> 297 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 297 ggcctgctga gatcaaagac 20 <210> 298 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 298 gtccactgtg gctgtgagaa 20 <210> 299 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 299 tgttcctcag gtcctcaatg gtcttg 26 <210> 300 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 300 cgaggattgg ttcttcagca a 21 <210> 301 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 301 actctgcacc agctcactgt tg 22 <210> 302 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 302 cacctcgcgg ttcagttcct ctgt 24 <210> 303 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 303 agagatcgag gctctcaagg 20 <210> 304 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 304 ggccttttac ttcctcttcg 20 <210> 305 <211> 27 =
<212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 305 tggttcttct tcatgaagag cagctcc 27 <210> 306 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 306 tgagcggcag aatcaggagt a 21 <210> 307 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 307 tgcggtaggt ggcaatctc 19 <210> 308 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 308 ctcatggaca tcaagtcgcg gctg 24 <210> 309 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 309 tcagtggaga aggagttgga 20 <210> 310 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe =
<400> 310 ccagtcaaca tctctgttgt cacaagca 28 <210> 311 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 311 tgccatatcc agaggaaaca 20 <210> 312 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 312 ggatgaagct tacatgaaca aggtaga 27 <210> 313 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 313 catatagctg cctgaggaag ttgat 25 <210> 314 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 314 cgtcggtcag cccttccagg c 21 <210> 315 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 315 ggaaagacca cctgaaaaac ca 22 <210> 316 =
<211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 316 gtacttcttc ccacactcct caca 24 <210> 317 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 317 acccacgacc ccaacaaaat ggc 23 <210> 318 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 318 cagatggcca ctttgagaac att 23 <210> 319 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 319 ggcagcatta accacaagga tt 22 <210> 320 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 320 agctgacaac agtgtgaacg accagacc 28 <210> 321 <211> 21 <212> DNA
<213> Artificial Sequence <220>
=
<223> forward primer <400> 321 gacttttgcc cgctaccttt c 21 <210> 322 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 322 gccactaact gcttcagtat gaagag 26 <210> 323 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 323 acagctcatt gttgtcacgc cgga 24 <210> 324 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 324 ggagaacaat ccccttgaga 20 <210> 325 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 325 atctcctgga tggtgatggt 20 <210> 326 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 326 tggcctttct gtctacaagg atcacca 27 =
<210> 327 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 327 tgatggtcct atgtgtcaca ttca 24 <210> 328 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 328 tgggacagga aacacaccaa 20 <210> 329 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 329 caggtttcat accaacacag gcttcagcac 30 <210> 330 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 330 ctacagggac gccatcgaa 19 <210> 331 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 331 atccaaccaa tcacctgaat gtt 23 <210> 332 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 332 cttacaccag catcaagatc cgg 23 <210> 333 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 333 gagaaccaat ctcaccgaca 20 <210> 334 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 334 cacccgagtg taaccatagc 20 <210> 335 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 335 acaggtattc ctctgccagc tgcc 24 <210> 336 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 336 ccgccctcac ctgaagaga 19 <210> 337 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 337 ggaataagtt agccgcgctt ct 22 =
<210> 338 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 338 cccagtgtcc gccaaggagc g 21 <210> 339 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 339 gccgagatcg ccaagatg 18 <210> 340 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 340 cttttgatgg tagagttcca gtgattc 27 <210> 341 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 341 cagcattgtc tgtcctccct ggca 24 <210> 342 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 342 ccctcgtgct gatgctact 19 <210> 343 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 343 catcatgacc tggtcttcta gg 22 <210> 344 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 344 ctgccctaga cgctggctcc tc 22 <210> 345 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 345 cggtggacca cgaagagtta a 21 <210> 346 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 346 ccgggacttg gagaagcact gca 23 <210> 347 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 347 ggctcgcctc ttccatgtc 19 <210> 348 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 348 =
ctttgaaccc ttgcttgcaa 20 <210> 349 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 349 aagtcctggg tgcttctgac gcaca 25 <210> 350 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 350 cccgggacaa agcaaatg 18 <210> 351 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 351 ccgcaacgtg gttttctca 19 <210> 352 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 352 ctcggtgttg gccatgctcc ag 22 <210> 353 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 353 tgctgggttt ctcctcctgt t 21 <210> 354 <211> 20 <212> DNA
=
<213> Artificial Sequence <220>
<223> forward primer <400> 354 ccagctctcc ttccagctac 20 <210> 355 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 355 gggtggctct cacttagctc 20 <210> 356 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 356 atcaatgtcc ctgtccgagt gctg 24 <210> 357 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 357 cacactagca ttttctccgc ata 23 <210> 358 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 358 ataccaatca ccgcacaaac c 21 <210> 359 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 359 tgcgctgtga ctggacttaa caaatagcct 30 <210> 360 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 360 gccatccgca aaggcttt 18 <210> 361 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 361 ggccattccg ccagtttc 18 <210> 362 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 362 tcgcttgtca ccttgccatg tgg 23 <210> 363 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 363 gcatcaggct gtcattatgg 20 <210> 364 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 364 agtagttgtg ctgcccttcc 20 <210> 365 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 365 tgtccttacc tgtgggagct gtaaggtc 28 <210> 366 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 366 tctccatatc tgccttgcag agt 23 <210> 367 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 367 gcacgtgggt cagattgct 19 <210> 368 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 368 tcctgcagca cctcatcggg ct 22 <210> 369 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 369 gccctcccag tgtgcaaat 19 <210> 370 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 370 tgctgtttcg acgacaccgt tog 23 <210> 371 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 371 cgtcgatggt attaggatag aagca 25 <210> 372 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 372 gaacttcttg agcaggagca taco 24 <210> 373 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 373 tccaccccca agaatatcat ctagt 25 <210> 374 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 374 agggcttcat aatcaccttc tgttc 25 <210> 375 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 375 cgaagccctt acaagtttcc 20 <210> 376 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 376 ggactcttca ggggtgaaat 20 <210> 377 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 377 cccttacgga ttcctggagg gaac 24 <210> 378 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 378 ccagacgagc gattagaagc 20 <210> 379 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 379 tcctcctctt cctcctcctc 20 <210> 380 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 380 tgtgaggtga atgatttggg gga 23 <210> 381 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 381 catcttccag gaggaccact 20 <210> 382 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 382 tccgaccttc aatcatttca 20 <210> 383 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 383 ctctgtggca ccctggacta cctg 24 <210> 384 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 384 cctggaggct gcaacatacc 20 <210> 385 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 385 tacaatggct ttggaggata gca 23 <210> 386 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 386 atcctcctga agcccttttc gcagc 25 =
<210> 387 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 387 tgttttgatt cccgggctta 20 <210> 388 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 388 tgccttcttc ctccctcact tctcacct 28 <210> 389 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 389 caaagctgtc agctctagca aaag 24 <210> 390 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 390 gcccgaaacg ccgaatata 19 <210> 391 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 391 taccgcagca aaccgcttgg g 21 <210> 392 <211> 23 <212> DNA
<213> Artificial Sequence =
<220>
<223> reverse primer <400> 392 cgtggctctc ttatcctcat gat 23 <210> 393 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 393 ggtgtgccac agaccttcct 20 <210> 394 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 394 acggagttct tgacagagtt ttga 24 <210> 395 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 395 ttggcctgta atcacctgtg cagcctt 27 <210> 396 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 396 tccctgcggt cccagatag 19 <210> 397 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 397 gtgggaacag ggtggacact 20 =
<210> 398 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 398 atcctgcccg gagtggaact gaagc 25 <210> 399 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 399 aatccaaggg ggagagtgat 20 <210> 400 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 400 catatggact ttgactcagc tgtggc 26 <210> 401 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 401 gtacagattt tgcccgagga 20 <210> 402 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 402 tgtggacatc ttcccctcag a 21 <210> 403 <211> 24 <212> DNA
<213> Artificial Sequence =
<220>
<223> probe <400> 403 ttccctactg agccaccttc tctg 24 <210> 404 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 404 ctagcccgac cggttcgt 18 <210> 405 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 405 ctatatgcag ccagagatgt gaca 24 <210> 406 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 406 acagcctgcc actcatcaca gcc 23 <210> 407 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 407 ccacgagttt cttactgaga atgg 24 <210> 408 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 408 =
gggccaaata ttcagaagc 19 <210> 409 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 409 ggatgggtat gatgggacag 20 <210> 410 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 410 ccaccatagc ggccatggag 20 <210> 411 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 411 cttcacagtg ctcctgcagt ct 22 <210> 412 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 412 catctgcttc agctcgttgg t 21 <210> 413 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 413 aagtacacgt aagttacagc cacaca 26 <210> 414 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 414 gcctcggtgt gcctttca 18 <210> 415 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 415 catcgccagc tacgccctgc tc 22 <210> 416 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 416 cgtgatgtgc gcaatcatg 19 <210> 417 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 417 gtggatgtgc cctgaagga 19 <210> 418 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 418 ctgcggatcc agggtaagaa 20 <210> 419 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe =
<400> 419 aagccaggcg tctacacgag agtctcac 28 <210> 420 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 420 gccctggatt tcagaaagag 20 <210> 421 <211> 20 <212> DNA
<212> Artificial Sequence <220>
<223> reverse primer <400> 421 agttacaagc cagggaagga 20 <210> 422 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 422 caagtctgga tctgggaccc tttcc 25 <210> 423 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 423 ctgctgtctt gggtgcattg 20 <210> 424 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 424 gcagcctggg accacttg 18 <210> 425 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 425 ttgccttgct gctctacctc cacca 25 <210> 426 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 426 tgacgatggc ctggagtgt 19 <210> 427 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 427 ggtaccggat catgaggatc tg 22 <210> 428 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 428 ctgggcagca ccaagtccgg a 21 <210> 429 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 429 agaggcatcc atgaacttca ca 22 <210> 430 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 430 caaactccac agtacttggg ttga 24 <210> 431 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 431 cgggctgcat cagcacacgc 20 <210> 432 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 432 gcagttggaa gacacaggaa agt 23 <210> 433 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 433 tccccaaatt gcagatttat caacggc 27 <210> 434 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 434 tgcgtggcac tattttcaag a 21 <210> 435 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 435 agactgtgga gtttgatgtt gttga 25 <210> 436 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 436 ggaacaccac caggacctgt aa 22 <210> 437 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 437 ttgctgcctc cgcacccttt tct 23 <210> 438 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 438 acccagtagc aaggagaagc 20 <210> 439 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 439 cagctggtgg taggttctga 20 <210> 440 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 440 cactcactgc tccgagtgcg g 21
is compared to the amount found in a breast cancer tissue reference set. The number (N) of breast cancer tissues in this reference set should be sufficiently high to ensure that different reference sets (as a whole) behave essentially the same way. If this condition is met, the identity of the individual breast cancer tissues present in a particular set will have no significant impact on the relative amounts of the genes assayed. Usually, the breast cancer tissue reference set consists of at least about 30, preferably at least about 40 different FPE
breast cancer tissue specimens. Unless noted otherwise, normalized expression levels for each mRNA/tested tumor/patient will be expressed as a percentage of the expression level measured in the reference set. More specifically, the reference set of a sufficiently high number (e.g. 40) of tumors yields a distribution of normalized levels of each mRNA species.
The level measured in a particular tumor sample to be analyzed falls at some percentile within this range, which can be determined by methods well known in the art. Below, unless noted otherwise, reference to expression levels of a gene assume normalized expression relative to the reference set although this is not always explicitly stated.
Further details of the invention will be described in the following non-limiting Example Example A Phase 11 Study of Gene Expression in 79 Malignant Breast Tumors A gene expression study was designed and conducted with the primary goal to molecularly characterize gene expression in paraffin-embedded, fixed tissue samples of invasive breast ductal carcinoma, and to explore the correlation between such molecular profiles and disease-free survival.
Study design Molecular assays were performed on paraffin-embedded, formalin-fixed primary breast tumor tissues obtained from 79 individual patients diagnosed with invasive breast cancer. All patients in the study had 10 or more positive nodes. Mean age was 57 years, and mean clinical tumor size was 4.4 cm. Patients were included in the study only if histopathologic assessment, performed as described in the Materials and Methods section, indicated adequate amounts of tumor tissue and homogeneous pathology.
Materials and Methods Each representative tumor block was characterized by standard histopathology for diagnosis, semi-quantitative assessment of amount of tumor, and tumor grade. A
total of 6 sections (10 microns in thickness each) were prepared and placed in two Costar Brand Microcentrifuge Tubes (Polypropylene, 1.7 mL tubes, clear; 3 sections in each tube). If the tumor constituted less than 30% of the total specimen area, the sample may have been crudely dissected by the pathologist, using gross microdissection, putting the tumor tissue directly into the Costar tube.
If more than one tumor block was obtained as part of the surgical procedure, the block most representative of the pathology was used for analysis.
Gene Expression Analysis mRNA was extracted and purified from fixed, paraffm-embedded tissue samples, and prepared for gene expression analysis as described in section 9 above.
Molecular assays of quantitative gene expression were performed by RT-PCR, using the ABI PRISM 79001m Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA). ABI PRISM 7900TM consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 384-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 384 wells, and detected at the CCD.
The system includes software for running the instrument and for analyzing the data.
Analysis and Results Tumor tissue was analyzed for 185 cancer-related genes and 7 reference genes.
The threshold cycle (CT) values for each patient were normalized based on the median of the 7 reference genes for that particular patient. Clinical outcome data were available for all patients from a review of registry data and selected patient charts.
Outcomes were classified as:
0 died due to breast cancer or to unknown cause or alive with breast cancer recurrence;
1 alive without breast cancer recurrence or died due to a cause other than breast cancer Analysis was performed by:
1. Analysis of the relationship between normalized gene expression and the binary outcomes of 0 or 1.
2. Analysis of the relationship between normalized gene expression and the time to outcome (0 or 1 as defined above) where patients who were alive without breast cancer recurrence or who died due to a cause other than breast cancer were censored.
This approach was used to evaluate the prognostic impact of individual genes and also sets of multiple genes.
Analysis of patients with invasive breast carcinoma by binary approach In the first (binary) approach, analysis was performed on all 79 patients with invasive breast carcinoma. A t test was performed on the groups of patients classified as either no recurrence and no breast cancer related death at three years, versus recurrence, or breast cancer-related death at three years, and the p-values for the differences between the groups for each gene were calculated.
Table 1 lists the 47 genes for which the p-value for the differences between the groups was <0.10. The first column of mean expression values pertains to patients who neither had a metastatic recurrence of nor died from breast cancer. The second column of mean expression values pertains to patients who either had a metastatic recurrence of or died from breast cancer.
Table 1 Mean Mean t-value df p Valid N
Valid N
Bc12 -0.15748 -1.22816 4.00034 75 0.000147 PR -2.67225 -5.49747 3.61540 75 0.000541 IGF1R -0.59390 -1.71506 3.49158 75 0.000808 BAG1 0.18844 -0.68509 3.42973 75 0.000985 35 CD68 -0.52275 0.10983 -3.41186 75 0.001043 EstR1 -0.35581 -3.00699 3.32190 75 0.001384 CTSL -0.64894 -0.09204 -3.26781 75 0.001637 IGFBP2 -0.81181 -1.78398 3.24158 75 0.001774 35 42 GATA3 1.80525 0.57428 3.15608 75 0.002303 35 TP53BP2 -4.71118 -6.09289 3.02888 75 0.003365 35 42 EstR1 3.67801 1.64693 3.01073 75 0.003550 35 CEGP1 -2.02566 -4.25537 2.85620 75 0.005544 SURV -3.67493 -2.96982 -2.70544 75 0.008439 p27 0.80789 0.28807 2.55401 75 0.012678 35 Chk1 -3.37981 -2.80389 -2.46979 75 0.015793 BBC3 -4.71789 -5.62957 2.46019 75 0.016189 ZNF217 1.10038 0.62730 2.42282 75 0.017814 35 EGFR -2.88172 -2.20556 -2.34774 75 0.021527 CD9 1.29955 0.91025 2.31439 75 0.023386 35 MYBL2 -3.77489 -3.02193 -2.29042 75 0.024809 HIF1A -0.44248 0.03740 -2.25950 75 0.026757 GRB7 -1.96063 -1.05007 -2.25801 75 0.026854 pS2 -1.00691 -3.13749 2.24070 75 0.028006 RIZ1 -7.62149 -8.38750 2.20226 75 0.030720 ErbB3 -6.89508 -7.44326 2.16127 75 0.033866 TOP2B 0.45122 0.12665 2.14616 75 0.035095 35 MDM2 1.09049 0.69001 2.10967 75 0.038223 35 PRAM E -6.40074 -7.70424 2.08126 75 0.040823 GUS -1.51683 -1.89280 2.05200 75 0.043661 RAD51C -5.85618 -6.71334 2.04575 75 0.044288 35 42 AIB1 -3.08217 -2.28784 -2.00600 75 0.048462 STK15 -3.11307 -2.59454 -2.00321 75 0.048768 GAPDH -0.35829 -0.02292 -1.94326 75 0.055737 35 42 FHIT -3.00431 -3.67175 1.86927 75 0.065489 KRT19 2.52397 2.01694 1.85741 75 0.067179 35 TS -2.83607 -2.29048 -1.83712 75 0.070153 GSTM1 -3.69140 -4.38623 1.83397 75 0.070625 G- 0.31875 -0.15524 1.80823 75 0.074580 35 Catenin AKT2 0.78858 0.46703 1.79276 75 0.077043 35 CCNB1 -4.26197 -3.51628 -1.78803 75 0.077810 PI3KC2A -2.27401 -2.70265 1.76748 75 0.081215 35 42 FBX05 -4.72107 -4.24411 -1.75935 75 0.082596 DR5 -5.80850 -6.55501 1.74345 75 0.085353 CIAP1 -2.81825 -3.09921 1.72480 75 0.088683 MCM2 -2.87541 -2.50683 -1.72061 75 0.089445 CCND1 1.30995 0.80905 1.68794 75 0.095578 35 El F4E -5.37657 -6.47156 1.68169 75 0.096788 In the foregoing Table 1, negative t-values indicate higher expression, associated with worse outcomes, and, inversely, higher (positive) t-values indicate higher expression associated with better outcomes. Thus, for example, elevated expression of the CD68 gene (t-value = -3.41, CT mean alive< CT mean deceased) indicates a reduced likelihood of disease free survival. Similarly, elevated expression of the BC12 gene (t-value =
4.00; CT mean alive> CT mean deceased) indicates an increased likelihood of disease free survival.
Based on the data set forth in Table 1, the expression of any of the following genes in breast cancer above a defined expression threshold indicates a reduced likelihood of survival without cancer recurrence following surgery: Grb7, CD68, CTSL, Chkl, Her2, STK15, AIB1, SURV, EGFR, MYBL2, HIFla.
Based on the data set forth in Table 1, the expression of any of the following genes in breast cancer above a defined expression threshold indicates a better prognosis for survival without cancer recurrence following surgery: TP53BP2, PR, Bc12, KRT14, EstR1, IGFBP2, BAG1, CEGP1, KLK10, 13 Catenin, GSTM1, FHIT, Rizl, IGF1, BBC3, IGFR1, TBP, p27, IRS1, IGF1R, GATA3, CEGP1, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, RAD51, and KRT19.
Analysis of ER positivepatients bybinaiy approach 57 patients with normalized CT for estrogen receptor (ER) >0 (i.e., ER
positive patients) were subjected to separate analysis. A t test was performed on the two groups of patients classified as either no recurrence and no breast cancer related death at three years, or recurrence or breast cancer-related death at three years, and the p-values for the differences between the groups for each gene were calculated. Table 2, below, lists the genes where the p-value for the differences between the groups was <0.105. The first column of mean expression values pertains to patients who neither had a metastatic recurrence nor died from breast cancer. The second column of mean expression values pertains to patients who either had a metastatic recurrence of or died from breast cancer.
Table 2 Mean Mean t-value df p Valid N Valid N
IGF1R -0.13975 -1.00435 3.65063 55 0.000584 BcI2 0.15345 -0.70480 3.55488 55 0.000786 CD68 -0.54779 0.19427 -3.41818 55 0.001193 HN F3A 0.39617 -0.63802 3.20750 55 0.002233 CTSL -0.66726 0.00354 -3.20692 55 0.002237 TP53BP2 -4.81858 -6.44425 3.13698 55 0.002741 30 27 GATA3 2.33386 1.40803 3.02958 55 0.003727 30 BBC3 -4.54979 -5.72333 2.91943 55 0.005074 RAD51C -5.63363 -6.94841 2.85475 55 0.006063 30 27 BAG1 0.31087 -0.50669 2.61524 55 0.011485 IGFBP2 -0.49300 -1.30983 2.59121 55 0.012222 30 27 FBX05 -4.86333 -4.05564 -2.56325 55 0.013135 EstR1 0.68368 -0.66555 2.56090 55 0.013214 PR -1.89094 -3.86602 2.52803 55 0.014372 SU RV -3.87857 -3.10970 -2.49622 55 0.015579 CD9 1.41691 0.91725 2.43043 55 0.018370 30 RBI -2.51662 -2.97419 2.41221 55 0.019219 EPHX1 -3.91703 -5.85097 2.29491 55 0.025578 CEGP1 -1.18600 -2.95139 2.26608 55 0.027403 CCN B1 -4.44522 -3.35763 -2.25148 55 0.028370 TRAIL 0.34893 -0.56574 2.20372 55 0.031749 EstR1 4.60346 3.60340 2.20223 55 0.031860 30 D R5 -5.71827 -6.79088 2.14548 55 0.036345 MCM2 -2.96800 -2.48458 -2.10518 55 0.039857 Chk1 -3.46968 -2.85708 -2.08597 55 0.041633 p27 0.94714 0.49656 2.04313 55 0.045843 30 MYBL2 -3.97810 -3.14837 -2.02921 55 0.047288 GUS -1.42486 -1.82900 1.99758 55 0.050718 P53 -1.08810 -1.47193 1.92087 55 0.059938 HIF1A -0.40925 0.11688 -1.91278 55 0.060989 cMet -6.36835 -5.58479 -1.88318 55 0.064969 EGFR -2.95785 -2.28105 -1.86840 55 0.067036 MTA1 -7.55365 -8.13656 1.81479 55 0.075011 RIZ1 -7.52785 -8.25903 1.79518 55 0.078119 ErbB3 -6.62488 -7.10826 1.79255 55 0.078545 TOP2B 0.54974 0.27531 1.74888 55 0.085891 30 ElF4E -5.06603 -6.31426 1.68030 55 0.098571 TS -2.95042 -2.36167 -1.67324 55 0.099959 STK15 -3.25010 -2.72118 -1.64822 55 0.105010 For each gene, a classification algorithm was utilized to identify the best threshold value (CT) for using each gene alone in predicting clinical outcome.
Based on the data set forth in Table 2, expression of the following genes in ER-positive cancer above a defined expression level is indicative of a reduced likelihood of survival without cancer recurrence following surgery: CD68; CTSL; FBX05;
SLTRV;
CCNB1; MCM2; Chkl; MYBL2; HIF1A; cMET; EGFR; TS; STK15. Many of these genes (CD68, CTSL, SLTRV, CCNB1, MCM2, Chkl, MYBL2, EGFR, and STK15) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-positive breast cancer. Based on the data set forth in Table 2, expression of the following genes in ER-positive cancer above a defined expression level is indicative of a better prognosis for survival without cancer recurrence following surgery: IGFR1; BC12; HNF3A;
TP53BP2;
GATA3; BBC3; RAD51C; BAG1; IGFBP2; PR; CD9; RB1; EPHX1; CEGP1; TRAIL; DR5;
p27; p53; MTA; RIZ1; ErbB3; TOP2B; ElF4E. Of the latter genes, IGFR1; BC12;
TP53BP2;
GATA3; BBC3; RAD51C; BAG1; IGFBP2; PR; CD9; CEGP1; DR5; p27; RIZ1; ErbB3;
TOP2B; EIF4E have also been identified as indicators of good prognosis in the previous analysis, not limited to ER-positive breast cancer.
Analysis of ER negative patients by binary approach Twenty patients with normalized CT for estrogen receptor (ER) <1.6 (i.e., ER
negative patients) were subjected to separate analysis. A t test was performed on the two groups of patients classified as either no recurrence and no breast cancer related death at three years, or recurrence or breast cancer-related death at three years, and the p-values for the differences between the groups for each gene were calculated. Table 3 lists the genes where the p-value for the differences between the groups was <0.118. The first column of mean expression values pertains to patients who neither had a metastatic recurrence nor died from breast cancer. The second column of mean expression values pertains to patients who either had a metastatic recurrence of or died from breast cancer.
Table 3 Mean Mean t-value df 13 Valid N
Valid N
KRT14 -1.95323 -6.69231 4.03303 18 0.000780 KLK10 -2.68043 -7.11288 3.10321 18 0.006136 CCND1 -1.02285 0.03732 -2.77992 18 0.012357 Upa -0.91272 -0.04773 -2.49460 18 0.022560 HNF3A -6.04780 -2.36469 -2.43148 18 0.025707 Maspin -3.56145 -6.18678 2.40169 18 0.027332 CDH1 -3.54450 -2.34984 -2.38755 18 0.028136 HER2 -1.48973 1.53108 -2.35826 18 0.029873 5 15 =
GRB7 -2.55289 0.00036 -2.32890 18 0.031714 AKT1 -0.36849 0.46222 -2.29737 18 0.033807 TGFA -4.03137 -5.67225 2.28546 18 0.034632 FRP1 1.45776 -1.39459 2.27884 18 0.035097 STMY3 -1.59610 -0.26305 -2.23191 18 0.038570 Contig 2 _4.27585 -7.34338 2.18700 18 0.042187 A-Catenin -1.19790 -0.39085 -2.15624 18 0.044840 5 15 VDR -4.37823 -2.37167 -2.15620 18 0.044844 GRO1 -3.65034 -5.97002 2.12286 18 0.047893 MCM3 -3.86041 -5.55078 2.10030 18 0.050061 B-actin 4.69672 5.19190 -2.04951 18 0.055273 HIFI A -0.64183 -0.10566 -2.02301 18 0.058183 MMP9 -8.90613 -7.35163 -1.88747 18 0.075329 VEGF 0.37904 1.10778 -1.87451 18 0.077183 PRAM E -4.95855 -7.41973 1.86668 18 0.078322 AlB1 -3.12245 -1.92934 -1.86324 18 0.078829 KRT5 -1.32418 -3.62027 1.85919 18 0.079428 KRT18 1.08383 2.25369 -1.83831 18 0.082577 KRT17 -0.69073 -3.56536 1.78449 18 0.091209 P14ARF -1.87104 -3.36534 1.63923 18 0.118525 5 15 =
Based on the data set forth in Table 3, expression of the following genes in ER-negative cancer above a defined expression level is indicative of a reduced likelihood of survival without cancer recurrence (p<0.05): CCND1; UPA; NF3A; CDH1; Her2;
GRB7;
AKT1; STMY3; a-Catenin; VDR; GROl. Only 2 of these genes (Her2 and Grb7) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-negative breast cancer. Based on the data set forth in Table 3, expression of the following genes in ER-negative cancer above a defined expression level is indicative of a better prognosis for survival without cancer recurrence (KT14; KLK10; Maspin, TGFa, and FRP1. Of the latter genes, only KLK10 has been identified as an indicator of good prognosis in the previous analysis, not limited to ER-negative breast cancer.
Analysis of multiple genes and indicators of outcome Two approaches were taken in order to determine whether using multiple genes would provide better discrimination between outcomes.
First, a discrimination analysis was performed using a forward stepwise approach.
Models were generated that classified outcome with greater discrimination than was obtained with any single gene alone.
According to a second approach (time-to-event approach), for each gene a Cox Proportional Hazards model (see, e.g. Cox, D. R., and Oakes, D. (1984), Analysis of Survival Data, Chapman and Hall, London, New York) was defined with time to recurrence or death as the dependent variable, and the expression level of the gene as the independent variable.
The genes that have a p-value < 0.10 in the Cox model were identified. For each gene, the Cox model provides the relative risk (RR) of recurrence or death for a unit change in the expression of the gene. One can choose to partition the patients into subgroups at any threshold value of the measured expression (on the CT scale), where all patients with expression values above the threshold have higher risk, and all patients with expression values below the threshold have lower risk, or vice versa, depending on whether the gene is an indicator of bad (RR>1.01) or good (RR<1.01) prognosis. Thus, any threshold value will define subgroups of patients with respectively increased or decreased risk.
The results are summarized in Table 4. The third column, with the heading: exp(coef), shows RR
values.
Table 4 Gene coef exp(coef) se(coef) TP53BP2 -0.21892 0.803386 0.068279 -3.20625 0.00134 GRB7 0.235697 1.265791 0.073541 3.204992 0.00135 PR -0.10258 0.90251 0.035864 -2.86018 0.00423 CD68 0.465623 1.593006 0.167785 2.775115 0.00552 Bc12 -0.26769 0.765146 0.100785 -2.65603 0.00791 KRT14 -0.11892 0.887877 0.046938 -2.53359 0.0113 PRAME -0.13707 0.871912 0.054904 -2.49649 0.0125 CTSL 0.431499 1.539564 0.185237 2.329444 0.0198 EstR1 -0.07686 0.926018 0.034848 -2.20561 0.0274 Chk1 0.284466 1.329053 0.130823 2.174441 0.0297 IGFBP2 -0.2152 0.806376 0.099324 -2.16669 0.0303 HER2 0.155303 1.168011 0.072633 2.13818 0.0325 BAG1 -0.22695 0.796959 0.106377 -2.13346 0.0329 CEGP1 -0.07879 0.924236 0.036959 -2.13177 0.033 STK15 0.27947 1.322428 0.132762 2.105039 0.0353 KLK10 -0.11028 0.895588 0.05245 -2.10248 0.0355 B.Catenin -0.16536 0.847586 0.084796 -1.95013 0.0512 EstR1 -0.0803 0.922842 0.042212 -1.90226 0.0571 GSTM1 -0.13209 0.876266 0.072211 -1.82915 0.0674 TOP2A -0.11148 0.894512 0.061855 -1.80222 0.0715 AlB1 0.152968 1.165288 0.086332 1.771861 0.0764 FHIT -0.15572 0.855802 0.088205 -1.7654 0.0775 RIZ1 -0.17467 0.839736 0.099464 -1.75609 0.0791 SURV 0.185784 1.204162 0.106625 1.742399 0.0814 IGF1 -0.10499 0.900338 0.060482 -1.73581 0.0826 BBC3 -0.1344 0.874243 0.077613 -1.73163 0.0833 IGF1R -0.13484 0.873858 0.077889 -1.73115 0.0834 DIABLO 0.284336 1.32888 0.166556 1.707148 0.0878 TBP -0.34404 0.7089 0.20564 -1.67303 0.0943 p27 -0.26002 0.771033 0.1564 -1.66256 0.0964 IRS1 -0.07585 0.926957 0.046096 -1.64542 0.0999 The binary and time-to-event analyses, with few exceptions, identified the same genes as prognostic markers. For example, comparison of Tables 1 and 4 shows that 10 genes were represented in the top 15 genes in both lists. Furthermore, when both analyses identified the same gene at [p<0.10], which happened for 21 genes, they were always concordant with respect to the direction (positive or negative sign) of the correlation with survival/recurrence.
Overall, these results strengthen the conclusion that the identified markers have significant prognostic value.
For Cox models comprising more than two genes (multivariate models), stepwise entry of each individual gene into the model is performed, where the first gene entered is pre-selected from among those genes having significant univariate p-values, and the gene selected for entry into the model at each subsequent step is the gene that best improves the fit of the model to the data. This analysis can be performed with any total number of genes. In the analysis the results of which are shown below, stepwise entry was performed for up to 10 genes.
Multivariate analysis is performed using the following equation:
RR----exp[coef(geneA) x Ct(geneA) + coef(geneB) x Ct(geneB) + coef(geneC) x Ct(geneC) + ......... ].
In this equation, coefficients for genes that are predictors of beneficial outcome are positive numbers and coefficients for genes that are predictors of unfavorable outcome are negative numbers. The "Ct" values in the equation are ACts, i.e. reflect the difference between the average normalized Ct value for a population and the normalized Ct measured for the patient in question. The convention used in the present analysis has been that ACts below and above the population average have positive signs and negative signs, respectively (reflecting greater or lesser mRNA abundance). The relative risk (RR) calculated by solving this equation will indicate if the patient has an enhanced or reduced chance of long-term survival without cancer recurrence.
Multivariate gene analysis of 79 patients with invasive breast carcinoma A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 79 patients with invasive breast carcinoma. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival:
(a) TP53BP2, Bc12, BAD, EPHX1, PDGFRJ3, DIABLO, XIAP, YB1, CA9, and KRT8.
(b) GRB7, CD68, TOP2A, Bc12, DIABLO, CD3, EDI, PPM1D, MCM6, and WISP1.
(c) PR, TP53BP2, PRAME, DIABLO, CTSL, IGFBP2, TIMP1, CA9, MMP9, and COX2.
(d) CD68, GRB7, TOP2A, Bc12, DIABLO, CD3, Dl, PPM1D, MCM6, and WISP1.
(e) Bc12, TP53BP2, BAD, EPHX1, PDGFRO, DIABLO, XIAP, YB1, CA9, and KRT8.
(f) KRT14, KRT5, PRAME, TP53BP2, GUS1, ADM, MCM3, CCNE1, MCM6, and ID1.
(g) PRAME, TP53BP2, EstR1, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB.
(h) CTSL2, GRB7, TOP2A, CCNB1, Bc12, DIABLO, PRAME, EMS1, CA9, and EpCAM.
(i) EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, BBC3, and VEGFB.
(k) Chkl, PRAME, p53BP2, GRB7, CA9, CTSL, CCNB1, TOP2A, tumor size, and IGFBP2.
(1) IGFBP2, GRB7, PRAME, DIABLO, CTSL, 0-Catenin, PPM1D, Chkl, WISP1, and LOT1 .
(in) HER2, TP53BP2, Bc12, DIABLO, TIMP1, EPHX1, TOP2A, TRAIL, CA9, and AREG.
(n) BAG1, TP53BP2, PRAME, IL6, CCNB1, PAIL AREG, tumor size, CA9, and Ki67.
(o) CEGP1, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, and AKT2, and FGF18.
(p) STK15, TP53BP2, PRAME, IL6, CCNE1, AKT2, DIABLO, cMet, CCNE2, and COX2.
(q) KLK10, EstR1, TP53BP2, PRAME, DIABLO, CTSL, PPM1D, GRB7, DAPK1, and BBC3.
(r) AD31, TP53BP2, Bc12, DIABLO, TIMP1, CD3, p53, CA9, GRB7, and EPHX1 (s) BBC3, GRB7, CD68, PRAME, TOP2A, CCNB1, EPHX1, CTSL
GSTM1, and APC.
(t) CD9, GRB7, CD68, TOP2A, Bc12, CCNB1, CD3, DIABLO, ID1, and PPM1D.
(w) EGFR, KRT14, GRB7, TOP2A, CCNB1, CTSL, Bc12, TP, KLK10, and CA9.
(x) HIF1a, PR, DIABLO, PRAME, Chkl, AKT2, GRB7, CCNE1, TOP2A, and CCNB1.
(y) MDM2, TP53BP2, DIABLO, Bc12, AJB1, TIMP1, CD3, p53, CA9, and HER2.
(z) MYBL2, TP53BP2, PRAME, IL6, Bc12, DIABLO, CCNE1, EPHX1, TIMP1, and CA9.
(aa) p27, TP53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, STK15, AKT2, and D31.
(ab) RAD51, GRB7, CD68, TOP2A, CIAP2, CCNB1, BAG1, IL6, FGFR1, and TP53BP2.
(ac) SURV, GRB7, TOP2A, PRAME, CTSL, GSTM1, CCNB1, VDR, CA9, and CCNE2.
(ad) TOP2B, TP53BP2, DIABLO, Bc12, TEMPI., AD31, CA9, p53, KRT8, and BAD.
(ae) ZNF217, GRB7, p53BP2, PRAME, DIABLO, Bc12, COX2, CCNE1, APC4, and 0-Catenin.
. .
While the present invention has been described with reference to what are considered to be the specific embodiments, it is to be understood that the invention is not limited to such embodiments. To the contrary, the invention is intended to cover various modifications and equivalents included within the scope of the appended claims. For example, while the disclosure focuses on the identification of various breast cancer associated genes and gene sets, and on the personali7ed prognosis of breast cancer, similar genes, gene sets and methods concerning other types of cancer are specifically within the scope herein.
=
Table 5A
Gene ¨Accession Seq AlB1 NM_006534GCGGCGAGTTTCCGATTTAAAGCTGAGCTGCGAGGAAAATGGCGGCGGGAGGATCAAAATACTTGCTGGA
TGGTGGACTCA
A =
AKT2 NM_001626TCCTGCCACCCTTCAAACCTCAGGTCACGTCCGAGGTCGACACAAGGTACTTCGATGATGAA1-TTACCGCC =
= APC
NM_000038GGACAGCAGGAATGTGTTTCTCCATACAGGTCACGGGGAGCCAATGGTTCAGAAACAAATCGAGTGGGT
AREG
NM_001657TGTGAGTGAAATGCC1ICTAGTAGTGAACCGTCCTCGGGAGCCGACTATGACTACTCAGAAGAGTATGAT
AACGAACCACAA
6-actin NM_001101 CAGCAGATGTGGATCAGCAAGCAGGAGTATGACGAGTCCGGCCCCTCCATCGTCCACCGCAAATGC' B.Catenin NAL001904 GGCTCTTGTGCGTACTGTCCITCGGGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCITCGICATCTG
A
BAD
CAG =
CGTTGTCAGCACTTGGAATACAAGATGGTTGCCGGGTCATGTTAATTGGGAAAAAGAACAGTCCACAGGAAGAGGTTGA
AC
NM_014417CCTGGAGGGTCCTGTACAATCTCATCATGGGACTCCTGCCCITACCCAGGGGCCACAGAGCCCCCGAGAT
GGAGCCCAATTAG
Bc12 NM_000633CAGATGGACCTAGTACCCACTGAGATITCCACGCCGAAGGACAGCGATGGGAAAAATGCCCTIAAATCAT
AGG
'0A9 AG
NM_03196ETTCAGGTTGTTGCAGGAGACCATGTACATGACTGTCTCCATTATTGATCGGTTCATGCAGAATAAITGTG
TGCCCAAGAAGATG
CCND1 NM_001758 GCATGTICGTGGCCTCTAAGATGAAGGAGACCATCCCCCTGACGGCCGAGAAGCTGTGCATCTACACCG .
NM_001238AAAGAAGATGATGACCGGGITTACCCAAACTCAACGTGCAAGCCTCGGATTATTGCACCATCCAGAGGCT
C.
CCNE2 NM_057749ATGCTGIGGCTCCTTCCTAACTGGGGCTITC1-CD3z NM_000734AGATGAAGTGGAAGGCGCTTTTCACCGCGGCCATCCTGCAGGCACAGTTGCCGATTACAGAGGCA
COBB NM_001251 TGGTTCCCAGCCCTGTGTCCACCTCCAAGCCCAGATTCAGATTCGAGTCATGTACACAACCCAGGGTGGAGGAG.
COB
NM_001769GGGCGTGGAACAGITTATCTCAGACATCTGCCCCAAGAAGGACGTACTCGAAACCTTCACCGM
CORI
NM_004360TGAGTGTCCCCCGGTATCTTCCCCG000TGCCAATCCCGATGAAATTGGAAATTTTATTGATGAAAATCT
GAAAGCGGCTG
NM_020974TGACAATCAGCACACCTGCATTCACCGCTCGGAAGAGGGCCTGAGCTGCATGAATAAGGATCACGGCTGT
AGTCACA
Chk1 NM_001274GATAAATTGGTACAAGGGATCAGCT1n-CCCAGCCCACATGTOCTGATCATATGCTTTTGAATAGTCAGTTACTTGGCACCC
NM_001166TGCCTGTGGTGGGAAGCTCAGTAACTGGGAACCAAAGGATGATGCTATGTCAGAACACCGGAGGCATTTT
CC
clAP2 NM_001165GGATATTTCCGTGGCTCT1-A1-cMet NM 000245 GACATTTCCAGTCCTGCAGTCAATGCCTCTCTGCCCCACCCTTTGITCAGIGTGGCTGGTGCCACGACAAATGTGTGCG
ATCGGAG
Contig278AKE00618."GGCATCCIGGCCCAAAGTTTCCCAAATCCAGGCGGCTAGAGGCCCACTGCTTCCCAACTA
CCAGCTGAGGGGGIC
COX2 NM_000963TCTGCAGAGTTGGAAGCACTCTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCC1-TCTGGTAGAAAAGCCTCGGC ' CTSL
NM..001912GGGAGGCTTATCTCACTGAGTGAGCAGAATCTGGTAGACTGCTCTGGGCCTCAAGGCAATGAAGGCTGC
AATGG
,NM_001333'TGTCTCACTGAGCGAGCAGAATCTGGTGGACTGTTCGCGTCCTCAAGGCAATCAGGGCTGCAATGGT
NM_004938CGCTGACATCATGAATGTTCCTCGACCGGCTGGAGGCGAGTITGGATATGACAAAGACACATCGTTGCTG
AAAGAGA
DIABLO NM_019887 CACAATGGCGGCTCTGAAGAGTTGGCTGTCGCGCAGCGTAACTTCATTCTTCAGGTACAGACAGTGITTGTGT
DRS
NM_003842CTCTGAGACAGTGCTTCGATGACTTTGCAGACTTGGTGCCCTTTGACTCCTGGGAGCCGCTCATGAGGAA
EGFR NN1_005228TGTCGATGGACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAAT
ElF4E
NM_001968GATCTAAGATGGCGACTGTCGAACCGGAAACCACCCCTACTCCTAATCCCCCGACTACAGAAGAGGAGAA
AACGGAATCTAA
GGCAGTGTCACTGAGTCCITGAAATCCTCCCCTGCCCCGCGGGTCTCTGGATTGGGACGCACAGTGCA
EpCAM
NM_002354.GGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGCGGGCTCTTT4AGGCCAAGC
AGTGCA
EPHX1 NM_000120 'EthB3 NM_001982CGG1TATGTCATGCCAGATACACACCTCAAAGGTACTCCCTCCTCCCGGGAAGGCACCOTTIC1TCAGTG
GGTCTCAGTTC =
EsiR1 NM_000125CGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCC
=
NM_012177GGCTATTCCTCATTTICTCTACAAAGIGGCCTCAGTGAACATGAAGAAGGTAGCCTCCIGGAGGAGAATT
TCGGTGACAGTCTACAATCC
CACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTGCCTGTGAAGTGGATGGCACCC
Fl-HT NM:002012 CCAGTGGAGCGCTTCCATGACCIGCGTCCTGATGAAGTGGCCGATTTGTTTCAGACGACCCAGAGAG
=FRP1 NM_003012TTGGTACCTGTGGGTTAGCATCAAG1TCTCCCCAGGGTAGAAT1-G-Catenin NM_002230 TCAGCAGCAAGGGCATCATGGAGGAGGATGAGGCCTGCGGGCGCCAGTACACGCTCAAGAAAACCACC =
. GAPDH
NM_002046ATTCCACCCATGGCAAATTCCATGGCACCGTCAAGGCTGAGAACGGGAAGCTTGTCATCAATGGAAATCC
CATC
GATA3 NM_002051 CAAAGGAGCTCACTGTGGTGTCTGTGTTCCAACCACTGAATCTGGACCCCATCTGTGAATAAGCCATTCTGACTC
NM_005310CCATCTGCATCCATCTTGTTTGGGCTCCCCACCC1TGAGAAGTGCCTCAGATAATACCCTGGTGGCC
GR01 NM_001511 CGAAAAGATGCTGAACAGTGACAAATCCAACTGACCAGAAGGGAGGAGGAAGCTCACTGGTGGCTGITCCTGA
NM_000561AAGCTATGAGGAAAAGAAGTACACGATGGGGGACGCTCCTGATTATGACAGAAGCCAGTGGCTGAATGA4 AAATTCAAGCTGGGCC
GUS NM_000181 CCCACTCAGTAGCCAAGTCACAATGTTTGGAAAACAGCCCGTTTACTTGAGCAAGACTGATACCACCTGCGTG
NN1_001530TGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGGCCACATTCACGTATATGATACCAACA
GTAACCAACCTCA
NM_004496TCCAGGATGTTAGGAACTGTGAAGATGGAAGGGCATGAAACCAGCGACTGGAACAGCTACTACGCAGACA
CGC
NM_002165AGAACCGCAAGGTGAGCAAGGTGGAGATTCTCCAGCACGTCATCGACTACATCAGGGACCTTCAGTTGGA
NM_000618TCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCTGCCAAGTCAGCTCGCTC
TGTCCG
11M_000875GCATGGTAGCCGAAGATTTCACAGTCAA4ATCGGAGAT1ITGGTATGACGCGAGATATCTATGAGACAG
ACTATTACCGGAAA
NM_000597GTGGACAGCACCATGAACATGTTIGGGCGGGGGAGGCAGTGCTGGCCGGAAGCCCCTCAAGTCGGGTATG
AAGG
ILB
NM_000600CCTGAACCTTCCAAAGATGGCTGAAAAAGATGGATGCTTCCAATCTGGATTCAATGAGGAGACTTGCCTG
GT "
NM_005544CCACAGCTCACCTTCTGTCAGGTGTCCATCCCAGCTCCAGCCAGCTCCCAGAGAGGAAGAGACTGGCACT
GAGG =
1<1-67 NM_002417CGGACITTGGGTGCGACTTGACGAGCGGTGGTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGGA
AGAGTTGTA.A.-NM_002776GCCCAGAGGCTCCATCGTCCATCCTC1TCCTCCCCAGTCGGCTGAACTCTCCCCTIGTCTGCACTG1-TCAAACCTCTG
AGCCACAGTGGAC
NM_000422CGAGGATTGGTTCTTCAGCA5GACAGAGGAACTGAACCGCGAGGTGGCCACCAACAGTGAGCTGGTGCAG
AGT =
NM_000224AGAGATCGAGGCTCTCAAGGAGGAGCTGCTCTTCATGAAGAAGAACCACGAAGAGGAAGTAAAAGGCC
=
KRTis NM_002276TGAGCGGCAGAATCAGGAGTACCAGCGGCTCATGGACATCAAGTCGCGGCTGGAGCAGGAGATTGCCACC
TACCGCA
KRT5 A1_000424 TCAGTGGAGAAGGAGTTGGACCAGTCAACATCTCTGTTGICACAAGCAGTGITTCCTCTGGATATGGCA
KRT8 NM_002.273 GGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAGATCAACTTCGTCAGGCAG
CTATATG
LOT1earisNM_002656GGAAAGACCACCTGAAAAACCACCTCCAGACCCACGACCCCAACAAAATGGCCTTTGGGTG
TGAGGAGTGIGGGAAGAAGTAC .
Maspin TOCTGCC
NM_004526GAC1TTTGCCCGCTACCITTCATTCCGGCGTGACAACAATGAGCTGTTGCTCTICATACTGAAGCAGTTA
GTGGC
NM_002386GGAGAACAATCCCCTTGAGACAQAATATGGCCITTCTGTCTACAAGGATCACCAGACCATCACCATCCAG
GAGAT
TGATGGICCTATGIGTCACATICATCACAGGTTTCATACCAACACAGGCTICAGCACTTCCTITGGTGTGITTCCTGTC
CCA
MDM2 NM_002392CTACAGGGACGCCATCGAATCCGGATC1-TGATGCTGGIGTAAGTGAACA1-TCAGGTGATTGGTTGGAT
NM_004994GAGAACCAATCTCACCGACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTG
NM_004689CCGCCCTCACCTGAAGAGAAACGCGCTCCTTGGCGGACACTGGGGGAGGAGAGGAAGAAGCGCGGCTAAC
MYBL2 NM_002466 GCCGAGATCGCCAAGATGTTGCCAGGGAGGACAGACAATGCTGTGAAGAATCACTGGAACTCTACCATCAAAAG
CCCTCGTGCTGATGCTACTGAGGAGCCAGCGTCTAGGGCAGGAGCCGCTTCCTAGAAGACCAGGICATGATG
p27 NM_004064 P53 NM_000546 CITTGAACCCTTGCTTGCAAJAGGTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGG
PAH NM_000602 CCGCAACGTGGlITTCTCACCCTATGGGGTGGCCTCGGIGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAG
CA
PDGFRb NM_002609CCAGCTCTCC1TCCAGCTACAGATCAATGTCCCTGTCCGAGTGCTGGAGCTAAGTGAGAGCCACCC
NM_002645ATACCAATCACCGCACAAACCCAGGCTATTTGITAAGTCCAGTCACAGCGCAAAGAAACATATGCGGAGA
AAATGCTAGTGTG
PPM113 NM_003620 GCCATCCGCAAAGGCTTTCTCGCTTGTCACCTTGCCATGTGGAAGAAACTGGCGGAATGGCC
PR
NM_000926GCATCAGGCTGICATTATGGTGTCCTTACCTGTGGGAGCTGTAAGGICTICTTTAAGAGGGCAATGGAAG
GGCAGCACAACTACT
PRAMS
pS2 NM 003225 GCCCTCCCAGTGTGCAAATAAGGGCTGCTGTITCGACGACACCGTTCGTGGGGTCCCCTGGTGCTTCTATCCTAATACC
ATCGACG
RAD51C NM_ 055218 GAACTTCTTGAGCAGGAGCATACCCAGGGCTTCATAATCACCTTCTGTTCAGCACTAGATGATATTCTTGGGGGTGGA
=
RB1 NM_000321 CGAAGCCCTTACAAGITTCCTAGTTCACCCTTACGGATTCCTGGAGGGAACATCTATATTTCACCCCTGAAGAGTCC
STK15 NM_003600 CATCTICCAGGAGGACCACTCTCTGTGGCACCCTGGACTACCTGCCCCCTGAAATGATTGAAGGTCGGA
STMY3 NM_005940 CCTGGAGGCTGCAACATACCTCAATCCTGIOCCAGGCCGGATCCTCCTGAAGCCCITTTCGCAGCACTGCTATCCTCCA
AAGCCATTGTA
=
Table 5B
=
. .
SURV =
NM_0011611TGTTITGATTCCCGGGCTTACCAGGTGAGAAGTGAGGGAGGAAGAAGGCAGTGTCC0TTITGCTAGAGC
TGACAGCTTTG
The NM_003194GCCCGAAACGCCGAATATAATCCCAAGCGG1TTGCTGCGGTAATCATGAGGA1AAGAGAGCCACG
TGFA NM_003236 GGTGTGCCACAGACCTTCCTACTTGGGCTGTAATCACOTGTGOAGCCT-Timpi Nm_003254 TCCOTGCGGTOCCAGATAGCCTGAATOCTGCCCGGAGTGGAACTGAAGCCTGCAGAGTGTGOACCCTGTTOCCAC
TOP2A NM_001087 AATCGAAGGGGGAGAGTGATGACTTCCATATGGACTTTGACTCAGOTGTGGCTOCTOGGGCAAAATOTGTAC
NN1_0010S5TGTGGACATOTTOCCCTCAGACTT000TACTGAGGCAOCTTCTOTGCCACGAA0CGGTCGGGCTAG
TP NM_001B53 CTATATGCAGCCAGAGATGTGACAGCOACCGTGGACAGCCTGCCACTCATCACAGCGTOCATTOTCAGTAAGAAACTCG
TGG
NM_005426GGGCCAAATATTCAGAAGCTTTTATATCAGAGGACCACCATAGGGGOCATGGAGACCATCTCTGTCC0AT
CATACCCATCO
TRAIL NM_003810 CTTCACAGTGOTCCTGCAGTCTCTOTOTGTGGCTGTAACTTACGTGTACTTTACCAAGGAGCTGAAGCAGATG
TS NM_001071 GCCTCGGTGTGOOTTTCAACATCGCCAGOTAGGCCCIGCTCACGTACATGATTGCGCACATCACG
upa W/1_002658 VOR NM_000376 GCGCTGGATTTCAGAAAGAGCCAAGTCTGGATCTGGGACCCITTOCTTCUTTOCCTGGCTTGTAACT =
GTGOTGICTIGGGTGCATTOGAGCCTTGCCTTGCTGCTOTACCTCCACGATGCCAAGTGGTOCCAGGCTGC
VEGFB NM_003377 TGACGATGGCCIGGAGTGTGTGCCCACTGGGCAGCACCAAGTCOGGATGCAGATCOTCATGATCCGGTACC
NASP1 NM_003882 AGAGGCATCCATGAACTTCACACTTGCGGGCTGCATGAGCACACGCTCGTATCAACCCAAGTAGTGTGGAGTTTG .
=
NM_001107GCAGTTGGAAGACACAGGAAAGTATC000AAAITGCAGATTTATCAACGGC1TTTATCTTGAAAATAGTG
CCACGCA
NM_004559AGACTGIGGAGITTGATG7TGTTGAAGGAGAAAAGGGTGCGGAGGCAGCA.AATGTTACA3GICCTGGTG
GIGTTCC
NN1_005526ACCCAGTAGCAAGGAGAAGCCCACTCACTGCTCCGAGTGCGGGAAAGCTTTCAGAACCTACCACCAGCT
G
=
'=
=
=
=
=
=
=
=
, .
Table 6A
. -.
.
Gene Accession = Probe Name S eq Len , .
AIB1 . NM .
_006534 S1994/A1B1f3 GCGGCGAGTTTCCGATTTA 19 ' Al B1 *NM 006534 S1995/AIB1r3 .TGAGTCCACCATCCAGCAAGT
_ . 21 ' A1B1 NM_006534 S5055/AIB1 .p3 AKT1 NM _005163 S0010/AKT1.13 AKT1 NM_005163 S0012/AKT1.r3 TCCCGGTACACCACGTTCTT 20 AKT1 NM 005163 S4776/AKT1.p3 _001626 S0828/AKT2.f3 TCCTGCCACCCTTCAAACC 19 AKT2 NM 001626 S0829/AKT2.r3 GGCGGTAAATTCATCATCGAA '.
_ 21 , AKT2 NM_001626 S4727/AKT2.p3 CAGGTCAC GTC C GA
GGTCGACACA = 24 APC NM_000038 S0022/APC.f4 GGACAGCAGGAATGTGTTTC
APC NM_000038 S0024/APC.r4 ACCCACTCGATTTGTTTCTG 20 APC NM_000038 S4888/APC.p4 CATTGGCTCCCCGTGACCTGTA 22 ' AREG NM_001657 S0025/AREG.f2 TGTGAGTGAAATGCCTTCTAGTAGTGA . 27 .
AREG NM_001657 S0027/AREG.r2 TTGTGGTTCGTTATCATACTCTTCTGA 27 AREG NM_001657 S4889/AREG.p2 CCGTCCTCGGGAGCCGACTATGA 23 B-actin NM_001101 S0034/B-acti.f2_ B-actin . NM_001101 S0036/B-acti.r2 B-actin NM_001101 S4730/B-acti.p2 B-Catenin NM_001904 S2150/B-Cate.f3 GGCTCTTGTGCGTACTGTCCTT 22 B-Catenin NM_001904 S2151/B-Cate.r3 TCAGATGACGAAGAGCACAGATG 23 B-Catenin NM 001904 . ' S5046/B-Cate.p3 AGGCTCAGTGATGTCTTCCCTGTCACCAG 29 BAD NM:032989 S2011/BAD.f1 GGGTCAGGTGCCTCGAGAT 19 BAD NM_032989 S2012/BAD.r1 CTGCTCACTCGGCTCAAACTC . 21 BAD .NM_032989 S5058/BAD.p1 . TGGGCCCAGAGCATGTTCCAGATC . . 24 BAG1 ', NM_004323 .S1386/BAG1.f2 = CGTTGTCAGCACTTGGAATACAA ' . 23 ' BAG1 NM_004323 S1387/BAG1.r2 GTTCAACCTCTTCCTGTGGACTGT 24 BAG1 . NM 004323 34731/BAG1 .p2 = CCCAATTAACATGACCCGGCAACCAT
26 =
BBC3 NM:014417 S1584/BBC3.f2 CCTGGAGGGTCCTGTACAAT = 20 ..
BBC3 NM_014417 = S1585/BBC3.r2 ,.= CTAATTGGGCTCCATCTCG 19 = BBC3 NM_014417 S4890/BBC3.p2 CATCATGGG,ACTCCTGCCCTTACC = - 24 Bc12 NM 000633 S0043/Bc12.f2 _ CAGATGGACCTAGTACCCACTGAGA ' 25 Bc12 NM 000633 S0045/Bc12.r2 CCTATGATTTAAGGGCA II ii I CC = . 24 BcI2 NM 000633 S4732/8c12.p2 CA9 NM:001216 S1398/CA9.f3 ATCCTAGCCCTGG I 1 1 1 1GG .20 CA9 NM 001216 .S1399/CA9.r3 CTGCCTTCTCATCTGCACAA
_ 20 CA9 NM 001216 S4938/CA9.p3 CCNB1 NM:031966 S1720/CCNB1.f2 TTCAGGTTGTTGCAGGAGAC . 20 CCNB1 NM_031966 S1721/CCNB1.r2 . CATCTTCTTGGGCACACAAT 20 CCNB1 NM 031966 S4733/CCNB1.p2 TGTCTCCATTATTGATCGGTTCATGCA 27 CCND1 NM 001758 S0053/CCND1.f3 GCATGTTCGTGGCCTCTAAGA 21 . CCND1 NM_001758 S0060/CCND1.r3 CGGTGTAGATGCACAGCTTCTC 22 CCND1 NM 001758 64986/CaND1.p3 AAGGAGACCATCCCCCTGACGGC 23. .
.
CCNE1 NM_001238 S1446/CCNE1.f1 WGAAGATGATGACCGGGTTTAC. 24 =
CCNE1 NM_001238 = 51447/CCNE1.r1 CCNE1 NM_001238 S4944/CCNE1.p1 CAAACTCAACGTGCAAGCCTCGGA 24 CCNE2 NM057749 .S1458/CCNE2.f2 . ATGCTGTGGCTCCTTCCTAACT 22 CCNE2 NM 057749 S1459/CCNE2.r2 ACCCAAATTGTGATATACAAAAAGGTT 27 CCNE2 NM_057749 S4945/CCNE2.p2 TACCAAGCAACCTACATGTCAAGAAAGCCC 30 CD3z NM 000734 S0064/CD3z.f1 AGATGAAGTGGAAGGCGCTT . 20 .
CD3z NM-000734 S0066/CD3z.r1 TGCCTCTGTAATCGGCAACTG 21 .
' CD3z NM 000734 S4988/CD3z.p1 CD68 NM_001251 S0067/CD68.f2 C D68 NM 001251 S0069/CD68.r2 C D68 NM:001251 S4734/CD68.p2 CD9 NM 001769 .S0686/C09,f1 .
=
CD9 NM 001769 S0687/CD9.r1 CACGGTGAAGGTTTCGAGT 19 .
CD9 NM_001769 34792/CD9.p1 AGACATCTGa cC CAAGAAG GAC GT 24 CDH1 NM_004360 S0073/CDH1.f3 TGAGTGTCCCCCGGTATCTTC 21 . .
=
' CDH1 NM_004360 S0075/CDH 1 .r3 ________ CAGCCGCTTTCAGA I I I I CAT
CDH1 NM_004360 S4990/CDH1.p3 TGCCAATCCCGATGAAATTGGAAATTT 27 CEGP1 NM_020974 S1494/CEGP1.f2 TGACAATCAGCACACCTGCAT 21 ..
_.. .
Table 6B
, .
. , CEGP1 NM_020974 S1495/CEGP1.r2 .TGTGACTACAGCCGTGATCCTTA 23 =
CEGP1 = NM_020974 S4735/CEGP1.p2 CAGGCCCTCTTCCGAGCGGT 20 Chk1 NM 001274 S1422/Chk1.f2 _ GATAAA1TGGTACAAGGGATCAGCTT 26 Chk1 NM 001274 Si23/Chk1.r2 ' GGGTGCCAAGTAACTGACTATTCA
_ 24 =
Chk1 NM 001274 S4941/Chk1.p2 CCAGCCCACATGTCCTGATCATATGC . 26 =
CIAP1 NM 001166 S0764/CIAPl.f2 TGCCTGTGGTGGGAAGCT
_ 18 CIAP1 NM 001166 S0765/CIAP1.r2 GGAAAATGCCTCCGGTGTT
_ 19 =
CIAP1 NM_001166 S4802/CIAP1.p2 TGACATAGCATCATCCITTGGTTCCCAGTT 30 clAP2 NM 001165 S0076/cIAP2.f2 GGATATTTCCGTGGCTCTTATTCA
_ 24 clAP2 . NM_001165 S0078/cIAP2.r2 CTTCTCATCAAGG6AGAAAAATCTT . 25 . clAP2 NM_001165 S4991/cIAP2.p2= TCTCCATCAAATCCTGTAAACTCCAGAGCA 30 cMet NM_000245 S0082./cM et.f2 cMet NM_000245 S0084/cMet.r2 CTCCGATCGCACACATTTGT 20 cMet NM_000245 S4993/cMet.p2 TGCCTCTCTGCCCCAC6CTTTGT 23 Contig 27882 AK00618 S2633/Contig.f3 GGCATCCTGGCCCAAAdT 18 Contig 27882 AK000618 - S2634/Contig.r3 Contig 27882 AK000618 . S4977/Contig.p3 COX2 NM_000963 S0088/C0X2J1 TCTGCAGAGTTGGAAGCACTCTA =23 COX2 NM_000963 S0090/C0X2.r1 GCCGAGGCTTTTCTACCAGAA 21 COX2 NM_000963 S4995/C0X2.p1 = CAGGATACAGCTCCACAGCATCGATGTC . . 28 , CTSL NM_001912 S1303/CTSL.f2 GGGAGGCTTATCTCACTGAGTGA . . 23 CTSL NM_001912 81304/CTSL.r2 CCATTGCAGCCTTCATTGC 19 CTSL NM_001912 = S4899/CTSL.p2 CTSL2 NM 001333 . S4354/CTSL2.f1 CTSL2 NM 001333 S4355/CTSL2.r1 CTSL2 ' NM_001333 S4356/CTS1.2.p1 DAP K1 i NM_004938 S1768/DAPK1.f3 CGCTGACATCATGAATGTTCCT . 22 DAPK1 = NM_004938 S1769/DAPK1.r3 TCTCTTTCAGCAACGATGTGTCTT 24 .DAPK1 NM 004938 84927/DAPK1.p3 TCATATCCAAACTCGCCTCCAGCCG 25 .
' DIABLO . NM:019887 S0808/DIABLO.f1 CACAATGGCGGCTCTGAAG 19 =
DIABLO . NM_019887 S0809/DIABLO.r1 ACACAAACACTGTCTGTACCTGAAGA 26 DIABLO NM_019887 ' S4813/DIABLO.p1 AAGTTACGCTGCGCGACAGCCAA . 23 DR5 NM_003842 S2551/DR5.f2 CTCTGAGACAGTGCTTCGATGACT 24 DR5 NM_003842 S2552/DR5.r2 = CCATGAdGCCCAACTTCCT 19 DR5 NM_003842 S4979/DR5.p2 CAGACTTGGTGCCCTTTGACTCC , 23 EGFR NM_005228 S0103/EGFR.f2 . TGTCGATGGACTTCCAGAAC 20 EGFR NM_005228 S0105/EGFR.r2 ATTGGGACAGCTTGGATCA 19 EGFR NM_005228 S4999/EGFR.p2 ' CACCIGGGCAGCTGCCAA 18 El F4E NM 001968 S0106/E1F4E.f1 ElF4E NM:001968 . S0108/E1F4E.r1 - TTAGATTCCG I 1 i i ElF4E NM_001968 55000/E1F4E.p1 ACCACCCCTACTCCTAATCCCCCGACT 27 , EMS1 NM_005231 =S2663/EMS1.11 GGCAGTGTCACTGAGTCCTTGA 22 ' EMS1 NM_005231 S2664/EMS1.r1 TGCACTGTGCGTCCCAAT 18 .
EMS1 NM_005231 . .S4956/ES1.p1 EpCAM . NM_002354 S1807/EpCAM.f1 GGGCCCTCCAGAACAATGAT 20 EpCAM . NM_002354 S1808/EpCAM.r1 TGCACTGCTTGGCCTTAAAGA 21 EpCAM NM_002354 S4984/EpCAM.p1 CCGCTCTCATCGCAGTCAGGATCAT 25 EPHX1 NM_000120 S 1 865/EPHX1.f2 AC C GTAGGCTCTGCTCTGAA 20 EPHX1 NM_000120 S1866/EPHX1:r2 TGGTCCAGGTGGAAAACTTC 20 EPHX1 = NM_000120 S4754/EPHX1.p2 AGGCAGCCAGACCCACAGGA . 20 =
ErbB3 NM_001982 $0112/ErbB3J1 CGGTTATGTCATGCCAGATACAC 23 ErbB3 NM_001982 S0114/ErbB3.r1 GAACTGAGACCCACTGAAGAAAGG . 24 ErbB3 NM_001982 S5002/ErbB3.pi - CCTCAAAGGTACTCCCTCCTCCCGG 25 EstR1 NM_000125 80115/EstR1.11 EstR1 NM 000125 S0117/EstR1.r1 ' GGCTAGTGGGCGCATGTAG 19 EstR1 NM_000125 S4737/EstR1.p1 CTGGAGATGCTGGACGCCC 19 FBX05 NM 012177 S2017/FBX05.r1 GGATTGTAGACTGTCACCGAAATTC . 25 FBX05 NM 012177 S2018/FBX05.fl FBX05 NM:012177 S5061/FBX05.p1 CCTCCAG GAG GCTACCTTCTTCATGTTCAC .30 .
FGF18 . NM_003862 S1665/FGF18.f2 CGGTAGTCAAGTCCGGATCAA 21 .
FGF18 NM_003862 81666/FGF.18.r2 GCTTOCCTITGCGGTTCA. 18 FGF18 NM_003862 S4914/FGF18.p2 CAAGGAGACGGAATTCTACCTGTGC 25 =
. .
. .
Table 6C
. .
FGFR1 NM _023109 S0818/FGFR1.f3 CACGGGACATTCACCACATC 20 =
FGFR1 NM_023109 S0819/FGFR1.r3 GGGTGCCATCCACTTCACA 19 FGFR1 NM 023109 S4816/FGFR1.p3 ATAAAAAGACAACCAACGGCCGACTGC 27 FHIT NM _002012 S2443/FH1T.f1 CCAGTGGAGCGCTTCCAT = ' 18' FHIT NM_ 002012 S2444/FHIT.r1 CTCTCTGGGTCGTCTGAAACAA .
FHIT NM_002012 S2445/FHIT.p1 TCGGCCACTTCATCAGGACGCAG 23 . FHIT NM_002012 S4921/FHIT.p1 . FRP1 NM_ 003012 S1804/FRP1.f3 FRP1 NM _003012 S1805/FRP 1.r3 FRP1 NM_003012 S4983/FRP1.p3 TCCCCAGGGTAGAATTCAATCAGAGC 26 G-Catenin NM_002230 S2153/G-Cate.f1 TCAGCAGCAAGGGCATCAT . 19 G-Catenin NM_002230 S2154/G-Cate.r1 GGTGG I il G-Catenin NM_002230 S5044/G-Cate.p1 GAP DH NM_002046 S0374/GAPDH.f1 ATTCCACCCATGGCAAATTC 20 GAPDH NM 002046 S0375/GAPDH.r1 GATGGGATTTCCATTGATGACA 22 _ GAPDH NM_002046 S4738/GAPDH.p1 CCGTTCTCAGCCTTGACGGTGC 22 GATA3 NM 002051 S0127/GATA3.f3 CAAAGGAGCTCACTGTGGTGTCT 23 _ GATA3 . NM_002051 S0129/GATA3.r3 GAGTCAGAATGGCTTATTCACAGATG 26 GATA3 NM_002051 S5005/GATA3.p3 TGTTCCAACCACTGAATCTGGACC 24 GRB7 NM_ 005310 50130/GRB7.f2 CCATCTGCATCCATCTTGTT 20 GRB7 NM _00531'0 50132/GRB7.r2 GRB7 NM_005310 S4726/GRB7.p2 CTCCCCACCCTTGAGAAGTGCCT 23.
6R01 NM_001511 S0133/GR01.f2 CGAAAAGATGCTGAACAGTGACA 23 GRO1 NM_001511 S0135/GR01.12 TCAGGAACAGCCACCAGTGA 20 GRO1 NM_001511 =S5006/GR01.p2 CTTCCTCCTCCCTTCTGGTCAGTTGGAT 28 GSTM1 , - NM_000561 S2026/GSTM1.r1 GGCCCAGCTTGAA H H ICA
GSTM1 = NM_000561 S2027/GSTM1.fl AAGCTATGAGGAAAAGAAGTACACGAT 27 GSTM1 NM_000561 54739/GSTM1.p1 TCAGCCACTGGCTTCTGTCATAATCAGGAG 30 GUS NM _000181 ' S0139/GUS.f1 CCCACTCAGTAGCCAAGTCA 20 . .
GUS NM _000181 S0141/GUS.r1 GUS NM_000181 S4740/GUS.p1 _______________________ TCAAGTAAACGGGCTG
HER2 NM _004448 S0142/HER2.f3 HER2 NM_ 004448 S0144/HER2.r3 CCTCTCGCAAGTGCTCCAT 19 HER2 NM 004448 S4729/HER2.p3 CCAGACCATAGCACACTCGGGCAC . 24 .
HIF1A NM:001530 S1207/H1F1A.f3 TGAACATAAAGTCTGCAACATGGA 24 HIF1A NM 001530 S1208/HIF1A.r3 HIF1A NM:001530 S4753/HIF1A.p3 TTGCACTGCACAGGCCACATTCAC 24 HNF3A NM 004496 S0148/HNF3A.f1 TCCAGGATGTTAGGAACTGTGAAG 24 HNF3A NM_ 004496 S0150/HNF3A.r1 HNF3A NM_004496 S5008/HNF3A.p1 AGTCGCTGGTTTCATGCCCTTCCA 24 ID1 NM _002165 SO820/101.11 101 . NM_002165 S0821/1131 .r1 ID-1 NM 002165 S4832/ID1.pl IGF1 NM 000618 S0154/1G.F1.f2 ToCGGAGCTGTGATCTAAGGA 21 ..
IGF1 NM_000618 30156/1GF1 .r2 IGF1 NM_000618 S5010/1GF1.p2 TGTATTGCGCACCCCTCAAGCCTG 24 IGF1R NM_000875 Si 249/1GF1R.f3 IGF1R NM_000875 S1250/1GF1R.r3 TTTCCGGTAATAGTCTGTCTCATAGATATC 30 IGF1R NM 000875 34895/IGF1R.p3 CGCGTCATACCAAAATCTCCGATTTTGA 28 IGFBP2 NM = 000597 S1129/IGFBP2s1 CCTTCATACCCGACTTGAGG 20 _ I GFBP2 NM_000597 S4837/1GF6P2.p1 CTTCCGGCCAGCACTGCCTC 20 IL6 NM 000600 S0760/1L6.f3 IL6 NM 000600 S0761/1L6.r3 11_6 NM 000600 S4800/IL6.p3 _______________________ CCAGATTGGAAGCATCCATC I I I I ICA 27 .
IRS1 NM_ 005544 S1943/IRS1.f3 CCACAGCTCACCTTCTGTCA 20 ' 1RS1 NM 005544 31944/IRS1s3 CCTCAGTGCCAGTCTCTTCC = 20.
1RS1 NM 005544 S5050/IRS1.p 3 Ki-67 NM:002417 S0436/K1-67.f2 CGGACTTTGGGTGCGACTT 19 Ki-67 NM 002417 S0437/K1-67.r2 TTACAACTCTTCCACTGGGACGAT 24 .
KI-67 NM:002417 S4741/11-67.p2 KLK10 NM_002776 32624/KLK10.13 . .
' Table 6D
_ = =
KLK10 NM_002776 S2625/KLK10.r3 ' CAGAGGTTTGAACAGTGCAGACA 23 ' KLK10 NM_002776 S4978/KLK10.p3 = CCTCTTCCTCCCCAGTCGGCTGA 23 KRT14 NM 000526 81853/KRT14f1 GGCCTGCTGAGATCAAAGAC
_ . 20 KRT14 NM 000526 S1854/KRT14.r1 GTCCACTGTGGCTGTGAGAA
_ 20 =
KRT14 NM_000526 S5037/KRT14.p1 TGTTCCTCAGGTCCTCAATGGTCTTG 26 KRT17 NM 000422 S0172/KRT17.f2 CGAGGATTGGTTCTTCAGCAA
_ 21 KRT17 NM 000422 S0174/KRT17.r2 ACTCTGCACCAGCTCACTGTTG
_ 22 KRT17 NM_000422 S5013/KRT17.p2 CACCTCGCGGTTCAGTTCCTCTGT 24 -KRT18 NM 000224 S1710/KRT18.f2 AGAGATCGAGGCTCTCAAGG
_ 20 .
=
KRT18 NM_000224 S1711/KRT18.r2 __ GGCC 1 HI
.
KRT18 NM_000224 S4762/KRT18.p2 TGGTTCTTCTTCATGAAGAGCAGCTCC 27 KRT19 NM_002276 S1515/KRT19.f3 TGAGCGGCAGAATCAGGAGTA
. 21 KRT19 NM_002276 S1516/KRT19.r3 TGCGGTAGGTGGCAATCTC 19 =
KRT19 NM_002276 S4866/KRT19.p3 CTCATGGACATCAAGTCGCGGCTG 24 KRT5 NM 000424 S0175/KRT5.f3 TCAGTGGAGAAGGAGTTGGA
_ 20 KRT5 NM_000424 S0177/KRT5.r3 TGCCATATCCAGAGGAAACA20 =
KRT5 NM_000424 S5015/KRT5.p3 KRT8 . NM_002273 S2588/KRT8.f3 KRT8 .NM_002273 S2589/KRT8.r3 CATATAGCTGCCTGAGGAAGTTGAT 25 =
KRT8 NM_002273 S4952/KRT8.p3 CGTCGGTCAGCCCTTCCAGGC 21 LOT1 variant 1 NM_002656 , S0692/LOT1 v.f2 . GGAAAGACCACCTGAAAAACCA 22 LOT1 variant 1 NM_002656= S0693/LOT1 v.r2 LOT1 variant 1 NM_002656 = S4793/LOT1 v.p2 ACCCACGACCCCAACAAAATGGC 23 Maspin NM_002639 S0836/Maspin.f2 CAGATGGCCACTTTGAGAACATT 23 Maspin NM_002639 S0837/Maspin.r2 GGCAGCATTAACCACAAGGATT 22 Maspin . NM_002639 . S4835/Maspin.p2 . AGCTGACAACAGTGTGAACGACCAG.ACC 28 MCM2 NM_004526 S1602./MCM2.f2 GACTTTTGCCCGCTACCTITC '21 ' MCM2 NM,004526 , . S1603/MCM2.r2 MCM2 NM_004526 54900/MCM2.p2 ACAGCTCATTGTTGTCACGCCG GA =24 , =
. MCM3 NM_002388 S1524/MCM3.f3 = GGAGAACAATCCCCTTGAGA
MCM3 .NM_002388 S1525/MCM3.r3 ' ATCTCCTGGATGGTGATGGT 20 . MCM3 NM_002388 S4870/MCM3.p3 TGGCCTTTCTGTCTACAAGGATCACCA 27 MCM6 ' . NM_005915 S1704/MCM6.f3 TGATGGTCCTATGTGTCACATTCA 24 MCM6 NM 005915 S1705/MCM6.r3 TGGGACAGGAAACACACCAA
_ 20 .
MCM6 NM_005915 S4919/MCM6.p3 CAGGTTTCATACCAACACAGGCTTCAGCAC 30 MDM2 NM 002392 S0830/MDM2.fl MDM2 NM 002392 S0831/MDM2.r1 MDM2 NM_002392 S4834/MDM2.p1 CTTACACCAGCATCAAGATCCGG , ' 23 MMP9 NM004994 S0656/MMP9.fl GAGAACCAATCTCACCGACA 20 .
MMP9 NM_004994 S0657/MMP9.r1 CACCCGAGTGTAACCATAGC 20 MMP9 NM 004994 = S4760/MMP9.p1 ACAGGTATTCCTCTGCCAGCTGCC = = 24 MTA1 NM_ 004689 S2369/MTA1.f1 CCGCCCTCACCTGAAGAGA 19 MTA1 NM_004689 S2370/MTA1.r1 GGAATAAGTTAGCCGOGOTTOT 22 MTA1 NM 004689 54855/MTAl.p1 COCAGTGTCCGCCAAGGAGCG 21 '=
MYBL2 NM_002466 S3270/MYBL2.f1 GCCGAGATCGCCAAGATG 18 MYBL2 NM_002466 S3271/MYBL.2.r1 __ C i 1 i MYBL2 NM 002466 S4742/MYBL2.p1 CAGCATTGTCTGTCCTCCCTGGCA 24 P14ARF S76-535 S2842JP14ARF.f1 CCCTCGTGCTGATGCTACT . 19 ' P14ARF S78535 S2843/P14ARF.r1 CATCATGACCTGGTCTTCTAGG 22 P14ARF S78535 S4971/P14ARF.p1 CTGCCCTAGACGCTGGCTCCTC 22 p27 NM_004064 S0205/p27.f3 CGGTGGACCACGAAGAGTTAA 21 p27 NM_004064 S0207/p27.r3 GGCTCGCCTCTTCCATGTC 19 p27 NM_004064 S4750/p27.p3 CCGGGACTTGGAGAAGCACTGCA . 23 P53 NM 000546 S0208/P53.f2 CTTTGAACCCTTGCTTGCAA 20 P53 NM_ 000546 S0210/P53.r2 CCCGGGACAAAGCAAATG 18 P53 . NM_000546 S5065/P53.p2 AAGTCCTGGGTGCTTCTGACGCACA , 25 PAH NM_000602 S0211/PAl1 .f3 _______ CCGCAACGTGG I I I I
PAll NM_ 000602 S5066/PAI1.p3 CTCGGTGTTGGCCATGOTCCAG 22 =
PDGFRb NM...0,02609 S1346/PDGFRb.f3 CCAGCTCTCCTTCCAGCTAC 20 =
PDGF.Rb NM 002609 Si47/PDGFRb.r3 GOGTGGCTCTCACTTAGCTC
_ 20 PDGFRb NM_002609 S4931/P DGFR b. p3 ATCAATGTCCCTGTCCGAGTGCTG 24 , * CA 02513117 2013-09-26 . =
Table 6E
= =
PI3KC2A NM_002645 S2020/P13KC2.1-1 ___ CACACTAGCAI i 11CTCCGCATA 23 =
P I3KC2A NM_002645 82021/P13KC2.f1 ATACCAATCACCGCACAAACC - 21 =
PI3KC2A , NM_002645 55062/P13KC2.p1 TGCGCTGTGACTGGACTTAACAAATAGCCT 30 PP MID " NM_003620 S3159/PPM1D.fl GCCATCCGCAAAGGCTTT = 18 P PM1D NM_003620 S3160/PPM1D.r1 GGCCATTCCGCCAGTTTC 18 ' = P PM1D NM_003620 S4856/PPM1D.p1 TCGCTTGTCAbCT7GCCATGTGG 23 PR NM- 000926 S1336/PR.f6 = GCATCAGGCTGTCATTATGG 20 _ PR NM 000926 S1337/PR.r6 AGTAGTTGTGCTGCCCTTCC ' 20 PR NM:000926 S4743/PR.p6 TGTCCITACCTGTGGGAGCTGTAAGGTC 28 FRAME NM 006115 S1985/PRAME.f3 TCTCCATATCTGCCTTGCAGAGT 23 _ .
FRAME NM 006115 S1986/PRAME.r3 GCACGTGGGTCAGATTGCT . 19 _ .
FRAME NM 006115 S4756/PRAME.p3 TCCTGCAGCACCTCATCGGGCT = 22 pS2 - NM:003225 S0241/pS2.f2 GC
pS2 NM_003225 S0243/pS2.r2 CGTCGATGGTATTAGGATAGAAGCA 25 pS2 NM_003225 S5026/pS2.p2 TGCTGTTTCGACGACACCGTTCG 23 RAD51C NM_058216 = S2606/RAD51C.f3 GAACTTCTTGAGCAGGAGCATACC = 24 RAD51C NM_058216 S2607/RAD51C.r3 TCCACCCCCAAGAATATCATCTAGT 25 RAD51C . NM_058216 S4764/RAD51 C. p3 AGGGCTTCATAATCACCTTCTGTTC 25 RB1 .NM_000321 S2700/RB1.fl CGAAGCCCTTACAAGTTTCC 20 RBI NM .000321 S2701/RB1.r1 RBI NM 000321 34765/RB1.p1 R1Z1 NM:012231 S1320/RIZ1J2 RIZ1 NM_012231 S1321/RIZ1.r2 R IZ1 NM_012231 S4761/RIZ1.p2 STK15 NM_ 003600 S0794/STK15.f2 CATCTTCCAGGAGGACCACT 20 STK15 NM 003600 S0795/STK1.5.r2 STK15 - NM 003600 ' S4745/STK15.p2 CTCTGTGGCACCCTGGACTACCTG 24 STMY3 NM:005940 = S2067/STMY3.f3 CCTGGAGGCTGCAACATACC 20 STMY3 NM_005940 S2068/STMY3.r3 TACAATGGCTTTGGAGGATAGCA 23 .
STMY3 = NM_005940 S4746/STMY3.p3 ATCCTCCTGAAGCCCTMCGCAGC = 25 . .
SURV NM_ 001168 S0259/SURV.f2 = TGTTTTGATTCCCGGGCTTA 20 SU RV NM_001168 S0261/SURV.r2 = SURV NM 001168 S4747/S U kv. p 2 TBP NM_ 003194 S 0262/TB P.f1 TB P NM 003194 S0264/TBP.r1 CGTGGCTCTCTTATCCTCATGAT " . 23 .
TBP NM:003194 S4751fTBP.p1 TACCGCAGCAAACCGCTTGGG 21 TGFA NM_003236 = S0489/TGFA.f2 , GGTGTGCCACAGACCTTCCT 20 .
TGFA NM_003236 S0490/TGFA.r2 ACGGAGTTCTTGACAGAG 1 1 i 1 GA 24 TGFA NM_003236 = S4768/TGFA.p2 TIMP1 NM_003254 S1695/11MP i .f3 TCCCTGCGGTCCCAGATAG = 19 TIMP1 NM_003254 S1696/TIMP1.r3 GTGGGAACAGGGTGGACACT 20 TIMP1 NM_003254 S4918/TIMPl.p3 ATCCTGCCCGGAGTGGAACTGAAGC 25 =
TOP2A NM_001067 60271TTOP2A.f4 AATCCAAGGGGGAGAGTGAT 20 =
TOP2A = NM 001067 S0273/TOP2A.r4 GTACAGATTTTGCCCGAGGA 20 .
TOP2A .NM_001067 S4777/TOP2A.p4 CATATGGACTTTGACTCAGCTGTGGC 26 .
TOP2B NM_001068 S0274/TOP2B.f2 TGTGGACATCTTCCCCTCAGA 21 TOP2B = NM 001068 S0276/TOP2B.r2 CTAGCCCGACC GGTTC GT 18 TOP2B NM_001068, S4778/TOP 2B. p2 TTCCCTACTGAGCCACCTTCTCTG 24 TP NM 001953 S0277/TP.13 CTATATGCAGCCAGAGATGTGACA 24 TP NM_001953 S0279/TP.r3 CCACGAGTTraTTACTGAGAATGG ' 24 TP NM_001953 S4779/TP.p3 ACAGCCTGCCACTCATCACAGCC 23 TP538P2 NM_005426 S1931/TP53BP.f2 GGGCCAAATATTCAGAAGC 19 TP533P2 NM 005426 S1932/TP53BP.r2 GGATGGGTATGATGGGACAG 20 TP53BP2 NM:005426 S5049/TP533P.p2 CCACCATAGCGGCCATGGAG 20 TRAIL NM_003810 S2539/TRA1L.f1 CTTCACAGTGCTCCTGCAGTCT 22 TRAIL = NM_003810 S2540/TRAIL.r1 CATCTGCTTCAG CTCGTTG
GT = = . 21 TRAIL NM 003810 S4980/TRAIL.p1 AAGTACACGTAAGTTACAGCCACACA ' 26 TS NM 001071 S0280/TS.f1 GCCTCGGTGTGCCTTTCA 18 TS NM-001071 80282/TS.r1 CGTGATGTGCGCAATCATG 19 TS NM:001071 S4780/TS.pl CATCGCCAGCTACGCCCTGCTC 22 =
up a NM_002658 S0283/upa.f3 GTGGATGTGCCCTGAAGGA. 19 up a NM_002658 S0285/upa.r3 CTGCGGATCCAGGGTAAGAA ' 20 =
40 .
Table 6F
=
upa NM_002658 S4769/upa.p3 AAGCCAGGCGTCTACACGAGAGTCTCAC 28 VDR = NM 000376 S2745NDR.f2 GCCCTGGATTTCAGAAAGAG 20 VDR NM 000376 S2746NDR.r2 AGTTACAAGCCAGGGAAGGA 20 VD R NM_000376 S4962N0 R. p2 VEGF NM 003376 60286NEGF.f1 VEGF NM-003376 60288NEGF.r1 GCAGCCTGGGACCACTTG . 18 VEGF NM_003376 64782NEGF.p1 TTGCCTTGCTGCTCTACCTCCACCA 25 VEGFB NM 003377 S2724NEGFB.f1 VEGFB NM 003377 S2725NEGFB.r1 GGTACCGGATCATGAGGATCTG 22 VEGFB NM_003377 64960NEGFB.p1 CTGGGCAGCACCAAGTCCGGA 21 WISP1 NM 003882 61671NVISP1 .f1 WISP1 NM 003882 S1672/WISP1 .r1 WISP1 NM_003882 S4915/VVISP1.pl CGGGCTGCATCAGCACACGC 20 GCAGTTGGAAGACACAGGAAAGT . 23 XIAP NM 001167 S0291/XIAP.r1 XIAP NM_001167 S4752/XIAP.p1 TCCCCAAATTGCAGATTTATCAACGGC 27 YB-1 NM 004559 S1194/YB-1.f2 YB-1 NM_004559 S1195NB-1.r2 GGAACACCACCAGGACCTGTAA 22 YB-1 NM_004559 S4843NB-1.p2 ______________ TTGCTGCCTCCGCACCC IIIi CT
ZNF217 NM 006526 S2739/ZNF217.f3 ACCCAGTAGCAAGGAGAAGC 20 ZNF217 NM_006526 S2740/ZNF217.r3 CAGCTGGTGGTAGGTTCTGA 20 ZNF2l 7 NM 006526 S4961/ZN F217. p3 CACTCACTGCTCCGAGTGCGG 21 =
=
=
=
SEQUENCE LISTING
<110> GENOMIC HEALTH, INC.
RUSH UNIVERSITY MEDICAL CENTER
COBLEIGH, Melody SHAK, Steven BAKER, Joffre CRONIN, Maureen <120> GENE EXPRESSION MARKERS FOR BREAST
CANCER PROGNOSIS
<130> 39740-0008 PCT
<140> PCT/US2004/000985 <141> 2004-01-14 <150> US 60/440,861 <151> 2003-01-15 <160> 440 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 1 gcggcgagtt tccgatttaa agctgagctg cgaggaaaat ggcggcggga ggatcaaaat 60 acttgctgga tggtggactc a 81 <210> 2 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 2 cgcttctatg gcgctgagat tgtgtcagcc ctggactacc tgcactcgga gaagaacgtg 60 gtgtaccggg a 71 <210> 3 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 3 tcctgccacc cttcaaacct caggtcacgt ccgaggtcga cacaaggtac ttcgatgatg 60 aatttaccgc c 71 <210> 4 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 4 ggacagcagg aatgtgtttc tccatacagg tcacggggag ccaatggttc agaaacaaat 60 cgagtgggt 69 <210> 5 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 5 tgtgagtgaa atgccttcta gtagtgaacc gtcctcggga gccgactatg actactcaga 60 agagtatgat aacgaaccac aa 82 <210> 6 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> amplicon <400> 6 cagcagatgt ggatcagcaa gcaggagtat gacgagtccg gcccctccat cgtccaccgc 60 aaatgc 66 <210> 7 <211> 80 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 7 ggctcttgtg cgtactgtcc ttcgggctgg tgacagggaa gacatcactg agcctgccat 60 ctgtgctctt cgtcatctga 80 <210> 8 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 8 gggtcaggtg cctcgagatc gggcttgggc ccagagcatg ttccagatcc cagagtttga 60 gccgagtgag cag 73 =
<210> 9 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 9 cgttgtcagc acttggaata caagatggtt gccgggtcat gttaattggg aaaaagaaca 60 gtccacagga agaggttgaa c 81 <210> 10 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 10 cctggagggt cctgtacaat ctcatcatgg gactcctgcc cttacccagg ggccacagag 60 cccccgagat ggagcccaat tag 83 <210> 11 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 11 cagatggacc tagtacccac tgagatttcc acgccgaagg acagcgatgg gaaaaatgcc 60 cttaaatcat agg 73 <210> 12 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 12 atcctagccc tggtttttgg cctccttttt gctgtcacca gcgtcgcgtt ccttgtgcag 60 atgagaaggc ag 72 <210> 13 <211> 84 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 13 ttcaggttgt tgcaggagac catgtacatg actgtctcca ttattgatcg gttcatgcag 60 aataattgtg tgcccaagaa gatg 84 <210> 14 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 14 gcatgttcgt ggcctctaag atgaaggaga ccatccccct gacggccgag aagctgtgca 60 tctacaccg 69 <210> 15 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 15 aaagaagatg atgaccgggt ttacccaaac tcaacgtgca agcctcggat tattgcacca 60 tccagaggct c 71 <210> 16 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 16 atgctgtggc tccttcctaa ctggggcttt cttgacatgt aggttgcttg gtaataacct 60 ttttgtatat cacaatttgg qt 82 <210> 17 <211> 65 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 17 agatgaagtg gaaggcgctt ttcaccgcgg ccatcctgca ggcacagttg ccgattacag 60 aggca 65 <210> 18 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 18 tggttcccag ccctgtgtcc acctccaagc ccagattcag attcgagtca tgtacacaac 60 ccagggtgga ggag 74 <210> 19 <211> 64 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 19 gggcgtggaa cagtttatct cagacatctg ccccaagaag gacgtactcg aaaccttcac 60 cgtg 64 <210> 20 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 20 tgagtgtccc ccggtatctt ccccgccctg ccaatcccga tgaaattgga aattttattg 60 atgaaaatct gaaagcggct g 81 <210> 21 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 21 tgacaatcag cacacctgca ttcaccgctc ggaagagggc ctgagctgca tgaataagga 60 tcacggctgt agtcaca 77 <210> 22 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 22 gataaattgg tacaagggat cagcttttcc cagcccacat gtcctgatca tatgcttttg 60 aatagtcagt tacttggcac cc 82 <210> 23 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 23 tgcctgtggt gggaagctca gtaactggga accaaaggat gatgctatgt cagaacaccg 60 gaggcatttt cc 72 <210> 24 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 24 ggatatttcc gtggctctta ttcaaactct ccatcaaatc ctgtaaactc cagagcaaat 60 caagattttt ctgccttgat gagaag 86 <210> 25 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 25 gacatttcca gtcctgcagt caatgcctct ctgccccacc ctttgttcag tgtggctggt 60 gccacgacaa atgtgtgcga tcggag 86 <210> 26 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 26 ggcatcctgg cccaaagttt cccaaatcca ggcggctaga ggcccactgc ttcccaacta 60 ccagctgagg gggtc 75 <210> 27 <211> 79 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 27 tctgcagagt tggaagcact ctatggtgac atcgatgctg tggagctgta tcctgccctt 60 ctggtagaaa agcctcggc 79 <210> 28 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 28 gggaggctta tctcactgag tgagcagaat ctggtagact gctctgggcc tcaaggcaat 60 gaaggctgca atgg 74 <210> 29 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 29 tgtctcactg agcgagcaga atctggtgga ctgttcgcgt cctcaaggca atcagggctg 60 caatggt 67 <210> 30 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 30 cgctgacatc atgaatgttc ctcgaccggc tggaggcgag tttggatatg acaaagacac 60 atcgttgctg aaagaga 77 <210> 31 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 31 cacaatggcg gctctgaaga gttggctgtc gcgcagcgta acttcattct tcaggtacag 60 acagtgtttg tgt 73 <210> 32 <211> 84 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 32 ctctgagaca gtgcttcgat gactttgcag acttggtgcc ctttgactcc tgggagccgc 60 tcatgaggaa gttgggcctc atgg 84 <210> 33 <211> 62 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 33 tgtcgatgga cttccagaac cacctgggca gctgccaaaa gtgtgatcca agctgtccca 60 at 62 <210> 34 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 34 gatctaagat ggcgactgtc gaaccggaaa ccacccctac tcctaatccc ccgactacag 60 aagaggagaa aacggaatct aa 82 <210> 35 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 35 ggcagtgtca ctgagtcctt gaaatcctcc cctgccccgc gggtctctgg attgggacgc 60 acagtgca 68 <210> 36 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 36 gggccctcca gaacaatgat gggctttatg atcctgactg cgatgagagc gggctcttta 60 aggccaagca gtgca 75 <210> 37 <211> 76 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 37 accgtaggct ctgctctgaa tgactctcct gtgggtctgg ctgcctatat tctagagaag 60 ttttccacct ggacca 76 <210> 38 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 38 cggttatgtc atgccagata cacacctcaa aggtactccc tcctcccggg aaggcaccct 60 ttcttcagtg ggtctcagtt c 81 <210> 39 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 39 cgtggtgccc ctctatgacc tgctgctgga gatgctggac gcccaccgcc tacatgcgcc 60 cactagcc 68 <210> 40 <211> 90 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 40 ggctattcct cattttctct acaaagtggc ctcagtgaac atgaagaagg tagcctcctg 60 gaggagaatt tcggtgacag tctacaatcc 90 <210> 41 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 41 cggtagtcaa gtccggatca agggcaagga gacggaattc tacctgtgca tgaaccgcaa 60 aggcaagc 68 <210> 42 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 42 cacgggacat tcaccacatc gactactata aaaagacaac caacggccga ctgcctgtga 60 agtggatggc accc 74 <210> 43 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 43 ccagtggagc gcttccatga cctgcgtcct gatgaagtgg ccgatttgtt tcagacgacc 60 cagagag 67 <210> 44 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 44 ttggtacctg tgggttagca tcaagttctc cccagggtag aattcaatca gagctccagt 60 ttgcatttgg atgtg 75 <210> 45 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 45 tcagcagcaa gggcatcatg gaggaggatg aggcctgcgg gcgccagtac acgctcaaga 60 aaaccacc 68 <210> 46 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 46 attccaccca tggcaaattc catggcaccg tcaaggctga gaacgggaag cttgtcatca 60 atggaaatcc catc 74 <210> 47 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 47 caaaggagct cactgtggtg tctgtgttcc aaccactgaa tctggacccc atctgtgaat 60 aagccattct gactc 75 <210> 48 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 48 ccatctgcat ccatcttgtt tgggctcccc acccttgaga agtgcctcag ataataccct 60 ggtggcc 67 <210> 49 <211> 73 <212> DNA
<213> Aritificial sequence <220>
<223> Amplicon <400> 49 cgaaaagatg ctgaacagtg acaaatccaa ctgaccagaa gggaggagga agctcactgg 60 tggctgttcc tga 73 <210> 50 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 50 aagctatgag gaaaagaagt acacgatggg ggacgctcct gattatgaca gaagccagtg 60 gctgaatgaa aaattcaagc tgggcc 86 <210> 51 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 51 cccactcagt agccaagtca caatgtttgg aaaacagccc gtttacttga gcaagactga 60 taccacctgc gtg 73 <210> 52 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 52 cggtgtgaga agtgcagcaa gccctgtgcc cgagtgtgct atggtctggg catggagcac 60 ttgcgagagg 70 <210> 53 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 53 tgaacataaa gtctgcaaca tggaaggtat tgcactgcac aggccacatt cacgtatatg 60 ataccaacag taaccaacct ca 82 <210> 54 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 54 tccaggatgt taggaactgt gaagatggaa gggcatgaaa ccagcgactg gaacagctac 60 tacgcagaca cgc 73 <210> 55 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 55 agaaccgcaa ggtgagcaag gtggagattc tccagcacgt catcgactac atcagggacc 60 ttcagttgga 70 <210> 56 <211> 76 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 56 tccggagctg tgatctaagg aggctggaga tgtattgcgc acccctcaag cctgccaagt 60 cagctcgctc tgtccg 76 <210> 57 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 57 gcatggtagc cgaagatttc acagtcaaaa tcggagattt tggtatgacg cgagatatct 60 atgagacaga ctattaccgg aaa 83 <210> 58 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 58 gtggacagca ccatgaacat gttgggcggg ggaggcagtg ctggccggaa gcccctcaag 60 tcgggtatga agg 73 <210> 59 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 59 cctgaacctt ccaaagatgg ctgaaaaaga tggatgcttc caatctggat tcaatgagga 60 gacttgcctg gt 72 <210> 60 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 60 ccacagctca ccttctgtca ggtgtccatc ccagctccag ccagctccca gagaggaaga 60 gactggcact gagg 74 <210> 61 <211> 80 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 61 cggactttgg gtgcgacttg acgagcggtg gttcgacaag tggccttgcg ggccggatcg 60 tcccagtgga agagttgtaa 80 <210> 62 <211> 78 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 62 gcccagaggc tccatcgtcc atcctcttcc tccccagtcg gctgaactct ccccttgtct 60 gcactgttca aacctctg 78 <210> 63 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 63 ggcctgctga gatcaaagac tacagtccct acttcaagac cattgaggac ctgaggaaca 60 agattctcac agccacagtg gac 83 <210> 64 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 64 cgaggattgg ttcttcagca agacagagga actgaaccgc gaggtggcca ccaacagtga 60 gctggtgcag agt 73 <210> 65 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 65 agagatcgag gctctcaagg aggagctgct cttcatgaag aagaaccacg aagaggaagt 60 aaaaggcc 68 <210> 66 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 66 tgagcggcag aatcaggagt accagcggct catggacatc aagtcgcggc tggagcagga 60 gattgccacc taccgca 77 <210> 67 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 67 tcagtggaga aggagttgga ccagtcaaca tctctgttgt cacaagcagt gtttcctctg 60 gatatggca 69 <210> 68 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 68 ggatgaagct tacatgaaca aggtagagct ggagtctcgc ctggaagggc tgaccgacga 60 gatcaacttc ctcaggcagc tatatg 86 a <210> 69 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 69 ggaaagacca cctgaaaaac cacctccaga cccacgaccc caacaaaatg gcctttgggt 60 gtgaggagtg tgggaagaag tac 83 <210> 70 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 70 cagatggcca ctttgagaac attttagctg acaacagtgt gaacgaccag accaaaatcc 60 ttgtggttaa tgctgcc 77 <210> 71 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 71 gacttttgcc cgctaccttt cattccggcg tgacaacaat gagctgttgc tcttcatact 60 gaagcagtta gtggc 75 <210> 72 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 72 ggagaacaat ccccttgaga cagaatatgg cctttctgtc tacaaggatc accagaccat 60 caccatccag gagat 75 <210> 73 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 73 tgatggtcct atgtgtcaca ttcatcacag gtttcatacc aacacaggct tcagcacttc 60 ctttggtgtg tttcctgtcc ca 82 a <210> 74 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 74 ctacagggac gccatcgaat ccggatcttg atgctggtgt aagtgaacat tcaggtgatt 60 ggttggat 68 <210> 75 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 75 gagaaccaat ctcaccgaca ggcagctggc agaggaatac ctgtaccgct atggttacac 60 tcgggtg 67 <210> 76 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 76 ccgccctcac ctgaagagaa acgcgctcct tggcggacac tgggggagga gaggaagaag 60 cgcggctaac ttattcc 77 <210> 77 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 77 gccgagatcg ccaagatgtt gccagggagg acagacaatg ctgtgaagaa tcactggaac 60 tctaccatca aaag 74 <210> 78 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 78 ccctcgtgct gatgctactg aggagccagc gtctagggca gcagccgctt cctagaagac 60 caggtcatga tg 72 =
<210> 79 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 79 cggtggacca cgaagagtta acccgggact tggagaagca ctgcagagac atggaagagg 60 cgagcc 66 <210> 80 <211> 68 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 80 ctttgaaccc ttgcttgcaa taggtgtgcg tcagaagcac ccaggacttc catttgcttt 60 gtcccggg 68 <210> 81 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 81 ccgcaacgtg gttttctcac cctatggggt ggcctcggtg ttggccatgc tccagctgac 60 aacaggagga gaaacccagc a 81 <210> 82 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 82 ccagctctcc ttccagctac agatcaatgt ccctgtccga gtgctggagc taagtgagag 60 ccaccc 66 <210> 83 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 83 ataccaatca ccgcacaaac ccaggctatt tgttaagtcc agtcacagcg caaagaaaca 60 tatgcggaga aaatgctagt gtg 83 <210> 84 <211> 62 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 84 gccatccgca aaggctttct cgcttgtcac cttgccatgt ggaagaaact ggcggaatgg 60 cc 62 <210> 85 <211> 85 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 85 gcatcaggct gtcattatgg tgtccttacc tgtgggagct gtaaggtctt ctttaagagg 60 gcaatggaag ggcagcacaa ctact 85 <210> 86 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 86 tctccatatc tgccttgcag agtctcctgc agcacctcat cgggctgagc aatctgaccc 60 acgtgc 66 <210> 87 <211> 86 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 87 gccctcccag tgtgcaaata agggctgctg tttcgacgac accgttcgtg gggtcccctg 60 gtgcttctat cctaatacca tcgacg 86 <210> 88 <211> 78 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 88 gaacttcttg agcaggagca tacccagggc ttcataatca ccttctgttc agcactagat 60 gatattcttg ggggtgga 78 =
<210> 89 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 89 cgaagccctt acaagtttcc tagttcaccc ttacggattc ctggagggaa catctatatt 60 tcacccctga agagtcc 77 <210> 90 <211> 74 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 90 ccagacgagc gattagaagc ggcagcttgt gaggtgaatg atttggggga agaggaggag 60 gaggaagagg agga 74 <210> 91 <211> 69 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 91 catcttccag gaggaccact ctctgtggca ccctggacta cctgccccct gaaatgattg 60 aaggtcgga 69 <210> 92 <211> 90 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 92 cctggaggct gcaacatacc tcaatcctgt cccaggccgg atcctcctga agcccttttc 60 gcagcactgc tatcctccaa agccattgta 90 <210> 93 <211> 80 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 93 tgttttgatt cccgggctta ccaggtgaga agtgagggag gaagaaggca gtgtcccttt 60 tgctagagct gacagctttg 80 <210> 94 <211> 65 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 94 gcccgaaacg ccgaatataa tcccaagcgg tttgctgcgg taatcatgag gataagagag 60 ccacg 65 <210> 95 <211> 83 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 95 ggtgtgccac agaccttcct acttggcctg taatcacctg tgcagccttt tgtgggcctt 60 caaaactctg tcaagaactc cgt 83 <210> 96 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 96 tccctgcggt cccagatagc ctgaatcctg cccggagtgg aactgaagcc tgcacagtgt 60 ccaccctgtt cccac 75 <210> 97 <211> 72 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 97 aatccaaggg ggagagtgat gacttccata tggactttga ctcagctgtg gctcctcggg 60 caaaatctgt ac 72 <210> 98 <211> 66 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 98 tgtggacatc ttcccctcag acttccctac tgagccacct tctctgccac gaaccggtcg 60 ggctag 66 =
<210> 99 <211> 82 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 99 ctatatgcag ccagagatgt gacagccacc gtggacagcc tgccactcat cacagcctcc 60 attctcagta agaaactcgt gg 82 <210> 100 <211> 81 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 100 gggccaaata ttcagaagct tttatatcag aggaccacca tagcggccat ggagaccatc 60 tctgtcccat catacccatc c 81 <210> 101 <211> 73 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 101 cttcacagtg ctcctgcagt ctctctgtgt ggctgtaact tacgtgtact ttaccaacga 60 gctgaagcag atg 73 <210> 102 <211> 65 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 102 gcctcggtgt gcctttcaac atcgccagct acgccctgct cacgtacatg attgcgcaca 60 tcacg 65 <210> 103 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 103 gtggatgtgc cctgaaggac aagccaggcg tctacacgag agtctcacac ttcttaccct 60 ggatccgcag 70 <210> 104 <211> 67 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 104 gccctggatt tcagaaagag ccaagtctgg atctgggacc ctttccttcc ttccctggct 60 tgtaact 67 <210> 105 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 105 ctgctgtctt gggtgcattg gagccttgcc ttgctgctct acctccacca tgccaagtgg 60 tcccaggctg c 71 <210> 106 <211> 71 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 106 tgacgatggc ctggagtgtg tgcccactgg gcagcaccaa gtccggatgc agatcctcat 60 gatccggtac c 71 <210> 107 <211> 75 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 107 agaggcatcc atgaacttca cacttgcggg ctgcatcagc acacgctcct atcaacccaa 60 gtactgtgga gtttg 75 <210> 108 <211> 77 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 108 gcagttggaa gacacaggaa agtatcccca aattgcagat ttatcaacgg cttttatctt 60 gaaaatagtg ccacgca 77 =
<210> 109 <211> 76 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 109 agactgtgga gtttgatgtt gttgaaggag aaaagggtgc ggaggcagca aatgttacag 60 gtcctggtgg tgttcc 76 <210> 110 <211> 70 <212> DNA
<213> Artificial Sequence <220>
<223> Amplicon <400> 110 acccagtagc aaggagaagc ccactcactg ctccgagtgc ggcaaagctt tcagaaccta 60 ccaccagctg 70 <210> 111 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 111 gcggcgagtt tccgattta 19 <210> 112 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 112 tgagtccacc atccagcaag t 21 <210> 113 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 113 atggcggcgg gaggatcaaa a 21 <210> 114 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 114 cgcttctatg gcgctgagat 20 <210> 115 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 115 tcccggtaca ccacgttctt 20 <210> 116 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 116 cagccctgga ctacctgcac tcgg 24 <210> 117 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 117 tcctgccacc cttcaaacc 19 <210> 118 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 118 ggcggtaaat tcatcatcga a 21 <210> 119 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 119 caggtcacgt ccgaggtcga caca 24 <210> 120 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 120 ggacagcagg aatgtgtttc 20 <210> 121 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 121 acccactcga tttgtttctg 20 <210> 122 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 122 cattggctcc ccgtgacctg ta 22 <210> 123 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 123 tgtgagtgaa atgccttcta gtagtga 27 <210> 124 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 124 ccgtcctcgg gagccgacta tga 23 <210> 125 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 125 ttgtggttcg ttatcatact cttctga 27 <210> 126 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 126 cagcagatgt ggatcagcaa g 21 <210> 127 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 127 gcatttgcgg tggacgat 18 <210> 128 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 128 aggagtatga cgagtccggc ccc 23 <210> 129 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 129 ggctcttgtg cgtactgtcc tt 22 <210> 130 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer =
<400> 130 tcagatgacg aagagcacag atg 23 <210> 131 <211> 29 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 131 aggctcagtg atgtcttccc tgtcaccag 29 <210> 132 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 132 gggtcaggtg cctcgagat 19 <210> 133 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 133 ctgctcactc ggctcaaact c 21 <210> 134 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 134 tgggcccaga gcatgttcca gatc 24 <210> 135 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 135 cgttgtcagc acttggaata caa 23 <210> 136 =
<211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 136 gttcaacctc ttcctgtgga ctgt 24 <210> 137 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 137 cccaattaac atgacccggc aaccat 26 <210> 138 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 138 cctggagggt cctgtacaat 20 <210> 139 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 139 ctaattgggc tccatctcg 19 <210> 140 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 140 catcatggga ctcctgccct tacc 24 <210> 141 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 141 cagatggacc tagtacccac tgaga 25 <210> 142 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 142 ttccacgccg aaggacagcg at 22 <210> 143 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 143 cctatgattt aagggcattt ttcc 24 <210> 144 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 144 atcctagccc tggtttttgg 20 <210> 145 <211> 20 <212> DNA
<213> Artificial sequence <220>
<223> reverse primer <400> 145 ctgccttctc atctgcacaa 20 <210> 146 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 146 tttgctgtca ccagcgtcgc 20 <210> 147 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 147 ttcaggttgt tgcaggagac 20 <210> 148 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 148 catcttcttg ggcacacaat 20 <210> 149 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 149 tgtctccatt attgatcggt tcatgca 27 <210> 150 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 150 gcatgttcgt ggcctctaag a 21 <210> 151 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 151 cggtgtagat gcacagcttc tc 22 <210> 152 <211> 23 <212> DNA
<213> Artificial Sequence =
<220>
<223> probe <400> 152 aaggagacca tccccctgac ggc 23 <210> 153 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 153 aaagaagatg atgaccgggt ttac 24 <210> 154 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 154 gagcctctgg atggtgcaat 20 <210> 155 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 155 caaactcaac gtgcaagcct cgga 24 <210> 156 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 156 atgctgtggc tccttcctaa ct 22 <210> 157 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 157 acccaaattg tgatatacaa aaaggtt 27 <210> 158 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 158 taccaagcaa cctacatgtc aagaaagccc 30 <210> 159 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 159 agatgaagtg gaaggcgctt 20 <210> 160 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 160 caccgcggcc atcctgca 18 <210> 161 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 161 tgcctctgta atcggcaact g 21 <210> 162 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 162 tggttcccag ccctgtgt 18 <210> 163 <211> 28 <212> DNA
<213> Artificial Sequence =
<220>
<223> probe <400> 163 ctccaagccc agattcagat tcgagtca 28 <210> 164 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 164 ctcctccacc ctgggttgt 19 <210> 165 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 165 gggcgtggaa cagtttatct 20 <210> 166 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 166 cacggtgaag gtttcgagt 19 <210> 167 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 167 agacatctgc cccaagaagg acgt 24 <210> 168 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 168 =
tgagtgtccc ccggtatctt c 21 <210> 169 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 169 cagccgcttt cagattttca t 21 <210> 170 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 170 tgccaatccc gatgaaattg gaaattt 27 <210> 171 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 171 tgacaatcag cacacctgca t 21 <210> 172 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 172 tgtgactaca gccgtgatcc tta 23 <210> 173 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 173 caggccctct tccgagcggt 20 <210> 174 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 174 gataaattgg tacaagggat cagctt 26 <210> 175 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 175 gggtgccaag taactgacta ttca 24 <210> 176 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 176 ccagcccaca tgtcctgatc atatgc 26 <210> 177 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 177 tgcctgtggt gggaagct 18 <210> 178 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 178 ggaaaatgcc tccggtgtt 19 <210> 179 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 179 tgacatagca tcatcctttg gttcccagtt 30 <210> 180 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 180 ggatatttcc gtggctctta ttca 24 <210> 181 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 181 tctccatcaa atcctgtaaa ctccagagca 30 <210> 182 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 182 cttctcatca aggcagaaaa atctt 25 <210> 183 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 183 gacatttcca gtcctgcagt ca 22 <210> 184 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 184 tgcctctctg ccccaccctt tgt 23 <210> 185 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 185 ctccgatcgc acacatttgt 20 <210> 186 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 186 ggcatcctgg cccaaagt 18 <210> 187 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 187 gaccccctca gctggtagtt g 21 <210> 188 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 188 cccaaatcca ggcggctaga ggc 23 <210> 189 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 189 tctgcagagt tggaagcact cta 23 <210> 190 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 190 caggatacag ctccacagca tcgatgtc 28 <210> 191 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 191 gccgaggctt ttctaccaga a 21 <210> 192 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 192 gggaggctta tctcactgag tga 23 <210> 193 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 193 ccattgcagc cttcattgc 19 <210> 194 <211> 29 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 194 ttgaggccca gagcagtcta ccagattct 29 <210> 195 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 195 tgtctcactg agcgagcaga a 21 <210> 196 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 196 accattgcag ccctgattg 19 <210> 197 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 197 cttgaggacg cgaacagtcc acca 24 <210> 198 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 198 cgctgacatc atgaatgttc ct 22 <210> 199 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 199 tctctttcag caacgatgtg tctt 24 <210> 200 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 200 tcatatccaa actcgcctcc agccg 25 <210> 201 <211> 19 <212> DNA
<213> Artificial Sequence <220>
=
<223> forward primer <400> 201 cacaatggcg gctctgaag 19 <210> 202 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 202 acacaaacac tgtctgtacc tgaaga 26 <210> 203 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 203 aagttacgct gcgcgacagc caa 23 <210> 204 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 204 ctctgagaca gtgcttcgat gact 24 <210> 205 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 205 ccatgaggcc caacttcct 19 <210> 206 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 206 cagacttggt gccctttgac tcc 23 <210> 207 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 207 tgtcgatgga cttccagaac 20 <210> 208 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 208 cacctgggca gctgccaa 18 <210> 209 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 209 attgggacag cttggatca 19 <210> 210 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 210 gatctaagat ggcgactgtc gaa 23 <210> 211 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 211 ttagattccg ttttctcctc ttctg 25 <210> 212 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 212 accaccccta ctcctaatcc cccgact 27 <210> 213 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 213 ggcagtgtca ctgagtcctt ga 22 <210> 214 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 214 tgcactgtgc gtcccaat 18 <210> 215 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 215 atcctcccct gccccgcg 18 <210> 216 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 216 gggccctcca gaacaatgat 20 <210> 217 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 217 tgcactgctt ggccttaaag a 21 =
<210> 218 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 218 ccgctctcat cgcagtcagg atcat 25 <210> 219 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 219 accgtaggct ctgctctgaa 20 <210> 220 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 220 tggtccaggt ggaaaacttc 20 <210> 221 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 221 aggcagccag acccacagga 20 <210> 222 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 222 cggttatgtc atgccagata cac 23 <210> 223 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 223 cctcaaaggt actccctcct cccgg 25 <210> 224 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 224 gaactgagac ccactgaaga aagg 24 <210> 225 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 225 cgtggtgccc ctctatgac 19 <210> 226 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 226 ctggagatgc tggacgccc 19 <210> 227 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 227 ggctagtggg cgcatgtag 19 <210> 228 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 228 ggattgtaga ctgtcaccga aattc 25 <210> 229 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 229 ggctattcct cattttctct acaaagtg 28 <210> 230 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 230 cctccaggag gctaccttct tcatgttcac 30 <210> 231 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 231 cggtagtcaa gtccggatca a 21 <210> 232 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 232 gcttgccttt gcggttca 18 <210> 233 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 233 caaggagacg gaattctacc tgtgc 25 <210> 234 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 234 cacgggacat tcaccacatc 20 <210> 235 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 235 gggtgccatc cacttcaca 19 <210> 236 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 236 ataaaaagac aaccaacggc cgactgc 27 <210> 237 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 237 ccagtggagc gcttccat 18 <210> 238 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 238 ctctctgggt cgtctgaaac aa 22 <210> 239 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 239 tcggccactt catcaggacg cag 23 <210> 240 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 240 ttggtacctg tgggttagca 20 <210> 241 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 241 cacatccaaa tgcaaactgg 20 <210> 242 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 242 tccccagggt agaattcaat cagagc 26 <210> 243 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 243 tcagcagcaa gggcatcat 19 <210> 244 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 244 ggtggttttc ttgagcgtgt act 23 <210> 245 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 245 cgcccgcagg cctcatcct 19 <210> 246 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 246 attccaccca tggcaaattc 20 <210> 247 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 247 gatgggattt ccattgatga ca 22 <210> 248 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 248 ccgttctcag ccttgacggt gc 22 <210> 249 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 249 caaaggagct cactgtggtg tct 23 <210> 250 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe =
<400> 250 tgttccaacc actgaatctg gacc 24 <210> 251 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 251 gagtcagaat ggcttattca cagatg 26 <210> 252 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 252 ccatctgcat ccatcttgtt 20 <210> 253 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 253 ctccccaccc ttgagaagtg cct 23 <210> 254 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 254 ggccaccagg gtattatctg 20 <210> 255 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 255 cgaaaagatg ctgaacagtg aca 23 <210> 256 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 256 tcaggaacag ccaccagtga 20 <210> 257 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 257 cttcctcctc ccttctggtc agttggat 28 <210> 258 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 258 ggcccagctt gaatttttca 20 <210> 259 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 259 aagctatgag gaaaagaagt acacgat 27 <210> 260 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 260 tcagccactg gcttctgtca taatcaggag 30 <210> 261 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 261 cccactcagt agccaagtca 20 <210> 262 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 262 tcaagtaaac gggctgtttt ccaaaca 27 <210> 263 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 263 cacgcaggtg gtatcagtct 20 <210> 264 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 264 cggtgtgaga agtgcagcaa 20 <210> 265 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 265 ccagaccata gcacactcgg gcac 24, <210> 266 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 266 cctctcgcaa gtgctccat 19 <210> 267 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 267 tgaacataaa gtctgcaaca tgga 24 <210> 268 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 268 tgaggttggt tactgttggt atcatata 28 <210> 269 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 269 ttgcactgca caggccacat tcac 24 <210> 270 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 270 tccaggatgt taggaactgt gaag 24 <210> 271 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 271 gcgtgtctgc gtagtagctg tt 22 <210> 272 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 272 agtcgctggt ttcatgccct tcca 24 <210> 273 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 273 agaaccgcaa ggtgagcaa 19 <210> 274 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 274 tccaactgaa ggtccctgat g 21 <210> 275 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 275 tggagattct ccagcacgtc atcgac 26 <210> 276 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 276 tccggagctg tgatctaagg a 21 <210> 277 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 277 tgtattgcgc acccctcaag cctg 24 =
<210> 278 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 278 cggacagagc gagctgactt 20 <210> 279 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 279 gcatggtagc cgaagatttc a 21 <210> 280 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 280 tttccggtaa tagtctgtct catagatatc 30 <210> 281 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 281 cgcgtcatac caaaatctcc gattttga 28 <210> 282 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 282 gtggacagca ccatgaaca 19 <210> 283 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 283 ccttcatacc cgacttgagg 20 <210> 284 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 284 cttccggcca gcactgcctc 20 <210> 285 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 285 cctgaacctt ccaaagatgg 20 <210> 286 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 286 accaggcaag tctcctcatt 20 <210> 287 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 287 ccagattgga agcatccatc tttttca 27 <210> 288 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 288 ccacagctca ccttctgtca 20 <210> 289 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 289 cctcagtgcc agtctcttcc 20 <210> 290 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 290 tccatcccag ctccagccag 20 <210> 291 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 291 ccacttgtcg aaccaccgct cgt 23 <210> 292 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 292 cggactttgg gtgcgactt 19 <210> 293 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 293 ttacaactct tccactggga cgat 24 <210> 294 <211> 18 <212> DNA
=
<213> Artificial Sequence <220>
<223> forward primer <400> 294 gcccagaggc tccatcgt 18 <210> 295 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 295 cagaggtttg aacagtgcag aca 23 <210> 296 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 296 cctcttcctc cccagtcggc tga 23 <210> 297 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 297 ggcctgctga gatcaaagac 20 <210> 298 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 298 gtccactgtg gctgtgagaa 20 <210> 299 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 299 tgttcctcag gtcctcaatg gtcttg 26 <210> 300 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 300 cgaggattgg ttcttcagca a 21 <210> 301 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 301 actctgcacc agctcactgt tg 22 <210> 302 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 302 cacctcgcgg ttcagttcct ctgt 24 <210> 303 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 303 agagatcgag gctctcaagg 20 <210> 304 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 304 ggccttttac ttcctcttcg 20 <210> 305 <211> 27 =
<212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 305 tggttcttct tcatgaagag cagctcc 27 <210> 306 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 306 tgagcggcag aatcaggagt a 21 <210> 307 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 307 tgcggtaggt ggcaatctc 19 <210> 308 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 308 ctcatggaca tcaagtcgcg gctg 24 <210> 309 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 309 tcagtggaga aggagttgga 20 <210> 310 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe =
<400> 310 ccagtcaaca tctctgttgt cacaagca 28 <210> 311 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 311 tgccatatcc agaggaaaca 20 <210> 312 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 312 ggatgaagct tacatgaaca aggtaga 27 <210> 313 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 313 catatagctg cctgaggaag ttgat 25 <210> 314 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 314 cgtcggtcag cccttccagg c 21 <210> 315 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 315 ggaaagacca cctgaaaaac ca 22 <210> 316 =
<211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 316 gtacttcttc ccacactcct caca 24 <210> 317 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 317 acccacgacc ccaacaaaat ggc 23 <210> 318 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 318 cagatggcca ctttgagaac att 23 <210> 319 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 319 ggcagcatta accacaagga tt 22 <210> 320 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 320 agctgacaac agtgtgaacg accagacc 28 <210> 321 <211> 21 <212> DNA
<213> Artificial Sequence <220>
=
<223> forward primer <400> 321 gacttttgcc cgctaccttt c 21 <210> 322 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 322 gccactaact gcttcagtat gaagag 26 <210> 323 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 323 acagctcatt gttgtcacgc cgga 24 <210> 324 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 324 ggagaacaat ccccttgaga 20 <210> 325 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 325 atctcctgga tggtgatggt 20 <210> 326 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 326 tggcctttct gtctacaagg atcacca 27 =
<210> 327 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 327 tgatggtcct atgtgtcaca ttca 24 <210> 328 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 328 tgggacagga aacacaccaa 20 <210> 329 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 329 caggtttcat accaacacag gcttcagcac 30 <210> 330 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 330 ctacagggac gccatcgaa 19 <210> 331 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 331 atccaaccaa tcacctgaat gtt 23 <210> 332 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 332 cttacaccag catcaagatc cgg 23 <210> 333 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 333 gagaaccaat ctcaccgaca 20 <210> 334 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 334 cacccgagtg taaccatagc 20 <210> 335 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 335 acaggtattc ctctgccagc tgcc 24 <210> 336 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 336 ccgccctcac ctgaagaga 19 <210> 337 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 337 ggaataagtt agccgcgctt ct 22 =
<210> 338 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 338 cccagtgtcc gccaaggagc g 21 <210> 339 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 339 gccgagatcg ccaagatg 18 <210> 340 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 340 cttttgatgg tagagttcca gtgattc 27 <210> 341 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 341 cagcattgtc tgtcctccct ggca 24 <210> 342 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 342 ccctcgtgct gatgctact 19 <210> 343 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 343 catcatgacc tggtcttcta gg 22 <210> 344 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 344 ctgccctaga cgctggctcc tc 22 <210> 345 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 345 cggtggacca cgaagagtta a 21 <210> 346 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 346 ccgggacttg gagaagcact gca 23 <210> 347 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 347 ggctcgcctc ttccatgtc 19 <210> 348 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 348 =
ctttgaaccc ttgcttgcaa 20 <210> 349 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 349 aagtcctggg tgcttctgac gcaca 25 <210> 350 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 350 cccgggacaa agcaaatg 18 <210> 351 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 351 ccgcaacgtg gttttctca 19 <210> 352 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 352 ctcggtgttg gccatgctcc ag 22 <210> 353 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 353 tgctgggttt ctcctcctgt t 21 <210> 354 <211> 20 <212> DNA
=
<213> Artificial Sequence <220>
<223> forward primer <400> 354 ccagctctcc ttccagctac 20 <210> 355 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 355 gggtggctct cacttagctc 20 <210> 356 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 356 atcaatgtcc ctgtccgagt gctg 24 <210> 357 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 357 cacactagca ttttctccgc ata 23 <210> 358 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 358 ataccaatca ccgcacaaac c 21 <210> 359 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 359 tgcgctgtga ctggacttaa caaatagcct 30 <210> 360 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 360 gccatccgca aaggcttt 18 <210> 361 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 361 ggccattccg ccagtttc 18 <210> 362 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 362 tcgcttgtca ccttgccatg tgg 23 <210> 363 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 363 gcatcaggct gtcattatgg 20 <210> 364 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 364 agtagttgtg ctgcccttcc 20 <210> 365 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 365 tgtccttacc tgtgggagct gtaaggtc 28 <210> 366 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 366 tctccatatc tgccttgcag agt 23 <210> 367 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 367 gcacgtgggt cagattgct 19 <210> 368 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 368 tcctgcagca cctcatcggg ct 22 <210> 369 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 369 gccctcccag tgtgcaaat 19 <210> 370 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 370 tgctgtttcg acgacaccgt tog 23 <210> 371 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 371 cgtcgatggt attaggatag aagca 25 <210> 372 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 372 gaacttcttg agcaggagca taco 24 <210> 373 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 373 tccaccccca agaatatcat ctagt 25 <210> 374 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 374 agggcttcat aatcaccttc tgttc 25 <210> 375 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 375 cgaagccctt acaagtttcc 20 <210> 376 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 376 ggactcttca ggggtgaaat 20 <210> 377 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 377 cccttacgga ttcctggagg gaac 24 <210> 378 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 378 ccagacgagc gattagaagc 20 <210> 379 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 379 tcctcctctt cctcctcctc 20 <210> 380 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 380 tgtgaggtga atgatttggg gga 23 <210> 381 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 381 catcttccag gaggaccact 20 <210> 382 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 382 tccgaccttc aatcatttca 20 <210> 383 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 383 ctctgtggca ccctggacta cctg 24 <210> 384 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 384 cctggaggct gcaacatacc 20 <210> 385 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 385 tacaatggct ttggaggata gca 23 <210> 386 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 386 atcctcctga agcccttttc gcagc 25 =
<210> 387 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 387 tgttttgatt cccgggctta 20 <210> 388 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 388 tgccttcttc ctccctcact tctcacct 28 <210> 389 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 389 caaagctgtc agctctagca aaag 24 <210> 390 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 390 gcccgaaacg ccgaatata 19 <210> 391 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 391 taccgcagca aaccgcttgg g 21 <210> 392 <211> 23 <212> DNA
<213> Artificial Sequence =
<220>
<223> reverse primer <400> 392 cgtggctctc ttatcctcat gat 23 <210> 393 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 393 ggtgtgccac agaccttcct 20 <210> 394 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 394 acggagttct tgacagagtt ttga 24 <210> 395 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 395 ttggcctgta atcacctgtg cagcctt 27 <210> 396 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 396 tccctgcggt cccagatag 19 <210> 397 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 397 gtgggaacag ggtggacact 20 =
<210> 398 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 398 atcctgcccg gagtggaact gaagc 25 <210> 399 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 399 aatccaaggg ggagagtgat 20 <210> 400 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 400 catatggact ttgactcagc tgtggc 26 <210> 401 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 401 gtacagattt tgcccgagga 20 <210> 402 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 402 tgtggacatc ttcccctcag a 21 <210> 403 <211> 24 <212> DNA
<213> Artificial Sequence =
<220>
<223> probe <400> 403 ttccctactg agccaccttc tctg 24 <210> 404 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 404 ctagcccgac cggttcgt 18 <210> 405 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 405 ctatatgcag ccagagatgt gaca 24 <210> 406 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 406 acagcctgcc actcatcaca gcc 23 <210> 407 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 407 ccacgagttt cttactgaga atgg 24 <210> 408 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 408 =
gggccaaata ttcagaagc 19 <210> 409 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 409 ggatgggtat gatgggacag 20 <210> 410 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 410 ccaccatagc ggccatggag 20 <210> 411 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 411 cttcacagtg ctcctgcagt ct 22 <210> 412 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 412 catctgcttc agctcgttgg t 21 <210> 413 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 413 aagtacacgt aagttacagc cacaca 26 <210> 414 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 414 gcctcggtgt gcctttca 18 <210> 415 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 415 catcgccagc tacgccctgc tc 22 <210> 416 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 416 cgtgatgtgc gcaatcatg 19 <210> 417 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 417 gtggatgtgc cctgaagga 19 <210> 418 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 418 ctgcggatcc agggtaagaa 20 <210> 419 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> probe =
<400> 419 aagccaggcg tctacacgag agtctcac 28 <210> 420 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 420 gccctggatt tcagaaagag 20 <210> 421 <211> 20 <212> DNA
<212> Artificial Sequence <220>
<223> reverse primer <400> 421 agttacaagc cagggaagga 20 <210> 422 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 422 caagtctgga tctgggaccc tttcc 25 <210> 423 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 423 ctgctgtctt gggtgcattg 20 <210> 424 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 424 gcagcctggg accacttg 18 <210> 425 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 425 ttgccttgct gctctacctc cacca 25 <210> 426 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 426 tgacgatggc ctggagtgt 19 <210> 427 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 427 ggtaccggat catgaggatc tg 22 <210> 428 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 428 ctgggcagca ccaagtccgg a 21 <210> 429 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 429 agaggcatcc atgaacttca ca 22 <210> 430 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 430 caaactccac agtacttggg ttga 24 <210> 431 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 431 cgggctgcat cagcacacgc 20 <210> 432 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 432 gcagttggaa gacacaggaa agt 23 <210> 433 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 433 tccccaaatt gcagatttat caacggc 27 <210> 434 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 434 tgcgtggcac tattttcaag a 21 <210> 435 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 435 agactgtgga gtttgatgtt gttga 25 <210> 436 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 436 ggaacaccac caggacctgt aa 22 <210> 437 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 437 ttgctgcctc cgcacccttt tct 23 <210> 438 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> forward primer <400> 438 acccagtagc aaggagaagc 20 <210> 439 <211> 20 <212> DNA
<213> Artificial Sequence <220>
<223> reverse primer <400> 439 cagctggtgg taggttctga 20 <210> 440 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 440 cactcactgc tccgagtgcg g 21
Claims (12)
1. A method of predicting the likelihood of long-term survival of a breast cancer patient without recurrence of breast cancer, comprising:
determining a level of an RNA transcript of MYBL2 or its expression product, in a breast cancer tumor sample from said patient;
normalizing said level of the RNA transcript of MYBL2 or its expression product, to obtain a normalized expression level of MYBL2;
wherein increased normalized expression level of MYBL2 indicates a decreased likelihood of long-term survival without breast cancer recurrence.
determining a level of an RNA transcript of MYBL2 or its expression product, in a breast cancer tumor sample from said patient;
normalizing said level of the RNA transcript of MYBL2 or its expression product, to obtain a normalized expression level of MYBL2;
wherein increased normalized expression level of MYBL2 indicates a decreased likelihood of long-term survival without breast cancer recurrence.
2. The method of claim 1, further comprising:
determining a normalized expression level of an RNA transcript of at least one further gene or its expression product, wherein the further gene is: GRB7, CTSL, Chk1 , AIB1, CCNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, HIF1.alpha., or TS;
wherein increased normalized expression level of the at least one further gene indicates a decreased likelihood of long-term survival without breast cancer recurrence.
determining a normalized expression level of an RNA transcript of at least one further gene or its expression product, wherein the further gene is: GRB7, CTSL, Chk1 , AIB1, CCNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, HIF1.alpha., or TS;
wherein increased normalized expression level of the at least one further gene indicates a decreased likelihood of long-term survival without breast cancer recurrence.
3. The method of claim 1, further comprising:
determining a normalized expression level of an RNA transcript of at least one further gene or its expression product, wherein the further gene is: TP53BP2, PR, Bcl2, EstR1, IGFBP2, BAG1, CEGP1, KLK10,.beta.-Catenin, .gamma.-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGF1, or KRT19;
wherein increased normalized expression level of the at least one further gene indicates an increased likelihood of long-term survival without breast cancer recurrence.
determining a normalized expression level of an RNA transcript of at least one further gene or its expression product, wherein the further gene is: TP53BP2, PR, Bcl2, EstR1, IGFBP2, BAG1, CEGP1, KLK10,.beta.-Catenin, .gamma.-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3, TBP, p27, IRS1, IGF1R, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGF1, or KRT19;
wherein increased normalized expression level of the at least one further gene indicates an increased likelihood of long-term survival without breast cancer recurrence.
4. The method of claim 1, 2 or 3, wherein the breast cancer is invasive breast carcinoma.
5. The method of any one of claims 1 to 4, wherein the breast cancer is estrogen-receptor positive breast cancer.
6. The method of any one of claims 1 to 5, wherein the breast cancer tumor sample is a fixed, wax-embedded tissue specimen.
7. The method of any one of claims 1 to 6, wherein the level of the RNA
transcript of MYBL2 is determined.
transcript of MYBL2 is determined.
8. The method of claim 7, wherein the level of the RNA transcript of MYBL2 is determined by quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
9. The method of any one of claims 1 to 6, wherein the level of the expression product of the RNA transcript of MYBL2 is determined.
10. The method of claim 9, wherein the level of the expression product is determined by immunohistochemistry or proteomics technology.
11. The method of any one of claims 1 to 10, further comprising providing a report based on the normalized expression level of MYBL2.
12. The method of claim 11, wherein the report comprises a prediction of the likelihood of long-term survival of said patient without breast cancer recurrence.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2829472A CA2829472C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829477A CA2829477C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829476A CA2829476C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44086103P | 2003-01-15 | 2003-01-15 | |
US60/440,861 | 2003-01-15 | ||
PCT/US2004/000985 WO2004065583A2 (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2829476A Division CA2829476C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829472A Division CA2829472C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829477A Division CA2829477C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2513117A1 CA2513117A1 (en) | 2004-08-05 |
CA2513117C true CA2513117C (en) | 2014-02-25 |
Family
ID=32771871
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2513117A Expired - Lifetime CA2513117C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829477A Expired - Lifetime CA2829477C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA3013889A Abandoned CA3013889A1 (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829476A Expired - Lifetime CA2829476C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829472A Expired - Lifetime CA2829472C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2829477A Expired - Lifetime CA2829477C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA3013889A Abandoned CA3013889A1 (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829476A Expired - Lifetime CA2829476C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
CA2829472A Expired - Lifetime CA2829472C (en) | 2003-01-15 | 2004-01-14 | Gene expression markers for breast cancer prognosis |
Country Status (11)
Country | Link |
---|---|
US (7) | US20040231909A1 (en) |
EP (4) | EP2230319B1 (en) |
JP (1) | JP4723472B2 (en) |
AT (1) | ATE470723T1 (en) |
AU (2) | AU2004205878B2 (en) |
CA (5) | CA2513117C (en) |
DE (1) | DE602004027600D1 (en) |
DK (3) | DK2230319T3 (en) |
ES (3) | ES2346967T3 (en) |
HK (1) | HK1148783A1 (en) |
WO (1) | WO2004065583A2 (en) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
US20030180296A1 (en) * | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
EP2241636A1 (en) * | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
PL3470535T3 (en) * | 2003-06-24 | 2020-08-24 | Genomic Health, Inc. | Prediction of likelihood of cancer recurrence |
ES2651849T3 (en) * | 2003-07-10 | 2018-01-30 | Genomic Health, Inc. | Expression profile and test algorithm for cancer prognosis |
US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
US20050112622A1 (en) | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
WO2006016110A1 (en) * | 2004-08-10 | 2006-02-16 | University College Cardiff Consultants Limited | Methods and kit for the prognosis of breast cancer |
US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
WO2006036788A2 (en) * | 2004-09-22 | 2006-04-06 | Tripath Imaging, Inc. | Methods and compositions for evaluating breast cancer prognosis |
US8065093B2 (en) * | 2004-10-06 | 2011-11-22 | Agency For Science, Technology, And Research | Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers |
PL1836629T3 (en) * | 2004-11-05 | 2020-06-15 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
JP4939425B2 (en) * | 2004-11-05 | 2012-05-23 | ジェノミック ヘルス, インコーポレイテッド | Molecular indicators of prognosis and prediction of treatment response in breast cancer |
KR20070085855A (en) * | 2004-12-07 | 2007-08-27 | 제넨테크, 인크. | Selecting patients for therapy with a her inhibitor |
CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
BRPI0606542A8 (en) * | 2005-02-23 | 2018-03-20 | Genentech Inc | methods to increase the time to disease progression (ttp) |
US20080275652A1 (en) * | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US8129114B2 (en) * | 2005-08-24 | 2012-03-06 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
CA2628255C (en) | 2005-10-31 | 2016-04-19 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
EP2177910A1 (en) * | 2005-11-10 | 2010-04-21 | Aurelium Biopharma Inc. | Tissue diagnostics for breast cancer |
TW200731980A (en) * | 2005-12-29 | 2007-09-01 | Alcon Mfg Ltd | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
WO2007123772A2 (en) | 2006-03-31 | 2007-11-01 | Genomic Health, Inc. | Genes involved in estrogen metabolism |
EP2258874B1 (en) * | 2006-06-02 | 2015-03-18 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
WO2008063521A2 (en) * | 2006-11-13 | 2008-05-29 | The General Hospital Corporation | Gene-based clinical scoring system |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
US9551033B2 (en) * | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CA3006428A1 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
AU2008289148A1 (en) * | 2007-08-16 | 2009-02-26 | Aventis Inc. | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
WO2009067655A2 (en) * | 2007-11-21 | 2009-05-28 | University Of Florida Research Foundation, Inc. | Methods of feature selection through local learning; breast and prostate cancer prognostic markers |
EP2065475A1 (en) * | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor |
US20110130296A1 (en) * | 2008-03-14 | 2011-06-02 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
US10359425B2 (en) * | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
US20100221752A2 (en) * | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
US20110195995A1 (en) * | 2008-10-14 | 2011-08-11 | Wittliff James L | Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers |
GB0821787D0 (en) * | 2008-12-01 | 2009-01-07 | Univ Ulster | A genomic-based method of stratifying breast cancer patients |
US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
WO2011005384A2 (en) * | 2009-05-29 | 2011-01-13 | Baylor College Of Medicine | Dna repair or brca1-like gene signature |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
EP2275569A1 (en) * | 2009-07-17 | 2011-01-19 | Centre Leon Berard | ZNF217 a new prognostic and predictive biomarker of recurrent, invasive and metastatic phenotypes in cancer |
GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
DK2504451T3 (en) * | 2009-11-23 | 2019-08-05 | Genomic Health Inc | Methods for predicting the clinical course of cancer |
WO2011088137A2 (en) * | 2010-01-12 | 2011-07-21 | H. Lee Moffitt Cancer Center & Research Institute | Bad pathway gene signature |
US20130143753A1 (en) * | 2010-03-01 | 2013-06-06 | Adelbio | Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2591126B1 (en) | 2010-07-07 | 2020-12-30 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
SG10201508656VA (en) | 2010-07-09 | 2015-11-27 | Somalogic Inc | Lung cancer biomarkers and uses thereof |
SI2603600T1 (en) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
CA2804857C (en) | 2010-08-13 | 2021-07-06 | Somalogic, Inc. | Pancreatic cancer biomarkers and uses thereof |
US9605319B2 (en) | 2010-08-30 | 2017-03-28 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
US10011876B2 (en) | 2010-11-23 | 2018-07-03 | Krisani Biosciences Pvt. Ltd | Method and system for prognosis and treatment of diseases using portfolio of genes |
WO2012109233A2 (en) * | 2011-02-07 | 2012-08-16 | Board Of Regents, The University Of Texas System | Methods for predicting recurrence risk in breast cancer patients |
BR112014009418A2 (en) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | peptidomimetic macrocycles |
AU2012336120B2 (en) * | 2011-11-08 | 2017-10-26 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
WO2013170174A1 (en) | 2012-05-10 | 2013-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature |
US9890430B2 (en) | 2012-06-12 | 2018-02-13 | Washington University | Copy number aberration driven endocrine response gene signature |
KR20150082307A (en) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | Disubstituted amino acids and methods of preparation and use thereof |
EP4190918A1 (en) | 2012-11-16 | 2023-06-07 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
KR102291355B1 (en) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Identification of patients in need of pd-l1 inhibitor cotherapy |
JP2016505043A (en) | 2013-01-18 | 2016-02-18 | クライン,エリス | Selective glycosidase regimens for immune programming and cancer treatment |
JP6576249B2 (en) | 2013-02-11 | 2019-09-18 | インクロン, インコーポレイテッド | Use of chromatin transcription factor (FACT) in cancer |
CN103465779B (en) * | 2013-09-17 | 2015-12-09 | 哈尔滨工程大学 | Omnidirectional with double engines 4 wheel driven walking mechanism |
CN103558382B (en) * | 2013-10-28 | 2015-11-18 | 深圳市第二人民医院 | The application of CCNE1 gene on detecting in bladder transitional cell carcinoma |
CN103558383B (en) * | 2013-10-28 | 2015-11-18 | 深圳市第二人民医院 | The application of ALDH2 gene on detecting in bladder transitional cell carcinoma |
KR20150088433A (en) | 2014-01-24 | 2015-08-03 | 삼성전자주식회사 | Biomarker TFF1 for predicting effect of a c-Met inhibitor |
WO2015175692A1 (en) | 2014-05-13 | 2015-11-19 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
WO2016025785A1 (en) * | 2014-08-15 | 2016-02-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for characterizing cancer |
CN106999541A (en) | 2014-09-24 | 2017-08-01 | 艾瑞朗医疗公司 | Peptidomimetic macrocyclic compound and application thereof |
WO2016049355A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
JP7065610B6 (en) | 2014-10-24 | 2022-06-06 | コーニンクレッカ フィリップス エヌ ヴェ | Medical prognosis and prediction of therapeutic response using multiple cellular signaling pathway activities |
JP6415712B2 (en) | 2014-10-24 | 2018-10-31 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Assessment of TGF-β cell signaling pathway activity using mathematical modeling of target gene expression |
ES2857953T3 (en) | 2014-10-24 | 2021-09-29 | Koninklijke Philips Nv | Medical prognosis and prediction of response to treatment using the activities of multiple cell signaling pathways |
SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
EP3073268A1 (en) | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
JP7028763B2 (en) | 2015-08-14 | 2022-03-02 | コーニンクレッカ フィリップス エヌ ヴェ | Assessment of NFkB cell signaling pathway activity using mathematical modeling of target gene expression |
CN107058523A (en) * | 2017-03-21 | 2017-08-18 | 温州迪安医学检验所有限公司 | A kind of genetic test primer of breast carcinoma recurring risk assessment 21 and its application |
EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
CN110045120A (en) * | 2018-01-15 | 2019-07-23 | 长庚医疗财团法人基隆长庚纪念医院 | Detect detection kit and its application of the concentration of WISP1 in biological sample in preparation for breast cancer screening and detecting recurrence |
WO2020013355A1 (en) * | 2018-07-10 | 2020-01-16 | 서울대학교산학협력단 | Composition for predicting prognosis of malignant phyllodes tumor and kit comprising same |
WO2021030460A1 (en) * | 2019-08-12 | 2021-02-18 | Baylor College Of Medicine | Proteogenomic methods for diagnosing cancer |
CN113862363A (en) * | 2021-10-27 | 2021-12-31 | 中山大学附属第一医院 | Application of immune related gene in kit and system for breast cancer prognosis |
CN114480650A (en) * | 2022-02-08 | 2022-05-13 | 深圳市陆为生物技术有限公司 | Marker and model for predicting three-negative breast cancer clinical prognosis recurrence risk |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699877A (en) | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
USRE35491E (en) | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
IE56509B1 (en) | 1982-11-04 | 1991-08-28 | Univ California | Methods for oncogenic detection |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5922855A (en) * | 1993-12-17 | 1999-07-13 | Oregon Health Sciences University | Mammalian DNA mismatch repair genes MLH1 and PMS1 |
US6037134A (en) | 1994-03-07 | 2000-03-14 | New York University Medical Center | Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes |
US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US5858678A (en) | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
US5830753A (en) | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
US6218529B1 (en) * | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
JP3944241B2 (en) | 1995-12-18 | 2007-07-11 | スージェン・インコーポレーテッド | Diagnosis and treatment of AUR-1 and / or AUR-2 related diseases |
US6716575B2 (en) | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US5670325A (en) | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US5741650A (en) | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
US5821082A (en) | 1996-05-23 | 1998-10-13 | St. Louis University Health Sciences Center | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same |
US6020137A (en) | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6100029A (en) | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6143529A (en) | 1996-08-14 | 2000-11-07 | Exact Laboratories, Inc. | Methods for improving sensitivity and specificity of screening assays |
US5952178A (en) | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
US6146828A (en) | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
US6203993B1 (en) | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
US5928870A (en) | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US5861278A (en) | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
EP0950103B1 (en) | 1996-11-20 | 2008-11-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US5830665A (en) | 1997-03-03 | 1998-11-03 | Exact Laboratories, Inc. | Contiguous genomic sequence scanning |
US6033893A (en) | 1997-06-26 | 2000-03-07 | Incyte Pharmaceuticals, Inc. | Human cathepsin |
WO1999002714A1 (en) | 1997-07-07 | 1999-01-21 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
EP1025220B1 (en) * | 1997-10-21 | 2007-01-03 | The University Court Of The University Of Glasgow | JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF |
DE69934222T2 (en) * | 1998-02-25 | 2007-10-25 | The United States Government As Represented By The Department Human Services | CELLULAR ARRANGEMENTS FOR FAST MOLECULAR PROFILE IDENTIFICATION |
US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
WO1999064626A2 (en) | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
AU4158799A (en) | 1998-06-06 | 1999-12-30 | Genostic Pharma Limited | Probes used for genetic filing |
US6696558B2 (en) | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
US6331396B1 (en) | 1998-09-23 | 2001-12-18 | The Cleveland Clinic Foundation | Arrays for identifying agents which mimic or inhibit the activity of interferons |
US9534254B1 (en) * | 1999-02-02 | 2017-01-03 | Abbott Molecular Inc. | Patient stratification for cancer therapy based on genomic DNA microarray analysis |
US6251601B1 (en) | 1999-02-02 | 2001-06-26 | Vysis, Inc. | Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays |
AU3246200A (en) | 1999-02-25 | 2000-09-14 | Boris Bilynsky | Nucleic acid molecules associated with melanoma and thyroid tumors |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
US20020039764A1 (en) | 1999-03-12 | 2002-04-04 | Rosen Craig A. | Nucleic, acids, proteins, and antibodies |
US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US6692916B2 (en) | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US6326148B1 (en) | 1999-07-12 | 2001-12-04 | The Regents Of The University Of California | Detection of copy number changes in colon cancer |
US6710170B2 (en) | 1999-09-10 | 2004-03-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
EP1218394A4 (en) | 1999-10-06 | 2004-04-14 | Univ California | Differentially expressed genes associated with her-2/neu overexpression |
EP1666494A1 (en) | 1999-12-01 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6750013B2 (en) | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
US6248535B1 (en) | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
WO2001051664A2 (en) * | 2000-01-12 | 2001-07-19 | Dana-Farber Cancer Institute, Inc. | Method of detecting and characterizing a neoplasm |
EP1276901A2 (en) | 2000-01-13 | 2003-01-22 | Amsterdam Support Diagnostics B.V. | A universal nucleic acid amplification system for nucleic acids in a sample |
US6322986B1 (en) | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
EP1257664A4 (en) | 2000-01-28 | 2006-04-05 | Althea Technologies Inc | Methods for analysis of gene expression |
CA2395872A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US20030165831A1 (en) | 2000-03-21 | 2003-09-04 | John Lee | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
US7157227B2 (en) | 2000-03-31 | 2007-01-02 | University Of Louisville Research Foundation | Microarrays to screen regulatory genes |
WO2002000677A1 (en) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
JP2004504059A (en) | 2000-07-21 | 2004-02-12 | グローバル ジェノミクス アクティエボラーグ | Method for analyzing and identifying transcribed gene, and finger print method |
WO2002008261A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Bstp-trans protein and related reagents and methods of use thereof |
WO2002008282A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Bstp-ras/rerg protein and related reagents and methods of use thereof |
WO2002008260A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Bstp-ecg1 protein and related reagents and methods of use thereof |
WO2002010436A2 (en) * | 2000-07-28 | 2002-02-07 | The Brigham And Women's Hospital, Inc. | Prognostic classification of breast cancer |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US6378397B1 (en) * | 2000-10-25 | 2002-04-30 | Jenn Jianq Co., Ltd. | Differential gearing device |
US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
WO2002046467A2 (en) * | 2000-12-08 | 2002-06-13 | Ipsogen | Gene expression profiling of primary breast carcinomas using arrays of candidate genes |
AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
JP4368110B2 (en) | 2001-01-12 | 2009-11-18 | エール ユニヴァーシティ | Detection of survivin in biological fluids of cancer patients |
US7776518B2 (en) | 2001-01-12 | 2010-08-17 | Yale University | Detection of survivin in the biological fluids of cancer patients |
JP2005503760A (en) | 2001-01-24 | 2005-02-10 | プロテイン デザイン ラブス, インコーポレイテッド | Breast cancer diagnosis method, composition and breast cancer modulator screening method |
WO2002059271A2 (en) | 2001-01-25 | 2002-08-01 | Gene Logic, Inc. | Gene expression profiles in breast tissue |
US6939670B2 (en) | 2001-03-12 | 2005-09-06 | Monogen, Inc. | Cell-based detection and differentiation of lung cancer |
WO2002072828A1 (en) * | 2001-03-14 | 2002-09-19 | Dna Chip Research Inc. | Method of predicting cancer |
US6655515B2 (en) * | 2001-05-24 | 2003-12-02 | Tecumseh Products Company | Modular bi-directional overrunning wheel clutch |
DK1410011T3 (en) | 2001-06-18 | 2011-07-18 | Netherlands Cancer Inst | Diagnosis and prognosis of breast cancer patients |
WO2003011897A1 (en) | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
US6898531B2 (en) * | 2001-09-05 | 2005-05-24 | Perlegen Sciences, Inc. | Algorithms for selection of primer pairs |
EP1444361A4 (en) | 2001-09-28 | 2006-12-27 | Whitehead Biomedical Inst | Classification of lung carcinomas using gene expression analysis |
KR20040064275A (en) | 2001-11-09 | 2004-07-16 | 소스 프리시전 메디슨, 인코포레이티드 | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
EP2241636A1 (en) | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
EP1492871A2 (en) | 2002-03-28 | 2005-01-05 | QLT Inc. | Cancer associated protein kinases and their uses |
EP1900827A3 (en) | 2002-05-21 | 2008-04-16 | Bayer HealthCare AG | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
AU2004203749A1 (en) * | 2003-01-06 | 2004-07-22 | Wyeth | Compositions and methods for diagnosing and treating colon cancers |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
JP4568716B2 (en) | 2003-02-20 | 2010-10-27 | ジェノミック ヘルス, インコーポレイテッド | Use of intron RNA to measure gene expression |
AU2004248120B2 (en) | 2003-05-28 | 2009-04-23 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
PL3470535T3 (en) * | 2003-06-24 | 2020-08-24 | Genomic Health, Inc. | Prediction of likelihood of cancer recurrence |
ES2651849T3 (en) | 2003-07-10 | 2018-01-30 | Genomic Health, Inc. | Expression profile and test algorithm for cancer prognosis |
CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
PL1836629T3 (en) | 2004-11-05 | 2020-06-15 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
JP4939425B2 (en) | 2004-11-05 | 2012-05-23 | ジェノミック ヘルス, インコーポレイテッド | Molecular indicators of prognosis and prediction of treatment response in breast cancer |
JP2009506777A (en) | 2005-09-01 | 2009-02-19 | プレシジョン セラピューティクス,インコーポレイテッド | Chemotherapy sensitivity assay using tumor cells with resistant phenotypic characteristics |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
WO2007123772A2 (en) | 2006-03-31 | 2007-11-01 | Genomic Health, Inc. | Genes involved in estrogen metabolism |
AU2008289148A1 (en) | 2007-08-16 | 2009-02-26 | Aventis Inc. | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
DK2568053T3 (en) | 2008-05-12 | 2014-07-21 | Genomic Health Inc | TESTS FOR PREVENTING THE RESPONSE OF CANCER PATIENTS ON DIFFERENT CHEMOTHERAPEUTIC TREATMENTS |
US9657112B2 (en) | 2009-07-02 | 2017-05-23 | Basf Se | Co-agglomerated latex polymer dispersions and methods of preparing and using same |
DK2504451T3 (en) | 2009-11-23 | 2019-08-05 | Genomic Health Inc | Methods for predicting the clinical course of cancer |
-
2003
- 2003-05-19 US US10/440,861 patent/US20040231909A1/en not_active Abandoned
-
2004
- 2004-01-14 AU AU2004205878A patent/AU2004205878B2/en not_active Expired
- 2004-01-14 EP EP10162868.3A patent/EP2230319B1/en not_active Expired - Lifetime
- 2004-01-14 CA CA2513117A patent/CA2513117C/en not_active Expired - Lifetime
- 2004-01-14 US US10/758,307 patent/US7569345B2/en active Active
- 2004-01-14 DK DK10162868.3T patent/DK2230319T3/en active
- 2004-01-14 DE DE602004027600T patent/DE602004027600D1/en not_active Expired - Lifetime
- 2004-01-14 DK DK15190640.1T patent/DK3059322T3/en active
- 2004-01-14 WO PCT/US2004/000985 patent/WO2004065583A2/en active Application Filing
- 2004-01-14 CA CA2829477A patent/CA2829477C/en not_active Expired - Lifetime
- 2004-01-14 DK DK04702177.9T patent/DK1587957T3/en active
- 2004-01-14 CA CA3013889A patent/CA3013889A1/en not_active Abandoned
- 2004-01-14 EP EP10162867A patent/EP2230318A1/en not_active Ceased
- 2004-01-14 ES ES04702177T patent/ES2346967T3/en not_active Expired - Lifetime
- 2004-01-14 EP EP15190640.1A patent/EP3059322B1/en not_active Expired - Lifetime
- 2004-01-14 ES ES15190640T patent/ES2725892T3/en not_active Expired - Lifetime
- 2004-01-14 CA CA2829476A patent/CA2829476C/en not_active Expired - Lifetime
- 2004-01-14 CA CA2829472A patent/CA2829472C/en not_active Expired - Lifetime
- 2004-01-14 AT AT04702177T patent/ATE470723T1/en active
- 2004-01-14 ES ES10162868.3T patent/ES2561179T3/en not_active Expired - Lifetime
- 2004-01-14 JP JP2006500964A patent/JP4723472B2/en not_active Expired - Lifetime
- 2004-01-14 EP EP04702177A patent/EP1587957B1/en not_active Expired - Lifetime
-
2009
- 2009-06-04 US US12/478,632 patent/US8034565B2/en active Active
- 2009-11-16 AU AU2009238287A patent/AU2009238287B2/en not_active Expired
-
2011
- 2011-03-17 HK HK11102676.4A patent/HK1148783A1/en not_active IP Right Cessation
- 2011-08-30 US US13/221,549 patent/US8206919B2/en not_active Expired - Lifetime
-
2012
- 2012-05-16 US US13/473,526 patent/US8741605B2/en not_active Expired - Lifetime
-
2014
- 2014-04-21 US US14/257,723 patent/US9944990B2/en active Active
-
2018
- 2018-02-15 US US15/897,617 patent/US11220715B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2513117C (en) | Gene expression markers for breast cancer prognosis | |
EP1641810B2 (en) | Prediction of likelihood of cancer recurrence | |
AU2012206980B2 (en) | Gene expression markers for breast cancer prognosis | |
AU2015202326B2 (en) | Gene expression markers for breast cancer prognosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20240115 |